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ABSTRACT 
The role of endogenous molecules in facilitating stem cell differentiation into 
cardiomyocytes is yet to be fully understood. SPC and S1P, common biolipids, 
promote cardiac differentiation of mesenchymal stem cells and cardiac progenitor 
cells, however, the same potential of closely related lysophosphatidic acid (LPA) has 
only recently become evident. The initial cardio-protection offered by elevated LPA 
levels in response to acute myocardial infarction and the ability of this biolipid to 
mediate other cellular fates served as a rationale to investigate the ability of LPA to 
mediate the cardiac differentiation of the murine P19 teratocarcinoma cell line and 
further examine the role of signalling molecules critical to lineage commitment.  
All experiments were carried out using P19 stem cells, cultured in supplemented 
alpha-minimal essential medium. Cells were aggregated into embryoid bodies in the 
presence of 5µM LPA in non-tissue grade Petri dishes over the course of 4 days to 
commence the differentiation process. Inhibitors were added 60 minutes before LPA 
while control cells were cultured in medium only. Embryoid bodies were transferred to 
6-well tissue culture grade plates and cultured for a further 6 days. Cardiac 
differentiation was assessed by examining the expression of ventricular myosin light 
chain (MLC1v) by western blot and the role of LPA receptors 1-4, PKC, PI3K, MAPKs, 
and NF-κB were determined by examining the changes in this expression in the 
presence of selective inhibitors. The induction and regulation of GATA4, MEF2C, ATF-
2, JNK, and YAP was also determined by western blotting. The activity and regulation 
of transcription factors, AP-1 and NF-κB, and the MAPKs was determined using ELISA 
kits.  
LPA induced the differentiation of P19 cells into cardiomyocytes most effectively when 
used at a concentration of 5µM as evidenced by the expression of MLC1v on day 10 
of the differentiation process. Inhibition of LPA receptor 4 (0.1mg/mL Suramin), LPA 
receptors 1/3 (20µM Ki16425), LPA receptor 2 (7.5nM H2L5186303), PKC (10µM BIM-
1), PI3K (20µM LY294002), ERK (20µM PD98059), JNK (10µM SP600125), and NF-
κB (0.01nM CAY10470) blocked LPA induced expression of MLC1v. GATA4, MEF2C, 
pcJun, pJunD, and pATF2 expression increased in a time-dependent manner peaking 
at day 10 in LPA treated cells. GATA4 and pcJun expression was suppressed by all 
the inhibitors whereas MEF2C expression was unaffected by CAY10470, pJunD 
expression was unaffected by H2L5186303, pATF2 and NF-κB expression was 
unaffected by LY294002, but the latter was enhanced by Suramin. JNK was transiently 
phosphorylated in all cells whereas YAP was dephosphorylated 24-48 hours after EB 
formation in LPA treated cells and were both affected by Ki16425 and partially by 
H2L5186303 treatment. 
In conclusion, the studies carried out in this thesis have shown that LPA mediates the 
cardiac differentiation of P19 cells through LPA receptor 2, partially through receptors 
1/3, and possibly through receptor 4. Conceivably downstream of these receptors, 
PKC, PI3K, MAPK, and NF-κB signalling pathways converge on the regulation of 
cardiac-specific transcription factors GATA4 and MEF2C along with ubiquitous 
transcription factor AP-1. JNK signalling is initiated through LPA receptors 1/3 and 
partially through receptor 2 to commence the cardiac program however the role of JNK 
and YAP in the proliferation of aggregating EBs is yet to be entirely established. 
 
ii 
 
ACKNOWLEDGEMENTS 
This work would not be possible without the support and guidance of my principal 
supervisor, Professor Anwar Baydoun. Thank you for the opportunity, encouragement, 
liberty, motivation, perspective, laughs, and always having an open door. A special 
thank you to Professor Soraya Dhillon (MBE) for being such a strong role model.  
Thank you to Dr Tamer Rabie, Dr Hema Pramod, and Dr Anupama Awachat for your 
guidance, support, and patience at the beginning of this journey. I am especially 
grateful to Lee Rixon, member of the fantastic technical staff, for always going above 
and beyond to ensure our research group was well supported. To my colleagues, Dr 
Nimer Alsabeelah, Dr Mahdi Alsugoor, Adem Nasraddin, and Thippayaporn 
Poonsawat, thank you for ensuring every day spent in 1G163 was memorable.  
Dr Ashish Patidar, Sonali Patidar, Dr Praveen Bingi, and Yugal Kalaskar…no words 
can express the gratitude in my heart for your support, friendship, and making UH feel 
like home. To my best friend, Lilia Pineda, thank you for being my pillar of strength.  
This work is dedicated to my family. Your patience, understanding, love, and support 
is responsible for this achievement. To Ronan and Kegan, thank you for being my 
sunshine. To my husband, I made it this far only because you never let me quit!  
iii 
 
Table of Contents 
 
Abstract  .................................................................................................................. i  
Acknowledgements ……………………………………………………………………… ii 
   List of Figures …………………………………………………………………………… viii 
   List of Tables ……………………………………………………………………………… x 
   Abbreviations …………………………………………………………………………….. xi 
 
Chapter 1 
Introduction 
 
Overview ................................................................................................................. 2 
1.1 Myocardial infarction ......................................................................................... 3 
1.1.1 Current treatments ..................................................................................... 3 
1.2 Cell therapy ....................................................................................................... 4 
1.2.1 Multipotent stem cells ................................................................................. 8 
1.2.2 Pluripotent stem cells ............................................................................... 11 
1.3 Signal transduction ......................................................................................... 14 
1.3.1 Transcription factors ................................................................................. 14 
1.3.2 Intracellular signalling kinases .................................................................. 16 
1.3.3 Extracellular targets ................................................................................. 18 
1.3.4 In vivo signalling associated with cardiomyocyte production .................... 22 
1.3.5 In vitro cardiomyocyte production ............................................................. 25 
1.3.6 Markers for in vitro cardiac differentiation ................................................ 27 
1.4 LPA ................................................................................................................. 29 
1.4.1 LPA characteristics .................................................................................. 29 
1.4.2 LPA synthesis .......................................................................................... 29 
1.4.3 LPA receptors .......................................................................................... 30 
1.4.4 LPA in vascular biology ............................................................................ 35 
1.4.5 LPA in stem cell differentiation ................................................................. 35 
1.5 Aim of the thesis ............................................................................................. 36 
 
 
 
iv 
 
Chapter 2 
Materials & Methods 
2.1 Cell culture ...................................................................................................... 38 
2.1.1 Recovery of P19 cells .............................................................................. 38 
2.1.2 Culturing of P19 cells ............................................................................... 40 
2.2 Differentiation Protocol ................................................................................... 40 
2.2.1 Preparation of lysophosphatidic acid ........................................................ 40 
2.2.2 Formation of embryoid bodies .................................................................. 40 
2.2.3 Cardiac differentiation of P19 cells ........................................................... 41 
2.2.4 Preparation of adherent cell cultures for ELISA analysis ......................... 42 
2.3 Protein quantification ...................................................................................... 45 
2.3.1 Cell lysis for the detection of MLC1v ........................................................ 45 
2.3.2 Cell lysis for the detection of total and phosphorylated proteins .............. 45 
2.3.3 The bicinchoninic acid assay (BCA) ......................................................... 46 
2.4 Protein analysis by western blot ..................................................................... 48 
2.5 Cell viability assay .......................................................................................... 50 
2.6 Mycoplasma testing ........................................................................................ 50 
2.7 Statistical analysis .......................................................................................... 51 
Chapter 3 
Establishment of the cardiac differentiation model 
& 
The role of LPA receptors and the PKC/PI3K pathway in LPA 
mediated cardiac differentiation of P19 cells 
3.1 Introduction ..................................................................................................... 53 
3.2 Materials and Methods ................................................................................... 55 
3.2.1 Determining the effect of LPA on P19 cells .............................................. 55 
3.2.2 Determining the role of LPA receptors in LPA mediated cardiac 
differentiation of P19 cells ....................................................................... 55 
3.2.3 Determining the role of PKC and PI3K in LPA mediated cardiac 
differentiation of P19 cells ....................................................................... 56 
3.3 Results ............................................................................................................ 57 
3.3.1 LPA induced differentiation of P19 cells into cardiomyocytes .................. 57 
3.3.2 LPA receptors 1-4 mediate cardiac differentiation in LPA treated 
P19 cells .................................................................................................. 62 
3.3.3 PKC and PI3K signalling mediate cardiac differentiation in LPA 
treated P19 cells ...................................................................................... 67 
3.4 Discussion ...................................................................................................... 71 
v 
 
Chapter 4 
The role and regulation of the MAPKs in LPA mediated cardiac 
differentiation of P19 cells 
4.1 Introduction ..................................................................................................... 78 
4.2 Materials and Methods ................................................................................... 80 
4.2.1 Determining the role of MAPKs in LPA mediated cardiac 
differentiation of P19 cells ....................................................................... 80 
4.2.2 Determining the effect of 20µM SP600125 on the aggregation 
and proliferation of EBs ........................................................................... 80 
4.2.3 Determining the phosphorylation of JNK during EB formation ................. 81 
4.2.4 Determining the effect of delayed inhibition of the JNK pathway 
in differentiating P19 cells........................................................................ 81 
4.2.5 Determining the regulation of JNK by LPA receptors ............................... 81 
4.2.6 Determining the phosphorylation of MAPKs by LPA ................................ 82 
4.2.7 Determining the cross-talk between MAPKs, and the regulation 
of MAPKs by LPA receptors 1-4, PKC, and PI3K .................................... 83 
4.3 Results ............................................................................................................ 84 
4.3.1 ERK and JNK signalling mediate cardiac differentiation in LPA 
treated P19 cells ...................................................................................... 84 
4.3.2 The time-dependent effect of 20µM SP600125 on the 
aggregation and size of EBs .................................................................... 89 
4.3.3 Phosphorylation of JNK during EB formation ........................................... 91 
4.3.4 The effect of delayed inhibition of the JNK pathway on the 
expression of MLC1v ............................................................................... 93 
4.3.5 LPA receptor mediated regulation of JNK ................................................ 95 
4.3.6 Phosphorylation of the MAPKs by LPA .................................................... 97 
4.3.7 Regulation of the MAPKs in LPA treated cells by LPA receptors 
1-4, PKC, and PI3K ............................................................................... 101 
4.4 Discussion .................................................................................................... 103 
Chapter 5 
The role and regulation of ubiquitous transcription factors in LPA 
mediated cardiac differentiation of P19 cells 
5.1 Introduction ................................................................................................... 112 
5.2 Materials and Methods ................................................................................. 114 
5.2.1 Determining the role of NF-κB in LPA mediated cardiac 
differentiation of P19 cells ..................................................................... 114 
5.2.2 Determining the phosphorylation of NF-κB by LPA ................................ 114 
5.2.3 Determining the early phosphorylation of NF-κB by LPA in 
adherent P19 cells ................................................................................. 115 
vi 
 
5.2.4 Determining the regulation of NF-κB in LPA treated cells by LPA 
receptors, MAPKs, PKC and PI3K ........................................................ 116 
5.2.5 Determining the phosphorylation of AP-1 subunits by LPA .................... 116 
5.2.6 Determining the regulation of AP-1 subunits in LPA treated cells 
by LPAR1-4, MAPKs, PKC, PI3K, and NF-κB. ...................................... 118 
5.2.7 Determining the phosphorylation of ATF2 by LPA .................................. 119 
5.2.8 Determining the regulation of ATF2 in LPA treated cells by 
LPAR1-4, MAPKs, PKC, PI3K, and NF-κB. ........................................... 119 
5.3 Results .......................................................................................................... 121 
5.3.1 NF-κB signalling mediates cardiac differentiation in LPA treated 
P19 cells ................................................................................................ 121 
5.3.2 Phosphorylation of NF-κB by LPA .......................................................... 124 
5.3.3 Early phosphorylation of NF-κB by LPA ................................................. 126 
5.3.4 The regulation of NF-κB in LPA treated cells by LPAR1-4, 
MAPKs, PKC and PI3K. ........................................................................ 128 
5.3.5 Phosphorylation of AP-1 subunits by LPA .............................................. 130 
5.3.6 Regulation of AP-1 subunits in LPA treated cells by LPAR1-4, 
MAPKs, PKC, PI3K, and NF-κB ............................................................ 135 
5.3.7 Phosphorylation of ATF2 by LPA ............................................................ 143 
5.3.8 The regulation of pATF2 in LPA treated cells by LPAR1-4, 
MAPKs, PKC, PI3K, and NF-κB. ........................................................... 145 
5.4 Discussion .................................................................................................... 147 
 
Chapter 6 
The regulation of cardiac specific transcription factors in LPA 
mediated cardiac differentiation of P19 cells 
6.1 Introduction ................................................................................................... 153 
6.2 Materials and Methods ................................................................................. 155 
6.2.1 Determining the effect of LPA treatment on the expression of 
cardiac-specific transcription factors ..................................................... 155 
6.2.2 Determining the regulation of cardiac-specific transcription 
factors in LPA treated cells by LPA receptors 1-4, MAPKs, 
PKC, PI3K, and NF-κB .......................................................................... 155 
6.3 Results .......................................................................................................... 156 
6.3.1 Expression of cardiac-specific transcription factors in LPA 
treated cells. .......................................................................................... 156 
6.3.2 The regulation of cardiac specific transcription factors in LPA 
treated cells by LPA receptors 1-4, MAPKs, PKC, PI3K, and 
NF-κB .................................................................................................... 160 
6.4 Discussion .................................................................................................... 164 
vii 
 
Chapter 7 
The regulation of the Hippo pathway in LPA mediated cardiac 
differentiation of P19 cells 
7.1 Introduction ................................................................................................... 168 
7.2 Materials and Methods ................................................................................. 169 
7.2.1 Determining the expression of phosphorylated YAP and MOB in 
LPA treated cells ................................................................................... 169 
7.2.2 Determining the regulation of YAP and MOB1 in LPA treated 
cells by JNK and LPAR1-4 .................................................................... 169 
7.2.3 Determining the expression of Hippo pathway members in LPA 
treated cells ........................................................................................... 170 
7.3 Results .......................................................................................................... 171 
7.3.1 The effect of LPA on phosphorylated YAP and MOB ............................. 171 
7.3.2 Regulation of YAP and MOB in LPA treated cells by JNK and 
LPAR1-4 ................................................................................................ 175 
7.3.3 Expression of Hippo pathway members ................................................. 179 
7.4 Discussion .................................................................................................... 181 
 
Chapter 8 
General Discussion 
   8.1 The Differentiation Protocol ........................................................................... 187 
   8.2 LPA receptors................................................................................................ 190 
   8.3 The JNK pathway .......................................................................................... 191 
   8.4 The NF-κB Pathway ...................................................................................... 192 
   8.5 Transcription Factors ..................................................................................... 193 
   8.6 Summary and Conclusion ............................................................................. 194 
 
Chapter 9 References ....................................................................... 196 
 
 
viii 
 
          List of Figures 
Figure 1.0. Markers for sequential steps required for obtaining cardiomyocytes 
from pluripotent stem cells ..................................................................... 28 
Figure 1.1. Summary of LPA synthesis and signalling ............................................. 34 
Figure 2.0. Growth of recovered P19 cells ............................................................... 39 
Figure 2.1. The differentiation of P19 cells into cardiomyocytes by the 
spontaneous formation of embryoid bodies in the presence of LPA ...... 43 
Figure 2.2. Preparation of adherent cell cultures for ELISA analysis ....................... 44 
Figure 3.0. The viability of P19 cells in the presence of LPA .................................... 59 
Figure 3.1. LPA induces the expression of MLC1v in P19 cells ............................... 60 
Figure 3.2. LPA induces the expression of MLC1v in P19 cells in a time-
dependent manner ................................................................................. 61 
Figure 3.3. The viability of P19 cells in the presence LPA receptor antagonists ...... 63 
Figure 3.4. Ki16425 blocks LPA induced MLC1v expression in a concentration 
dependent manner ................................................................................. 64 
Figure 3.5. H2L5186303 blocks LPA induced MLC1v expression in a 
concentration dependent manner........................................................... 65 
Figure 3.6. Suramin blocks LPA induced MLC1v expression in a concentration 
dependent manner ................................................................................. 66 
Figure 3.7. The viability of P19 cells in the presence of BIM-1 and LY294002 ......... 68 
Figure 3.8. BIM-1 blocks LPA induced MLC1v expression in a concentration 
dependent manner ................................................................................. 69 
Figure 3.9. LY294002 blocks LPA induced MLC1v expression in a 
concentration dependent manner........................................................... 70 
Figure 4.0. The viability of P19 cells in the presence of MAPK inhibitors ................. 85 
Figure 4.1. 20µM PD98059 blocks LPA induced MLC1v expression ....................... 86 
Figure 4.2. SB203580 does not block LPA induced MLC1v expression .................. 87 
Figure 4.3. SP600125 blocks LPA induced MLC1v expression in a 
concentration dependent manner........................................................... 88 
Figure 4.4. Time-dependent effects of 20µM SP600125 on aggregating P19 
cells ........................................................................................................ 90 
Figure 4.5. Phosphorylation of JNK during EB formation of P19 cells ...................... 92 
Figure 4.6. Delayed inhibition of the JNK pathway blocks LPA induced MLC1v 
expression .............................................................................................. 94 
Figure 4.7. Ki16425 and H2L5186303 block JNK phosphorylation in LPA 
treated cells ............................................................................................ 96 
Figure 4.8. Phosphorylation of ERK by LPA in adherent P19 cells .......................... 98 
Figure 4.9. Phosphorylation of p38 by LPA in adherent P19 cells ............................ 99 
Figure 4.10. Phosphorylation of JNK by LPA in adherent P19 cells ....................... 100 
ix 
 
Figure 4.11. Regulation of the MAPKs in LPA treated cells ................................... 102 
Figure 5.0. The viability of P19 cells in the presence of CAY10470 ....................... 122 
Figure 5.1. CAY10470 blocks LPA induced MLC1v expression in a 
concentration dependent manner......................................................... 123 
Figure 5.2. p65 at serine 536 is phosphorylated during early EB formation ........... 125 
Figure 5.3. Effect of LPA on NF-κB activation in adherent P19 cells ...................... 127 
Figure 5.4. Regulation of NF-κB in LPA treated P19 cells ...................................... 129 
Figure 5.5. The effect of LPA on the activation of c-Fos......................................... 131 
Figure 5.6. The effect of LPA on the activation of FosB ......................................... 132 
Figure 5.7. The effect of LPA on the activation of JunD ......................................... 133 
Figure 5.8. The effect of LPA on the activation of c-Jun ......................................... 134 
Figure 5.9. Regulation of c-Fos in LPA treated P19 cells ....................................... 136 
Figure 5.10. Regulation of FosB in LPA treated P19 cells ...................................... 138 
Figure 5.11. Regulation of JunD in LPA treated P19 cells ...................................... 140 
Figure 5.12. Regulation of c-Jun in LPA treated P19 cells ..................................... 142 
Figure 5.13. The effect of LPA on the expression of pATF2. ................................... 144 
Figure 5.14. Regulation of pATF2 in LPA treated P19 cells .................................... 146 
Figure 6.0. LPA induces GATA4 expression in a time-dependent manner ............ 157 
Figure 6.1. LPA induces MEF2C expression in a time-dependent manner ............ 158 
Figure 6.2. Optimization of the NKX2.5 antibody ................................................... 159 
Figure 6.3. Regulation of GATA4 in LPA treated P19 cells .................................... 161 
Figure 6.4. Regulation of MEF2C in LPA treated P19 cells .................................... 163 
Figure 7.0. The effect of LPA treatment on p-YAP (Ser127) in P19 cells ............... 172 
Figure 7.1. The effect of LPA treatment on p-YAP (Ser397) in P19 cells ............... 173 
Figure 7.2. The effect of LPA treatment on p-MOB1 in P19 cells ........................... 174 
Figure 7.3. Regulation of p-YAP (Ser127) in LPA treated P19 cells ....................... 176 
Figure 7.4. Regulation of p-YAP (Ser397) in LPA treated P19 cells ....................... 177 
Figure 7.5. Regulation of p-MOB1 in LPA treated P19 cells ................................... 178 
Figure 7.6. The effect of LPA treatment on kinases of the Hippo cascade ............. 180 
Figure 8.0. Signal transduction mechanisms for LPA induced cardiac 
differentiation of P19 stem cells. .......................................................... 189 
 
 
 
 
x 
 
List of Tables 
Table 1.0. Preclinical studies of cell therapy for cardiac regeneration …………………….. 6 
Table 1.1. Clinical studies of cell therapy for cardiac regeneration ………………….......... 7 
Table 1.2. Pluripotent stem cell characteristics………………………………….…………...12 
Table 1.3. Efficiency of established protocols for cardiac differentiation of stem cells.…. 26 
Table 2.0. Preparation of BSA standards…………………………………………………….. 47 
Table 2.1. Preparation of a 96-well plate for protein quantification by BCA …….............. 47 
Table 2.2. Preparation of 2x Sample Buffer………………………………………………….. 49 
Table 2.3. Preparation of resolving and stacking gel for SDS-PAGE…………..................49 
Table 2.4. Preparation of buffers……………………………………………………………… 49
xi 
 
Abbreviations 
αMEM Alpha-minimum essential medium 
AC Adenylate Cyclase 
Akt Protein Kinase B 
ANOVA Analysis of Variance  
AP-1 Activator Protein 1 
APC Adenomatous Polyposis Coli  
ASK Apoptosis Stimulating Kinase  
ATF2 Activating Transcription Factor 2 
ATP Adenosine Triphosphate 
BCA Bicinchoninic Acid  
BIM-1 Bisindolylmaleimide-1 
BM Bone Marrow 
BMP Bone Morphogenic Protein  
BSA Bovine Serum Albumin 
cAMP cyclic Adenosine Monophosphate  
CVD Cardiovascular Disease 
DAG 1, 2-diacyglycerol  
DDW Double Distilled Water  
DKK1 Dickkopf-related protein 1  
DLK Dual Leucine zipper bearing Kinase 
DMSO Dimethyl sulfoxide 
EB Embryoid body 
ECC Embryonal Carcinoma Cell 
Edg Endothelial differentiation gene  
EDTA Ethylene Diamine Tetra Acetic Acid 
ELISA Enzyme Linked Immunosorbent Assay 
ERK Extracellular signal-regulated kinase  
ESC Embryonic Stem Cell 
FBS Foetal Bovine Serum 
FGF Fibroblast Growth Factor 
FGFR Fibroblast Growth Factor Receptor 
FHF First Heart Field 
FoxO Forkhead box O 
Gab1 Grb2-associated binding protein 1  
GF Growth Factor 
GPCR G protein-coupled receptor 
G-Protein Guanine nucleotide-binding protein 
Grb2 Growth factor receptor-bound protein 2  
GSK3 Glycogen Synthase Kinase 3 
HAND Heart and neural crest derivatives expressed proteins  
HEPES 4-(2-hydroxyethy)-1-peperazine ethane sulphonic acid  
xii 
 
HRP Horse Radish Peroxidase  
ICM Inner Cell Mass 
IgG Immunoglobulin  
IP3 Inositol (1,4,5) tris-phosphate  
iPSC Induced Pluripotent Stem Cell 
Isl1 Insulin gene enhancer protein1  
JNK c-Jun N-terminal kinase  
JSAP JNK/Stress activated protein kinase associated protein 
kDa Kilo Daltons  
Klf-4 Kruppel-like factor-4  
LATS Large tumour suppressor  
LCAT Lecithin cholesterol acyltransferase  
LIF Leukaemia Inhibitory Factor 
LP Lysophospholipid 
LPA Lysophosphatidic Acid 
LPAR Lysophosphatidic Acid Receptor  
LPC Lysophosphatidylcholine 
LPE Lysophosphatidylethanolamine  
LPL Lipoprotein Lipase 
LPS Lysophosphatidylserine 
LVEF Left ventricular ejection fraction  
LVEDV Left ventricular end diastolic volume  
LVESV Left ventricular end systolic volume  
MAG Monoacyl glycerol  
MAPK Mitogen Activated Protein Kinase 
MAPKAPK MAPK Activated Protein Kinase 
MAPKK/MKK/MEK Mitogen Activated Protein Kinase Kinase 
MAPKKK/MEKK Mitogen Activated Protein Kinase Kinase Kinase 
MEF Mouse Embryonic Fibroblast  
MEF2 Myocyte Enhancer Factor 2  
mEpiSC Mouse Epiblast Stem Cell 
MESP1 Mesoderm posterior 1  
MGAT Monoacyl glycerophosphate acyltransferase  
MHC Myosin heavy chain  
MI Myocardial Infarction 
MK2, 3, 5 MAPK-activated protein kinase 2/3/5 
MLC Myosin Light Chain 
MLK3 Mixed lineage kinase 3  
MNK MAPK interacting kinase  
MOB Mps One Binder 
MSK Mitogen and stress activated kinase  
MST Mammalian Ste20-like 
MTT (3-[4, 5-dimethylthiazol-2-yl] 2, 5-diphenyl-tetrazolium bromide  
NFAT Nuclear Factor of Activated T cells  
xiii 
 
NFκB Nuclear Factor kappa B  
NKX2.5 NK2 homeobox 5 
Oct3/4 Octamer-binding protein-3/4  
PA Phosphatidic Acid 
PBS Phosphate Buffered Saline 
PI Phosphoinositide 
PI3K Phosphatidylinositol-3 Phosphate Kinase  
PIP2 Phosphatidylinositol (1, 4) bis-phosphate  
PIP3 Phosphatidylinositol (3,4,5)-triphosphate  
PKC Protein Kinase C 
PKG Protein kinase G 
PL Phospholipid 
PLA1 Phospholipase A1  
PLA2 Phospholipase A2  
PLC Phospholipase C  
PLD Phospholipase D   
PMSF Phenyl Methyl Sulfonyl Fluoride  
PPARγ Peroxisome proliferator-activated receptor gamma  
PSC Pluripotent Stem Cell 
PTK Protein tyrosine kinase 
PVDF Polyvinylidene fluoride  
RSK Ribosomal S6 protein kinases 
SAV Salvador  
S.E.M Standard Error Mean  
S1P Sphingosine 1-phosphate   
SDS Sodium Dodecyl Sulphate  
SDS-PAGE Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis  
SH2 Src Homology Domain 2  
SHF Second Heart Field 
SM Skeletal Myoblasts 
SMAD Similar to Mothers Against Decapentaplegic  
SOS Son Of Sevenless  
Sox2 Sex determining region Y-box 2  
SPC Sphingosylphosphorylcholine  
SRE Serum Response Element 
SSEA Stage specific embryonic antigen  
STAT Signal Transducers and Activators of Transcription  
TAK Transforming growth factor-β-activated kinase  
TBS Tris buffered saline  
TBS-T Tris buffered saline - Tween 
TEMED N,N,N′,N′-tetramethylethylenediamine  
TGF Transforming growth factor  
Wnt Wingless-related integration site 
YAP Yes-associated protein 
1 
 
 
 
 
 
 
 
 
Chapter 1 
Introduction  
2 
 
Overview 
Cardiovascular diseases (CVDs) are amongst the leading cause of death worldwide 
and become more prevalent with age. Amongst all CVDs, the manifestation of 
myocardial infarction (MI) is the most devastating to the cardiomyocyte population. 
Injury to the human heart due to sudden damage, disease, or age-related 
degeneration is traditionally treated in a palliative manner. In contrast to current 
treatments, cell therapy aims to restore functional cardiomyocytes. Cell therapy 
harnesses the unique potential of stem cells to generate multi-lineage cells. The past 
twenty years have been dedicated to evaluating cardiac repair by several sources of 
stem cells. There is growing evidence that the introduction of multipotent stem cells 
into the damaged human heart does not restore functional cardiomyocytes but offer 
improvement, albeit limited, via unknown paracrine mechanisms. Another approach is 
the directed differentiation of stem cells into a cardiac fate before introduction into the 
damaged myocardium, the accomplishment of which is largely dependent on the 
thorough understanding of the signalling transduction mechanisms responsible for 
driving the production of cardiomyocytes. In vitro manipulation of the signalling 
pathways that control cardiac development in vivo have allowed for more efficient 
directed differentiation, however, the complexity of these signalling networks and the 
role of endogenous molecules in initiating the program of cardiac differentiation 
remains poorly described.  
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1.1 Myocardial infarction  
Myocardial infarction (MI) is brought on by both genetic and environmental factors 
such as diet, exercise, stress, and smoking, and can be further modified by age, 
gender, obesity, hypertension, and diabetes. MI is most often caused by the build-up 
of plaque within the artery. Over time the plaque may either block the artery or rupture, 
facilitating thrombus formation thereby, blocking the flow of oxygen-rich blood to the 
heart. Cardiac physiology is rapidly altered in this ischemic environment, and 
physiological stresses induce multi-level adaptive responses. As reviewed by Webster 
(2009), a decrease in the mitochondrial ATP is initially compensated by increased 
production of glycolytic ATP but later leads to lactate accumulation and a decrease in 
cytosolic pH. Ultimately, the excessive depletion in ATP results in cell necrosis, 
initiated in the central zone of the infarcted area, and further damage is caused by 
ischemia related calcium overload, generation of reactive oxygen species, and the 
activation of inflammatory and cytokine signalling pathways. Apoptosis resulting from 
reperfusion of the myocardium can lead to secondary damage (Yellon & Hausenloy, 
2007). Ischaemic events, such as MI, are the most devastating to the cardiomyocyte 
population where upwards of a billion cardiomyocytes are lost (Laflamme & Murry, 
2005), resulting in the formation of fibrotic scar tissue and left ventricular remodelling 
(Sutton & Sharpe, 2000), diminishing the pumping capacity of the heart. 
1.1.1 Current treatments  
Endogenous repair mechanisms cannot restore the number of cardiomyocytes that 
are lost during an ischaemic event. Pharmaceutical interventions either at the onset of 
MI or prescribed as aftercare including aspirin, statins, nitrates, β-blockers, and 
fibrinolytic drugs may attenuate the symptoms but do not address the loss of 
cardiomyocytes (Sutton & Sharpe, 2000). Surgical interventions such as balloon 
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angioplasty and coronary stents also fail in this regard. Currently, the only treatment 
that restores lost cardiomyocytes is a heart transplant. Aside from the potential risk of 
organ rejection, this treatment is not a viable option on a large scale. In 2015 the World 
Health Organization reported over 17 million deaths worldwide were attributed to 
CVDs with the majority being due to MI, therefore, there is an immediate need for an 
alternative treatment with global availability.  
1.2 Cell therapy 
Experimental and clinical studies continue to focus on alternative therapies to address 
cardiomyocyte regeneration including stimulating the proliferation of existing 
cardiomyocytes, although terminally differentiated cardiomyocytes are resistant to cell 
cycle re-entry, and cell therapy. Cell therapy is the introduction of cells into the 
damaged myocardium, directly or indirectly, that are either not terminally differentiated 
or differentiated into cardiomyocytes in vitro. The former, known as stem cells, can 
differentiate into more mature cell types while maintaining the ability to undergo self-
renewal. The differentiation capacity of stem cells varies depending on the source and 
potency of the cells. Several sources of multipotent stem cells for cardiac repair have 
been evaluated in preclinical and clinical settings and select studies are summarised 
in table 1.0 and 1.1 respectively.  Preclinical and clinical trials have demonstrated that 
bone marrow mononuclear cells and mesenchymal cells are safe for cardiac cell 
therapy whereas skeletal myoblasts, although promising in preclinical studies with an 
increase in LVEF, result in higher incidences of arrhythmia in clinical trials. Amongst 
all cell types, bone marrow derived stem cells represent the greatest number 
evaluated in clinical trials. A meta-analysis of 50 publications including 2500 patients 
collectively concluded that although there is a moderate ~4% increase in LVEF, 
patients that have received cell therapy had lower mortality, reoccurrence of MI, and 
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rehospitalization for heart failure (Zimmet et al., 2012; Jeevanantham et al., 2012). A 
limited number of clinical trials have evaluated cardiac stem cells but a meta-analysis 
of 80 preclinical publications including over 1950 animals collectively by Zwetsloot et 
al. (2016) concluded that LVEF increased by ~12% and ~5% in small and large 
animals respectively compared to placebo groups. The effects of cell therapy for 
cardiac regeneration have been modest but a fair comparison between trials, both 
preclinical and clinical, is challenging due to the variation in cell isolation, delivery, 
dose, and patient cohort but it is evident that the beneficial outcomes of cell therapy 
may be due to paracrine effects rather than direct tissue regeneration.
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Table 1.0. Preclinical studies of cell therapy for cardiac regeneration   
↓ decreased, ↑ increased, ↔ no change, + observed, - not observed, CD – Cardiac Differentiation, LV – Left 
Ventricular, LVEF – Left ventricular ejection fraction, LVFS – Left ventricular fractional shortening. Amended from Bolli 
et al., 2013.  
Cell type Study Host Dose/Route Follow up Outcome 
Skeletal 
Myoblasts 
Suzuki et al. 
(2001) 
Rat 1x106 cells 
Intracoronary 
4 weeks ↓Mortality 
Chachques et al. 
(2004b) 
Sheep 70x106 cells  
Intramyocardial 
3 months ↑LVEF  
↓LV remodelling 
He et al. 
(2005) 
Dog 270-830x106 cells 
Intramyocardial 
10 weeks  ↑LVEF  
↓LV remodelling 
Farahmand et al. 
(2008) 
Rat 5x106 cells 
Intramyocardial  
30 days ↑LVFS  
↓LV remodelling 
Bone Marrow 
Stem Cells 
Tomita et al.  
(1999) 
Rat 1x106 cells 
Intramyocardial 
3 weeks ↓LV remodelling  
↑Angiogenesis  
CD+ 
Bel et al. 
(2003) 
Sheep 422 x106 cells 
Intramyocardial 
2 months ↔LVEF 
↔LV remodelling  
CD- 
Waksman et al. 
(2004) 
Pig 24 x106 cells 
Intramyocardial 
4 weeks ↓Infarct size  
↑Angiogenesis  
Mesenchymal 
Cells 
Nagaya et al. 
(2005) 
Rat 5x106 cells 
Intramyocardial 
4 weeks  ↑Angiogenesis  
↓Fibrosis  
CD+ 
Silva et al. 
(2005) 
Dog 100x106 cells 
Intramyocardial 
30 days ↑LVEF  
Neovascularization+ 
Liu et al. 
(2008) 
Rat 1x106 cells 
Intramyocardial 
4 weeks ↓Infarct size  
↓LV remodelling  
↑LVEF 
↓Fibrosis  
↑Angiogenesis  
CD+ 
Mazo et al. 
(2008) 
Rat 1x106 cells 
Intramyocardial 
3 months ↓Infarct size  
↑LVEF  
↓Fibrosis 
Neovascularization+ 
Li et al.  
(2009) 
Rat 3x106 cells 
Intramyocardial 
4 weeks  ↑LVEF  
↓Fibrosis 
Schuler et al. 
(2009) 
Pig 200x106 cells 
Intramyocardial 
24 weeks ↑LVEF  
↓Infarct size 
Mazo et al. 
(2010) 
Rat 1x106 cells 
Intramyocardial 
4 weeks ↑LVEF  
↓Fibrosis  
↑Angiogenesis 
Cardiac Stem 
Cells 
Rota et al. 
(2008) 
(cKit+ cells) 
Rat 4x104 cells 
Intramyocardial 
2 weeks ↑LVEF  
↓Fibrosis  
↓LV remodelling 
Cardiac regeneration+ 
Johnston et al. 
(2009) 
 
Pig 10x106 cells 
Intracoronary 
 
8 weeks ↓Infarct size   
↓LV remodelling 
Cardiac regeneration+ 
Tang et al. 
(2010) 
(cKit+ cells) 
Rat 4x104 cells 
Intracoronary 
35 days ↑LVEF 
↓Fibrosis  
↓LV remodelling 
Cardiac regeneration+ 
Lee et al. 
(2011) 
(cardiospheres) 
Pig 1x106 cells 
Intracoronary 
8 weeks ↑LVEF  
↓LV remodelling 
Bolli et al. 
(2013)  
(cKit+ cells) 
Pig 5x105 cells  
Intracoronary  
31 days ↑LVEF  
↓Fibrosis 
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Table 1.1.  Clinical studies of cell therapy for cardiac regeneration 
↓ decreased, ↑ increased, ↔ no change, LVEF – Left ventricular ejection fraction, LVESV – Left 
ventricular end systolic volume, LVEDV – Left ventricular end diastolic volume. Amended from Cahill, 
Choudhury, and Riley (2017) and Hao, Wang, and Wang (2017). 
Cell type Name Patients Follow up Dose/Route Outcome 
Skeletal 
Myoblasts 
Menasche et al. 
(2001) 
1 5 months 800x106 cells 
Intramyocardial 
during CABG 
↑Wall motion 
and perfusion 
on PET 
MAGIC 97 6 months 400-800x106 cells 
Surgical injection 
during CABG 
↔LVEF 
↓LVESV 
↓LVEDV 
↑Arrhythmia  
 SEISMIC 40 6 months 150-800x106 cells 
Intramyocardial 
↔LVEF 
↑Arrhythmia 
 CAUSMIC 23 12 months 3-600x106 cells 
Intramyocardial 
↑LVEF 
↑Arrhythmia 
Bone Marrow 
Mononuclear 
Stem cells 
BOOST 60 60 months 24.6x108 cells 
Intracoronary 
↑LVESV 
↑LVEDV 
ASTAMI 100 36 months 80x106 cells 
Intracoronary 
↔LVEF 
↔infarct size 
REPAIR-AMI 204 24 months 200x106 cells 
Intracoronary 
↑LVEF 
↓LVESV 
TOPCARE-AMI 59 60 months 5.5x106 cells 
Intracoronary 
↑LVEF 
↓LVESV 
↓LVEDV 
SWISS-AMI 200 12 months 140-160x106 cells 
Intracoronary 
↔LVEF 
↓infarct size 
↓LVESV 
↓LVEDV 
REGENERATE-
AMI 
100 12 months 59.8x106 cells 
Intracoronary 
↑LVEF 
↓infarct size 
Mesenchymal 
Stem Cells 
Prochymal 60 12 months 30-300x106 cells 
Intravenous 
infusion 
↑LVEF 
POSEIDON 31 13 months 20-200x106 cells 
Intramyocardial 
↑LVEF 
↓infarct size 
PROMETHEUS 9 18 months 20-200x106 cells 
Intramyocardial 
↑LVEF 
↓infarct size 
PRECISE 27 18 months 42 x106 cells 
Intramyocardial 
↔LVEF 
↓infarct size 
Cardiac 
Stem Cells 
CADUCEUS 25 12 months 12.5-25x106 cells 
Intracoronary 
↔LVEF 
↔LVESV 
↔LVEDV 
↓infarct size 
SCIPIO 23 12 months 1x106 cells 
Intracoronary 
↑LVEF 
↓infarct size 
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1.2.1 Multipotent stem cells  
The organ or tissue in which multipotent stem cells reside influences both their 
differentiation capacity; limited to maturing into cell types of that organ or tissue, and 
the rate of self-renewal. Several sources of multipotent stem cells for cardiac repair 
have been evaluated in clinical trials but with limited success. Aside from identifying 
the most appropriate cell type, dose, and method of transplantation, the other hurdles 
to be addressed include the poor survival of transplanted cells and further 
differentiation and integration into the myocardium with proper electrophysiological 
coupling.  
1.2.1.1 Skeletal myoblasts 
The use of multipotent stem cells as a means of reversing the damage ensued by MI 
was triggered by studies using a murine model demonstrating that skeletal myoblasts 
(SMs) engrafted the heart (Koh et al., 1993) and promoted cardiac repair (Taylor et 
al., 1998). SMs differentiate in response to muscle injury and show resistance to 
ischaemia (Chachques et al., 2004a). The ease of in vitro expansion and autologous 
availability translated quickly into clinical trials (Menasche et al., 2001) after success 
was achieved in both small and large animal models (Farahmand et al., 2008; He et 
al., 2005; Pouly et al., 2004). However, trans-differentiation into cardiomyocytes or 
integration into the myocardium has not been seen (Menasche et al., 2008; Reinecke 
et al., 2002). Furthermore, compound procedures including coronary artery bypass 
grafting make it difficult to distinguish between effects of revascularization and cell 
treatment. Higher incidence of arrhythmia is also documented that may be caused by 
the myofibers derived from the transplanted SMs failing to electromechanically couple 
with the host myocytes posing a challenge for using this cell source for therapeutic 
purposes (Menasche et al., 2003; Pagani et al., 2003).   
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1.2.1.2 Bone marrow  
In the late 1990's, investigators demonstrated reasonable repair, involving migration 
and differentiation of stem cells, after injury in muscle, the liver, and the brain. Orlic et 
al. (2001a, 2001b) found that direct transplantation of autologous bone marrow (BM) 
into the damaged myocardium of mice displayed the same repair. Numerous clinical 
trials have now evaluated BM mononuclear cells for cardiac myopathy with different 
cell dose, delivery route, follow up interval, and the number of patients. Evidence of 
BM stem cell plasticity in vivo (Assmus et al., 2002; Perin et al., 2003; Tse et al., 2003) 
is lacking, and only a handful of clinical trials have provided long-term results. The 
ASTAMI (Beitnes et al., 2009; Beitnes et al., 2011; Lunde et al., 2006), BOOST (Meyer 
et al., 2006; Wollert et al., 2004), and REPAIR-AMI (Assmus et al., 2010) trials showed 
little to no improvement after 3-5 years although the latter reported reduction in infarct 
size and increased wall thickening of the infarcted region at a 2 year follow up. Of the 
several dozen trials, none have shown significant improvement in all the outcomes 
assessed (reduction in infarct size, change in LVESV and LVEDV, and improved 
LVEF) (Jeevanantham et al., 2012). However, no major adverse events were reported 
showcasing the safety of this treatment (Sanganalmath & Bolli, 2013).  
1.2.1.3 Mesenchymal stem cells  
In the 1950's, it was revealed that bone marrow had two residing cell populations, 
namely hematopoietic and mesenchymal, responsible for the formation of all blood 
cells, and bone, cartilage, and fat cells respectively. Adipose tissue is another source 
of mesenchymal stem cells and are easily obtained through minimally invasive 
procedures such as liposuction (Lindroos, Suuronen, & Miettinen, 2011). 
Mesenchymal stem cells differentiate into multiple cell types including cardiomyocytes 
(Planat-Benard et al., 2004; Toma et al., 2002). The effects of mesenchymal stem 
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cells, isolated from both the bone marrow and adipose tissue, have been evaluated in 
several clinical trials (Hare et al.,2009; Hare et al., 2012; Karantalis et al., 2014) after 
observing improvement in cardiac function in animal models (Liu et al., 2008; Mazo et 
al., 2008; Mazo et al., 2010; Schuleri et al., 2009). The PRECISE trial has shown 
modest effects with adipose derived cells (Perin et al., 2014). However, the emerging 
consensus is that the therapeutic effect achieved by these cells may be due to 
paracrine effects and their ability to evade the immune system (Aggarwal & Pittenger, 
2005).  
1.2.1.4 Cardiac stem cells  
The mammalian heart, earlier thought to be a post-mitotic organ composed of 
terminally differentiated cardiomyocytes, has recently shown a little intrinsic rate of cell 
turnover (Ali et al., 2014; Kajstura et al., 2010; Senyo et al., 2013). Bergmann et al. 
(2009) elucidated with carbon dating that over an average human lifespan half the 
cardiomyocyte population is replaced with approximately 1% turnover per year in the 
early 20's to less than 0.5% turnover per year by the age of 75. Beltrami et al. (2001) 
also suggested that limited cell division occurred in ischaemic hearts. Debate exists 
over the attribution to this turnover by the proliferation of existing cardiomyocytes or 
by the differentiation of a progenitor population. A minuscule progenitor cell population 
within the heart exists (Chong, Forte, & Harvey, 2014) and cells capable of 
differentiating into cardiomyocytes have been isolated from myocardial biopsies 
(Smith et al., 2007). Reported populations include c-Kit+ (Beltrami et al., 2003), side 
populations (Martin et al., 2004), cardiosphere derived cells (Messina et al., 2004), 
and Sca1+ (Oh et al., 2003), however, no Sca1+ homolog in humans has been 
described. Cardiospheres form because of free-floating cardiac progenitor cell 
aggregation and express c-kit in the inner cells although in limited numbers. 
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Improvement of heart function in animal models in respect to MI has been documented 
with treatment of cells derived from cardiospheres. However, the CADUCEUS trial 
(Makkar et al., 2012) evaluating the use of cardiosphere derived cells demonstrated 
improvement in regional function only (Malliaras et al., 2014). The SCIPIO trial (Bolli 
et al., 2011) showed promise with an increase in LVEF using c-kit+ cells however the 
authenticity of cardiac progenitor cell identity is under debate (Sultana et al., 2015). 
1.2.2 Pluripotent stem cells  
Pluripotent stem cells (PSCs) have the greatest differentiation potential, forming 
mature cell types derived from all three germ layers, and although pluripotency in vivo 
is a transient developmental stage, it can be captured or induced in vitro in defined 
growth conditions. PSCs can be propagated in culture for long periods, however, 
cannot be used in cell therapy without prior differentiation into specific cell types. 
Inadequate differentiation risks teratoma formation after treatment and this has been 
one of the greatest challenges facing the use of PSCs in cardiac repair. Additionally, 
guided in vitro differentiation of PSCs towards a specific cell fate through the 
manipulation of the growth conditions has highlighted the differences in PSC 
characteristics and the culture conditions required to maintain pluripotency amongst 
species and the source of cells. A brief review of these differences is offered in table 
1.2.
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Table 1.2. Pluripotent stem cell characteristics 
  mECCs mESCs miPSCs mEpiScs hESCs hiPSCs 
Origin  Teratoma ICM Somatic Late Epiblast ICM Somatic 
Teratoma formation YES YES YES YES YES YES 
Chimera/germ line 
contribution 
YES YES YES NO ND ND 
Culture Conditions  LIF, FBS LIF, BMP4 LIF FGF2, A FGF2, A, MEF CM FGF2, A, MEF CM 
Morphology  Domed Domed Domed Flat Flat Flat 
Pluripotency state Naïve Naïve Naïve Primed ND ND 
Pluripotency 
Factors 
O-S-N-K O-S-N-K O-S-N-K O-S-N O-S-N O-S-N 
Response to LIF SR-P SR-P SR-P None None None 
Response to FGF2 D D D SR-P SR-P SR-P 
Response to BMP SR-P SR-P SR-P D D D 
Response to 2i SR-P SR-P SR-P D and CD D and CD D and CD 
SSEA 1 1 1  3 and 4 3 and 4 
2i - 2 inhibitor system, A – Activin, BMP - bone morphogenic protein, CD - cell death, D - Differentiation, FBS - foetal bovine serum, 
FGF - fibroblast growth factor, ICM - inner cell mass, K - Klf, LIF - leukaemia inhibitory factor, mECCs - mouse embryonic carcinoma 
cells, MEF CM - mouse embryonic fibroblast conditioned medium, m/hESCS - mouse/human embryonic stem cells, mEpiSCs - mouse 
epiblast stem cells, m/hiPSCs - mouse/human induced pluripotent stem cells, N - Nanog, ND - not determined, O - Oct4, P - 
Pluripotency, S - Sox2, SR - self renewal. Amended from Bieberich and Wang, 2013.
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1.2.2.1 Sources of pluripotent stem cells  
The establishment of pluripotent cells in culture was propelled by researchers 
exploring teratocarcinoma. In the 1960's, Kleinsmith and Pierce, demonstrated cells 
derived from a teratocarcinoma tumour, and ectopically transplanted, gave rise to 
specialized cells representative of the three germ layers. The cells were termed as 
embryonal carcinoma cells (ECCs) and exhibited in vitro characteristics that now 
define stem cells: the potential to self-renew without undergoing senescence and to 
mature into multiple cell types. Chimera formation resulted from the incorporation of 
these cells into a blastocyst. Additional findings showing the similarities between the 
early differentiation of cultured ECCs and the in vivo inner cell mass (ICM) led to the 
isolation of cells from the ICM of a pre-implantation blastocyst without an intermediate 
teratocarcinoma stage and termed embryonic stem cells (ESCs) (Evans & Kaufman, 
1981; Martin, 1981). Maintaining the pluripotency of these cells in vitro required the 
addition of leukaemia inhibitory factor (LIF) to the culture medium. Cells from mouse 
epiblast post-implantation (mEpiSCs) have also been isolated with naïve and primed 
pluripotency states displayed by mESCs and mEpiSCs respectively (Nicholas & Smith, 
2009).  
Human pluripotent stem cells were derived by Thomson and colleagues in 1998. The 
ethical concern stemming from the origin of these cells was by-passed with the advent 
of the induced pluripotent stem cell (iPSC) technology. In 2006, Takahashi and 
Yamanaka, successfully reverted terminally differentiated mouse fibroblasts into a 
pluripotent state using four pluripotent genes; Oct4, Sox2, c-Myc, and Klf4. A year later 
the same was accomplished in human fibroblasts (Takahashi et al., 2007). Concern 
over the use of c-Myc and viral vectors in inducing pluripotency in somatic cells have 
since pushed researchers to create other combinations of genes, such as Oct3/4, 
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SOX2, Lin28, and Nanog (Yu et al., 2007), and non- integrating methods using 
episomal DNAs (Okita et al., 2011; Yu et al., 2009), synthetic mRNAs (Warren et al., 
2010), and Sendai virus (Fusaki et al., 2009) amongst others (Jia et al., 2010; Kim et 
al., 2009; Lin et al., 2008; Miyoshi et al., 2011; Stadtfeld et al.,2008; Woltjen et al., 
2009) to generate iPSCs.  
1.3 Signal transduction  
A cells decision to proliferate, migrate, differentiate, or undergo cell death, is 
dependent on the cues provided by the environment including neighbouring cells, 
hormones, growth factors, and physiological and chemical stress. Extracellular signals 
are transmitted into the cell most often via cell surface receptors and intracellular 
signalling pathways carry the message into the nucleus to alter gene expression 
through the regulation of transcription factors.  
1.3.1 Transcription factors  
Gene expression is regulated by the binding of transcription factors to regulatory 
regions in DNA, in enhancing or silencing regions, to activate or repress activity. This 
is a highly regulated process and frequently requires the binding of multiple activator 
or repressor transcription factors in a specific order or number. There are several 
families of transcription factors including helix-turn-helix, zinc finger, helix-loop-helix, 
basic protein-leucine zipper, and β-sheet motifs. Dimerization, phosphorylation, and 
ubiquitination are some of the regulatory mechanisms that allow versatility in 
transcription factor activity which is furthered by cooperation with other transcription 
factors and co-activators. Transcription factors can be ubiquitously expressed or 
confined to specific tissues and cell types. Transcription factors specific to in vivo 
mesoderm and cardiac development have been identified and are frequently used as 
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markers to assess in vitro cardiac differentiation. One of the most extensively studied 
is the GATA family of transcription factors which are members of the zinc finger family 
and divided into two subfamilies; GATA1-3 regulate hematopoietic stem cells and 
GATA4-6 regulate endoderm and mesoderm development (Arceci et al., 1993; Kelley 
et al., 1993; Laverriere et al., 1994; Molkentin et al., 2000; Morrisey et al., 1996; 
Morrisey et al., 1997; Suzuki et al., 1996). Of the six GATA members, GATA4 is a 
critical regulator of cardio-myogenesis and is one of the earliest expressed 
transcription factors in cardiac progenitor cells. The diversity of cardiac genes 
regulated by GATA4 includes cardiac troponin I and C (Bhavsar et al., 2000; Di Lisi et 
al., 1998; Ip et al., 1994; Murphy et al., 1997), myosin heavy chain (Molkentin, 
Kalvakolanu, & Markhan, 1994), myosin light chain (McGrew et al., 1996), and atrial 
natriuretic factor (Grepin et al., 1994) amongst others (Cheng et al., 1999; Nicholas & 
Philipson, 1999; Rivkees et al., 1999). Regulation by GATA4 and differentiation of 
cardiac progenitor cells occurs through the interaction of several other transcription 
factor families including myocyte enhancer factor 2 (MEF2), NK2 transcription factor 
related locus 5 (NKX2.5), T-box (Tbx), and heart and neural crest derivatives (Hand) 
(Dodou et al., 2004; Garg et al., 2003; Lien et al., 1999; Maitra et al., 2008; Searcy et 
al., 1998; Zeisberg et al., 2005). Other co-factors include ubiquitous transcription 
factors such as activator protein 1 (AP-1).  
AP-1 consists of dimers formed by members of the Jun and Fos protein families (Angel 
& Karin, 1991; Vogt & Bos, 1990). The Jun family includes c-Jun, JunB, and JunD and 
the Fos family includes c-Fos, FosB, and Fos-related antigen 1/2 (Fra1/2). The dimer 
composition of these families dictates which genes are regulated (Hai & Curran, 1991; 
Kouzarides & Ziff, 1988; Smeal et al., 1989). The complete upstream regulatory 
network of these transcription factors is currently unknown however many intracellular 
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transduction pathways have been evaluated and implicated in both in vivo and in vitro 
cardiac differentiation models including the mitogen-activated protein kinases 
(MAPKs), protein kinase C (PKC), phosphoinositide 3-kinase (PI3K), and SMAD 
(Pandur, 2005; Rose, Force, & Wang, 2010).  
1.3.2 Intracellular signalling kinases  
1.3.2.1 MAPK 
Mitogen-activated protein kinase (MAPK) catalytic activity relies on the 
phosphorylation of their activation loop and forms a three-tier kinase cascade involving 
the sequential activation of MAPK kinase kinase (MAPKKK), MAPK kinase (MAPKK) 
and MAPKs. MAPKKKs are Ser/Thr kinases frequently activated through interaction 
with small G proteins such as Ras/Rho. MAPKKKs including TAK1, ASK1, TAO, 
MLK2, Raf, and DLK, act on specific MAPKKs. Activation of a specific MEK further 
phosphorylates and activates a MAPK subfamily through dual phosphorylation on Thr 
and Try residues within a conserved Thr-X-Tyr motif. MAPKs are subdivided into three 
kinase subfamilies: extracellular signal-regulated kinases (ERK), p38, and c-jun N-
terminal kinases (JNK).  
ERK, divided into ERK1/2 and ERK 3-5, was the first of the mammalian MAPKs to be 
characterized. ERK can be activated by multiple stimuli including growth factors, lipids, 
cytokines, and osmotic stress through the Ras/Raf pathway acting on MEK1-2 
(Cooper et al., 1982; Kazlauskas & Cooper, 1988; Raman, Chen, & Cobb, 2007; Ray 
& Sturgill, 1988; Shaul & Seger, 2007). The p38 MAPK has four isoforms; α, β, γ, and 
δ (Cuadrado & Nebreda, 2010; Han et al., 1994; Lee et al., 1994; Rouse et al., 1994). 
The α and β isoforms are more ubiquitously expressed with α expression being higher 
between the two (Jiang et al., 1996). The p38 subfamily is more responsive to stress 
stimuli and inflammatory cytokines including hypoxia and ischaemia and can be 
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activated by the recruitment of TRAF by tumour necrosis factor alpha and interleukin 
1 or by small G proteins Rac/Cdc42 (Bagrodia et al., 1995; Bradley & Pober, 2001; 
Goldsmith & Dhanasekaran, 2007). Both pathways act on MAPKKKs that further 
stimulates MKK3 and 6. The former shows more selectivity in p38 isoform activation 
whereas MKK6 activates all isoforms (Derijard et al., 1995; Han et al., 1996; Stein et 
al., 1996). There are three JNK genes with ten splice variations; JNK1 has splice 
variations of JNK1α1/2 and JNK1β1/2, JNK2 has spice variations of JNK2α1/2 and 
JNK2β1/2, and JNK3 has splice variations of JNK3α1/2 (Derijard et al., 1994; Gupta 
et al., 1996; Kyriakis et al., 1994). JNK1 and 2 are ubiquitously expressed whereas 
JNK3 is more restricted but is expressed in myocytes (Bode & Dong, 2007). As 
reviewed by Bogoyevitch et al. (2010) the JNKs can be activated by a plethora of 
stimuli including cellular stresses such as oxidative stress, DNA and protein synthesis 
inhibitors, heat shock, and UV irradiation and by growth factors, serum, and GPCR 
ligands. MAPKKs, MKK4 and 7, activate the JNKs (Lawler et al., 1998). The MAPKs 
regulate a vast number of substrates independently while other targets are mutually 
regulated such as AP-1 or MAPK activated protein kinases (MAPKAPKs); MK2/3 and 
5, MNKs, MSKs, and RSKs (Arthur, 2008; Buxade, Parra-Palau & Proud, 2008; 
Carriere et al., 2008; Gaestel, 2008; Perander, Keyse, & Seternes, 2008; Ronkina, 
Kotlyarov, & Gaestel, 2008; Roux & Blenis, 2004). 
1.3.2.2 PI3K 
PI3K is sub-divided into three classes: class I PI3Ks, (further divided into IA and IB), 
are heterodimers of regulatory (p85, p55, or p101) and catalytic subunits (p110α, β, δ, 
and γ) as is the class III Vsp34 enzyme. Class II are monomeric proteins without 
adapter subunits (PI3K-C2α/β/γ). PI3Ks are activated by both receptor tyrosine 
kinases (IA) and GPCRs (IB) along with Ras and generate phosphatidylinositol (3,4,5)-
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triphosphate (PIP3) through the phosphorylation of phosphoinositide (PI) (Aoyagi & 
Matsui, 2011; Crackower et al., 2002; Maehama & Dixon, 1998).  
1.3.2.3 PKC 
Protein kinase C (PKC) consists of three subfamilies and several isozymes: classical 
PKCs consist of α, β1/2, and γ isozymes. Novel PKCs include μ, δ, ε, η, and θ 
isozymes and atypical PKCs are formed of ζ, ι, and λ isozymes (Musashi, Ota, & 
Shiroshita, 2000; Newton, 2003; Nishizuka, 1995). Classic isozymes contain domains 
for both DAG and anionic lipid binding in a calcium-dependent manner with a strong 
preference for PIP2. Novel isozymes are not sensitive to calcium and bind DAG with 
higher affinity than classic isozymes (Giorgione et al., 2006; Nalefski & Newton, 2001). 
Atypical isozymes differ in the sense that their function is controlled by protein-protein 
interactions and not DAG, calcium, or phorbol esters.  
1.3.3 Extracellular Targets 
Intracellular signalling pathways, highlighted above, are typically initiated by the 
binding of a ligand to a cell surface receptor. Several classes of receptors are known 
to exist on a cells surface, with some, such as the ligand-gated ion channel receptors, 
limited to specific cell types, or present in most cells, such as the G-protein coupled 
receptors and tyrosine kinase receptors. Cooper (2000) has discussed the major 
classes of cell surface receptors which are summarised below.  
1.3.3.1 Cell surface receptors 
G-protein coupled receptors (GPCRs) are formed of a single polypeptide containing 
seven regions, three intracellular loops, and three extracellular loops. The N-terminus 
contains glycosylation sites located on the extracellular side, and the C-terminus 
contains sites for phosphorylation located on the intracellular side. Conformational 
changes occur after a ligand is bound on the extracellular side, mediating events 
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through both heterotrimeric guanine nucleotide binding proteins (G proteins) and non-
G proteins. The activation of heterotrimeric G proteins causes the dissociation from 
the receptor and its subunits (α and βγ). The α subunit and the βγ complex then 
individually interact with specific intracellular targets. Several hundred GPCRs have 
been identified and different Gα-proteins, such as Gαi, GαS, Gα12/13, and Gαq, associate 
with different receptors.  Several enzyme-coupled receptors are also found on the cell 
surface including receptor protein tyrosine kinases. These receptors are formed of a 
single transmembrane α helix with both an extracellular and intracellular domain for 
ligand binding and with protein-tyrosine kinase (PTK) activity respectively. Upon ligand 
binding, dimerization and autophosphorylation of the receptor occurs. Recruitment of 
specific enzymes to the membrane by protein domains that bind specifically to 
phospho-tyrosine containing peptides such as SH2 domains in turn recruit and activate 
further proteins. A group of receptors also phosphorylate other residues for instance 
serine/threonine instead of tyrosine in their substrate enzymes. Ligand binding to 
these receptors leads to the hetero-dimerization of two distinct polypeptide chains that 
cross-phosphorylate one another. Cytokine receptors function similarly but do not 
possess an intracellular domain with catalytic activity. Dimerization of these receptors 
upon ligand binding phosphorylates non-receptor protein-tyrosine kinases which in 
turn phosphorylate the receptor.  
1.3.3.2 Ligands 
Growth factors (GFs) are secreted peptides that control cellular responses through 
specific binding of transmembrane receptors triggering intracellular secondary 
messengers. Groups of GFs are evolutionary conserved and can be divided into 
families and super-families based on amino acid sequence similarity and shared 
structural folds respectively.  
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Fibroblast growth factors 
Members of the fibroblast growth factor (FGF) family regulate various cellular 
responses including growth and cell survival by binding to four tyrosine kinase FGF 
receptors (FGFRs) which have been extensively reviewed by Ornitz and Itoh (2015). 
FGFs are found in nearly all tissues and function in tissue maintenance and repair in 
the adult and are vital in early embryonic development. Currently, seven subfamilies 
of secreted FGFs are known. The endocrine FGF15/19 subfamily is comprised of 
FGF15/19, 21 and 23. The intracellular FGF11 subfamily is comprised of FGF11-14. 
The remaining five subfamilies are paracrine FGFs: the FGF1 subfamily is comprised 
of FGF1 and 2, the FGF4 subfamily is comprised of FGF4-6, the FGF7 subfamily is 
comprised of FGF3, 7, 10, and 22, the FGF8 subfamily is comprised of FGF 8, 17-18, 
and the FGF9 subfamily is comprised of FGF9, 16 and 20. 
Activation of FGFRs by the binding of a specific FGF triggers the phosphorylation of 
adaptor proteins such as FGFR substrate 2α (FRS2α) initiating the activation of 
intracellular signalling pathways. The growth factor receptor-bound 2 (GRB2) 
membrane anchored adaptor protein is bound by active FRS2α and further recruits 
either SOS or GAB1. Recruitment of SOS to the plasma membrane by GRB2 activates 
the G protein Ras leading to the activation of the three-tiered MAPK cascade. 
Recruitment of GAB1 leads to the activation of PI3K and phosphorylation of PI in the 
plasma membrane. The synthesis of PIP3 causes the translocation of AKT to the 
plasma membrane where it is phosphorylated by PKD1. AKT regulates both proteins 
and transcription factors such as GSK3 and FoxO respectively. The FGFR1 requires 
the phosphorylation of six tyrosine residues to activate the RAS-MAPK and PI3K-AKT 
pathways and the phosphorylation of a further two residues to activate the PLCγ and 
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STAT pathways. Activated PLCγ leads to the production of IP3 and DAG which 
increase intracellular calcium and activate PKC respectively.  
Transforming Growth Factor-β superfamily   
Over forty members of the transforming growth factor-β superfamily (TGF-β) are 
known and regulate a variety of cellular responses including development, apoptosis, 
and inflammation (Beyer et al., 2013). Bone morphogenetic proteins (BMPs), Nodal, 
and Activin are some of the subfamilies of the TGF-β superfamily. Ligands of this 
family can form both homo- or heterodimers and activate receptors with 
serine/threonine activity. TGF-β receptors are divided into type I and type II receptors 
with the type I receptor being phosphorylated by the type II receptor prompting 
activation of Smad proteins (Smad1-8). Smad 1-5, and 8 translocate into the nucleus 
whereas Smad 6 and 7 are inhibitory proteins. Non-Smad signalling pathways are also 
activated by ligand bound TGF-β receptors including RAS-MAPK, PI3K-AKT, and TAK 
(de Caestecker, 2004). 
As reviewed by Bragdon et al. (2011) the largest subgroup of the TGF-β superfamily 
are the BMPs with over twenty members and further subdivided into four groups: 
BMP2/4, BMP5-8, BMP9-10, and BMP12-14. Eight BMP receptors have been 
identified: five type I, ALK1 (Acvrl1), ALK2 (ActRI), ALK3 (BRIa), ALK4 (ActRIb) and 
ALK6 (BRIb), and three type II receptors, BRII, ActRIIa, and ActRIIb. BMPs regulate 
cell survival, migration, and differentiation and activate several Smad independent 
pathways such as the MAPK pathway and the transcription factor NF-κB through the 
activation of the BRIa complexes along with other pathways including PKA/C/D and 
PI3K through the activation of other complexes.  
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Wnt – Secreted signalling proteins  
Approximately 20 mammalian Wnt proteins are currently known that regulate cell 
survival, migration, proliferation, and cell fate through the binding and activation of 
Frizzled receptors. The transduction of Wnt signals is mediated by canonical and non-
canonical pathways. Canonical Wnt pathways are activated by Wnt1, 2, 3A, 8A/B/C, 
and 10A/B whereas non-canonical Wnt pathways are activated by Wnt 4, 5A/B, 6, 
7A/B and 11 (Parikh et al., 2015). Canonical Wnt signalling results in the stabilization 
and accumulation of β-catenin in the nucleus by the inactivation of the multiprotein 
complex composed of APC, Axin, and GSK3β mediated by dishevelled (Dvl) proteins. 
Dvl proteins, when activated by the binding of non-canonical Wnt members to Frizzled 
receptors, activate RhoA and Rac resulting in the activation of downstream ROCK and 
JNK that modulate the activity of transcription factors such as ATF. Non-canonical Wnt 
signalling is β-catenin independent and is also mediated via the activation of G 
proteins resulting in the increase of calcium, in turn, activating calcium-dependent PKC 
(Komiya & Habas, 2008).  
1.3.4 In vivo signalling associated with cardiomyocyte production   
Proper development of the heart requires the induction of mesoderm formation and 
specification into cardiac mesoderm with a sophisticated program of migration, 
proliferation, and further differentiation of four distinct progenitors; the first heart field, 
the second heart field, the proepicardial organ, and the cardiac neural crest. The 
spatiotemporal activity of the extracellular signalling families discussed above 
regulates these processes. 
Wnt3a, BMP4, and Nodal gradients established in the epiblast are critical for 
mesendoderm patterning and lineage specification. Early decisions between 
mesoderm, neuroectoderm, and extra-embryonic fates are affected by BMP signalling 
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(Parikh et al., 2015) whereas canonical Wnt signalling is crucial in the formation of the 
anterior/posterior axis, primitive streak and node, and mesoderm (Huelsken et al., 
2000; Liu et al., 1999). Nodal signalling is involved in the formation of the anterior 
mesoderm and endoderm (Beck et al., 2002; Shen, 2007).  
During gastrulation, the T-box Brachyury, initially expressed in the mesoderm, node, 
notochordal plate, and notochord, undergoes upregulation by canonical Wnt and 
further synergy with BMP and FGF8 signalling promote a mesodermal fate (Evans et 
al., 2012; Paige et al., 2015; Parikh et al., 2015; Schultheiss, Burch, & Lassar, 1997).  
Canonical Wnt inhibitors, DKK1 and Crescent, are secreted by the adjacent endoderm 
whereas BMP antagonists, Noggin and Chordin, are emitted by the notochord to 
further mesoderm specification (Kwon et al., 2007; Marvin et al., 2001; Pandur et al., 
2002; Schneider & Mercola, 2001; Tzahor & Lasser, 2001). As the cells migrate 
through the primitive streak, Brachyury is downregulated, and the upregulation of T-
box Eomes activates MESP1 (Costello et al., 2011; David et al., 2011; van den Ameele 
et al. 2012). MESP1 expressing cardiac progenitors arising from the anterior lateral 
mesoderm migrate to the cranial and cranio-lateral regions of the embryo forming the 
first heart field (FHF). The fusion of bilateral FHFs forms the cardiac crescent, the first 
morphological sign of heart development (Harvey, 2002). The earliest known cardiac-
specific transcription factors expressed in the cardiac crescent include members of the 
Gata, Nkx, MEF2, Hand, and Tbx families. MESP1 is partly responsible for the 
activation of GATA4/6, Tbx20, Hand2, and Nkx2.5 (Bondue et al., 2008), while BMP 
also induces activation of GATA4, MEF2c, and Nkx2.5 (Klaus et al., 2012; Lien et al., 
2002) with cardiac neural crest cells later regulating FGF8 in the endoderm to further 
induce Nkx2.5 and MEF2 in cells exposed to BMP (Alsan & Schultheiss, 2002). Cells 
of the first heart field undergo rapid differentiation and proliferation forming the linear 
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heart tube and a gradient in Tbx5 is established, with higher levels observed 
posteriorly (Bruneau et al., 1999).  
Earlier belief was that all cardiomyocytes originated from the cardiac crescent until the 
discovery of a second source of cells in 2001, the pharyngeal mesoderm-derived 
second heart field (SHF) progenitors (Kelly, Brown, & Buckingham, 2001; Mjaatvedt 
et al., 2001; Waldo et al., 2001). Development of SHF progenitors has been linked to 
the suppression of canonical Wnt signalling by non-canonical Wnt5A and Wnt11 
(Cohen et al., 2012). The proliferation of both cell populations occurs, but the FHF 
cells differentiate quickly whereas a delay in differentiation occurs in cells of the SHF, 
which undergo differentiation as they contribute to the elongation of the heart tube at 
both the venous and atrial poles (Buckingham, Meilhac, & Zaffran, 2005; Paige et al., 
2015; Rochais, Mesbah, & Kelly, 2009). BMP signalling and inhibition of FGF may 
influence the switch from proliferating to differentiating cells (Hami et al., 2011; Hutson 
et al., 2010). The FHF contributes to the left ventricle and minimally to the atria while 
the anterior SHF adds to the right ventricle and outflow tract, and posterior SHF 
contributes to atria and inflow myocardium. Further proliferation and myocardial 
subpopulation specification with septation and valve development eventually form the 
four-chambered heart (Paige et al., 2015).   
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1.3.5 In vitro cardiomyocyte production 
The first pluripotent stem cell lines were established in culture over half a century ago 
with efficient differentiation of ECCs being dependent on the formation of three-
dimensional aggregates in suspension called embryoid bodies (EBs). Two commonly 
used protocols for initiating the formation of EBs include allowing a definite number of 
cells to self-aggregate in non-adherent dishes for a period (e.g. 4 days) before being 
transferred to cell culture grade dishes to grow in monolayers or cultured using the 
hanging drop method. The latter allows for better control of EB size as the EBs 
aggregate in a droplet of medium suspended from the lid of a culture dish for a short 
period (e.g. 2 days). The EBs are collected and further cultured in suspension for 
several days before being plated on gelatin-coated culture dishes (Burridge et al., 
2007; Doetschman et al., 1985; Ng et al., 2005).  
The use of an extensive variety of growth factors, small molecules, and organic 
chemicals during spontaneous EB formation has allowed several research groups to 
derive differentiated cardiomyocytes from PSCs with variable efficiency (Kawai et al., 
2004; Laflamme et al., 2007; McBurney et al., 1982; Ren et al., 2011; Tran et al., 2009; 
Ueno et al., 2007). Inhibiting DNA methylation, using 5-azacytidine (Choi et al., 2004; 
Yang et al., 2009), or using hormones, such as oxytocin (Fathi et al., 2009; Paquin et 
al., 2002), have also been shown to persuade cells to commit to a cardiac fate. 
Highlighted by developmental studies, the critical role of the anterior endoderm in the 
cardiac induction of the mesoderm in vivo was applied to in vitro differentiation by co-
culturing PSCs with visceral endoderm-like cells (END-2) (Mummery et al., 1991).  
Further dissection of the signal transduction mechanisms that regulate cardiac 
development in vivo has allowed researchers to mimic and modulate key factors to 
26 
 
further enhance in vitro cardiac differentiation (Kattman et al., 2011; Lian et al., 2012). 
The importance of Wnt signalling with timed activation and inhibition of canonical and 
non-canonical pathways in initiating cardiomyocyte differentiation (Gessert & Kuhl, 
2010; Tzahor, 2007) has been studied in both mouse and human ESCs. Temporal 
modulation of Wnt in which canonical signalling is initially enhanced and then 
suppressed results in high yields of cardiomyocytes from several hESCs lines (Lian et 
al., 2012; Mehta et al., 2014). Canonical Wnt signalling is required by both mECCs 
(Nakamura et al. 2003) and hESCs (Paige et al., 2010) to differentiate into 
cardiomyocytes whereas mESCs lack mesodermal precursors in which Wnt/β-catenin 
activity is suppressed by soluble DKK1 (Lindsley et al., 2006). Temporary addition of 
both BMP4 and Activin A also induce cardiac mesoderm formation in both mouse and 
human cell lines with greater cardiomyocyte differentiation achieved using additional 
factors including FGF2, VEGFA, and DKK1 in combination with the inhibition of Nodal 
or TGFβ-R2 (Kattman et al., 2011; Laflamme et al., 2007; Yang et al., 2008). The 
differentiation efficiency of human PSCs using the methods described above are 
summarised in table 1.3. In addition to deriving cardiomyocytes from stem cells, 
fibroblasts have also been reprogrammed into cardiomyocytes without an intermediate 
pluripotent stage. As reviewed by Chen and Qian (2015), several investigators have 
achieved this with varying efficiency using cardiac-specific transcription factors 
including a combination of GATA4, MEF2C, and Tbx5.   
Table 1.3. Efficiency of established protocols for cardiac differentiation from stem cells 
      Amended from Rajala, Pekkanen-Mattila and Aalto-Setala, 2011. 
Method Differentiation Efficiency % 
Spontaneous differentiation by EB formation <10% 
END-2 method 20-25% 
Guided differentiation method using  
Activin A and BMP4 
>30% 
Guided differentiation method using  
Activin A, BMP4, bFGF, VEGF, and DKK-1 
40-50% 
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1.3.6 Markers for in vitro cardiac differentiation 
The progression of cardiac differentiation attained in vitro is measured by the 
expression of proteins, discussed earlier, at different stages and is summarised in 
Figure 1.0. Mesoderm lineages are confirmed by the early presence of Brachyury or 
Eomes and markers including MESP1/2 are used to confirm early cardiac 
differentiation. The differentiation cascade can be further followed by the expression 
of transcription factors including GATA4, MEF2c, and NKX2.5. Immature 
cardiomyocytes often display spontaneous beating and confirmed by the expression 
of cardiac-specific structural proteins including atrial and ventricular myosin. Cardiac 
troponin T and I, the former a subunit of the troponin complex responsible for the 
regulation of muscle contraction in response to changes in calcium ion concentrations, 
are also used as markers to evaluate cardiac differentiation as are connexin proteins. 
Atrial and ventricular connexin proteins, Cx43 and Cx40 respectively, are commonly 
used. A pure population of cardiomyocytes or a specific subset of cardiomyocytes has 
not been achieved, however, purification methods have been developed including the 
isolation of cells, from a heterogenous pool, that express differences in glucose versus 
lactate metabolism (Tohyama et al., 2013) and the expression of signal regulatory 
protein alpha (Dubois et al., 2011). 
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Figure 1.0. Markers for sequential steps required for obtaining cardiomyocytes from pluripotent stem cells 
Image amended from Rajala, Pekkanen-Mattila and Aalto-Setala, 2011. 
cTnT – Cardiac muscle troponin T, Dkk1 – Dickkopf-1, Flk1 – Fetal liver kinase 1, Fox C1 – Forkhead Box C1, Hand – heart and 
neural crest derivatives expressed proteins 1/2, Isl1 – Insulin gene enhancer protein 1, Mef2c – Myocyte enhancer factor 2c, Mesp1 
– Mesoderm posterior 1, MHC – Myosin heavy chain, MLC2a/v – Myosin light chain 2 atrial/ventricular, Nkx2.5 - NK2 homeobox 5, 
Oct4 – Octamer binding protein 4, Sox – Sex determining region Y, Tbx5/20 – Tbox 5/20. 
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1.4 LPA 
Wnt, FGF, and TGF-β signalling converge on the regulation of the MAPKs, PKC, and 
PI3K amongst others to mediate their actions. Lysophospholipids, a group of bioactive 
lipids, are also reported to regulate the same pathways via GPCRs to mediate cellular 
events including proliferation, apoptosis, differentiation, migration, and survival (Choi 
et al., 2010). Sphingosylphosphorylcholine (SPC), sphingosine 1-phosphate (S1P), 
and lysophosphatidic acid (LPA) comprise this group of lipids and their role during 
cellular differentiation and development has recently become evident.  
1.4.1 LPA characteristics    
Lysophosphatidic acid (LPA) is a small ubiquitous phospholipid typically ester-linked 
to an acyl chain of various length and saturation, and these different chemical forms 
are present both extracellularly and intracellularly. Derived from a triglyceride 
backbone, LPA has low solubility in aqueous solution; therefore, water-soluble carrier 
proteins such as albumin or gelosin are typically bound to LPA (Eichholtz et al., 1993; 
Goetzl et al., 2000; Osborne & Stainier, 2003; Yatomi et al., 2000). LPA concentrations 
of serum and plasma vary (Aoki, 2004), with the concentration being much lower in 
plasma under physiological conditions but increasing significantly following an 
infarction (Chen et al., 2003). 
1.4.2 LPA synthesis 
The availability of precursor metabolites and catalytic enzyme expression regulate the 
production of LPA. Intracellular LPA, a precursor for glycerolipid synthesis, is produced 
enzymatically from the mitochondria and endoplasmic reticulum by either glycerol 3-
phosphate being acylated by glycerophosphate acyltransferase or by degrading LPA 
into monoacylglycerol by monoacylglycerol phosphate acyltransferase which is re-
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phosphorylated by monoacylglycerol kinase (Pages et al., 2001). Other pathways 
derive LPA from phosphatidic acid produced from phospholipids by the hydrolysis of 
fatty acid at either the sn-1 or sn-2 position of phosphatidic acid by phospholipase A1 
or A2 respectively (Aoki, Inoue, & Okudaira, 2008). Extracellular LPA is produced from 
lysophospholipids (LP) derived from phospholipids. LPs, lysophosphatidylcholine 
(LPC), lysophosphatidylethanolamine (LPE), and lysophosphatidylserine (LPS), can 
be enzymatically processed to produce LPA. Autotaxin, with lysophospholipase D 
(lysoPLD) activity, is responsible for the conversion of LPC, the major source of LPA 
(Aoki, Inoue, & Okudaira, 2008; Tanaka et al., 2006; Watanabe et al., 2007a). 
Sequential actions of lecithin-cholesterol acyltransferase (LCAT) and lysoPLD 
converting phosphatidylcholine to LPC also generate LPA. Enzymes secreted from 
activated platelets causes upregulation of LPA, during blood coagulation, by acting on 
plasma phospholipids (Aoki et al., 2002; Baker et al., 2001; Tokumara et al., 2002; 
Umezu-Goto et al., 2002; Watanabe et al., 2007b). 
 
1.4.3 LPA receptors 
LPA influences developmental, physiological, and pathological processes through 
GPCR and PPARγ signalling but also functions as a direct intracellular messenger. 
Extracellular LPA confers its bioactive effects through at least eight GPCRs, LPA 
receptors (LPAR) 1-8, with the first identified in 1996 (Hecht et al., 1996). LPARs 1-3 
are members of the endothelial differentiation gene (EDG) family whereas the other 
receptors are members of the purinoreceptor family.  
LPARs classified as members of the EDG family have a more ubiquitous expression 
whereas receptors identified as members of the P2Y cluster of GPCRs exhibit limited 
expression (Meyer zu Heringdorf & Jakobs, 2007). LPA receptors of both families 
31 
 
couple to Gαi, Gαq, Gαs, and Gα12/13 proteins allowing a diverse range of biological 
functions to be controlled.  
1.4.3.1 EDG family 
LPAR1 (Hecht et al., 1996) is found in several human and mouse tissues including the 
heart, brain, GI tract, and reproductive organs (An et al., 1998; Contos et al., 2000; 
Dancs et al., 2017; Ohuchi et al., 2008; Yang, Ishii, & Chun, 2002). This receptor 
couples with Gαi, Gαq, and Gα12/13 to alter a range of cellular responses including cell-
cell contact through SRE, cell proliferation, survival, migration, calcium mobilization, 
cytoskeletal changes, and adenylyl cyclase (AC) inhibition through Rho, PLC, Akt, and 
MAPK signalling (Fukushima et al., 2001; Meyer zu Heringdorf & Jakobs, 2007; 
Pebay, Bonder, & Pitson, 2007). LPAR2 is found in several mouse tissues, including 
both embryonic and neonatal brain tissues, and human tissues such as the thymus 
and spleen (An et al., 1998; Ohuchi et al., 2008). This receptor also couples with Gαi, 
Gαq, and Gα12/13 to regulate cell proliferation and survival, through Rho, Ras, Rac, 
PLC, DAG, PI3K, and MAPK signalling (Fukushima et al., 2001; Ishii et al., 2000; 
Meyer zu Heringdorf & Jakobs, 2007). LPAR3 is found in heart and brain tissue 
amongst others in both humans and mice (Im et al., 2000; McGiffert et al., 2002; 
Ohuchi et al., 2008; Ye et al., 2005). LPAR3 couples to Gαi, and Gαq, with a preference 
for 2-acyl LPA unsaturated fatty acids, and calcium mobilization and AC modulation 
are mediated via PLC and MAPK signalling (Fukushima et al., 2001; Meyer zu 
Heringdorf & Jakobs, 2007).  
1.4.3.2 P2Y family  
LPAR4 is found in the heart, thymus, and ovaries, amongst other tissues, of both mice 
and humans (Noguchi, Ishii, & Shimizu, 2003; Ohuchi et al., 2008). This receptor 
couples to Gαs and Gα12/13 to modulate cAMP accumulation and calcium mobilization. 
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LPAR4 also has suppressive effects on both cell motility and migration (Ishii, Noguchi, 
& Yanagida, 2009; Lee et al., 2007; Yanagida & Ishii, 2011). LPAR5 is found in many 
mouse tissues (Dancs et al., 2017; Kotarsky et al., 2006; Lee et al., 2006; Oh et al., 
2008; Ohuchi et al., 2008) but is limited to the heart, spleen, small intestine, liver, 
platelets, colon, placenta, and mast cells in humans (Amisten et al., 2008; Lundequist 
& Boyce, 2011) and acts through Gα12/13 signalling to regulate stress fibre formation 
(Lee et al., 2006) and possibly Gαq to increase intracellular calcium (Yung, Stoddard, 
& Chun, 2014). LPAR6 is found in the heart, brain, lung, and kidney tissues amongst 
others (Lee et al., 2009; Pasternack et al., 2008; Yukiura et al., 2015) and acts through 
Gα12/13 signalling (Lee et al., 2009; Yanagida et al., 2009). LPAR7 is found in both skin 
and hair, and LPAR8 is found in the uterus, placenta, prostate, brain, lung, and skeletal 
muscle (Murakami et al., 2008; Pasternack et al., 2008; Tabata et al., 2007).  
LPA also signals independently of GPCRs through peroxisome proliferator-activated 
receptor gamma (PPARγ) (McIntyre et al., 2003). This receptor has shown to play a 
role in several diseases including atherosclerosis, diabetes, and cancer (Lehmann et 
al, 1995; Li et al., 2000; Sarraf et al., 1998) as it regulates cell proliferation and 
apoptosis but also mediates inflammation and lipid and glucose homeostasis (Elstner 
et al., 1998; Evans, 2005; Lehrke & Lazar, 2005; Mueller et al., 1998; Ricote & Glass, 
2007; Tigyi, 2010). PPARγ has shown to be activated by unsaturated LPA species 
only (Tsukahara et al., 2006). LPA synthesis and signalling are summarised in Figure 
1.1.  
1.4.3.3 LPA receptor antagonists 
Most of the commercially available LPAR antagonists target the EDG family and 
frequently lack selectivity between receptors 1-3 or target enzymes, such as ATX, that 
regulate LPA production (Yung, Stoddard, & Chun, 2014). Amongst the available 
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LPAR1-3 antagonists, Ki16425 is the most established and has been used to disrupt 
LPA signalling in various stem cells. Ki16425 targets LPAR1 and 3 with an IC50 of 
0.34µM, 0.93µM, but also targets LPAR2 with an IC50 of 6.5µM (Ohta et al., 2003). In 
contrast, the less established, H2L5186303 targets LPAR2 with much higher 
selectivity than LPAR 3 and 1 with an IC50 of 8.9, 1230, and 27534nM, respectively 
(Fells et al., 2008). Currently, highly selective antagonists for the P2Y family of LPA 
receptors have not been described. The P2Y family of LPA receptors, notably receptor 
4, have traditionally been targeted with broad spectrum antagonists, such as Suramin. 
Aside from targeting P2Y receptors Suramin also inhibits the binding of several 
extracellular targets (Coffrey et al., 1987; Kathir et al., 2006; Smolich et al., 1993) and 
promotes the differentiation of mESCs towards a sinus node phenotype (Wiese et al., 
2011).  
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Figure 1.1. Summary of LPA synthesis and signalling 
Image amended from Yung, Stoddard, and Chun, 2014. 
AC – Adenylate Cyclase, ATX - Autotaxin, Ca2+- Calcium, cAMP – cyclic adenosine 
monophosphate, DAG – 1, 2, diacyglyerol, IP3 – Inositol (1,4,5) triphosphate, LCAT – 
Lecithin cholesterol acyltransferase, LPA – Lysophosphatidic acid, LPAR – LPA 
receptor, LPC - Lysophosphatidylcholine, LPE - Lysophosphatidylethanolamine, LPS 
- Lysophosphatidylserine, MAPK – Mitogen Activated Protein Kinase, PA – 
Phosphatidic acid, PC - Phosphatidylcholine, PE - Phosphatidylethanolamine, PI3K - 
Phosphatidylinositol-3-kinase, PKC – Protein Kinase C, PLA - Phospholipase, PLC – 
Phospholipase C, PLD – Phospholipase D, PS - Phosphatidylserine, ROCK - Rho-
associated protein kinase, SRF – Serum Response Factor.  
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1.4.4 LPA in vascular biology  
LPA exerts both protective and damaging effects on the cardiovascular system (Chen 
et al., 2006a). Damage to myocytes during a heart attack occurs primarily due to 
ischaemia and hypoxia. LPA is elevated in atherosclerotic lesions and after acute 
myocardial infarction but how LPA confers a protective role in the early stages of each 
event is elusive. However, through Gi-coupled signalling, activation of downstream 
pathways, PI3K/AKT and ERK, elevated levels of LPA have been shown to increase 
myocyte (Karliner et al., 2001), and mesenchymal stem cell (Chen et al., 2008a) 
survival from hypoxia-induced apoptosis, whereas activation of downstream pathways 
Rho, PI3K/AKT, and NF-κB contribute to the hypertrophic response (Chen et al., 
2008b; Hilal-Dandan et al., 2004). CD34+ cells derived from umbilical cord blood 
treated with LPA also exhibit higher survival under ischaemic conditions through 
activation of PPARγ mediated ERK/AKT signalling (Kostic et al., 2015). LPA also 
regulates myocyte contractibility (Cremers et al., 2003), increased protein synthesis in 
cultured cardiomyocytes (Goetzl et al., 2000), and increased LPL activity (Pulinikunnil 
et al., 2005), however, topical application of LPA to the arterial wall prompts neointima 
formation associated with atherosclerosis (Zhang et al., 2004).  
1.4.5 LPA in stem cell differentiation 
LPARs are expressed in both pluripotent and multipotent stem cells. Bone marrow and 
mesenchymal stem cells of human and murine origin express LPAR1-3 whereas 
distinct expression levels for LPAR1-6 are found in PSCs between species. Both 
hESCs and hiPSCs express higher levels of LPAR2, 3, and 4 whereas mESCs 
express higher levels of LPAR1, 2, 4-6 and miPSCs express higher levels of LPAR1 
and 6 (Kleger et al 2011, Pebay, Bonder, & Pitson, 2007). 
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LPA induces the differentiation of multiple cell types into different lineages including 
mesenchymal stem cell differentiation into myofibroblasts (Jeon et al., 2008, Tang et 
al., 2014) and osteoblasts (Liu et al., 2010), neuroblast differentiation (Fukushima et 
al., 2007), neural stem cell differentiation into neuroglial and cholinergic committed 
neurons (Cui & Qiao, 2006; Cui & Qiao, 2007), and CD34+ myeloid differentiation 
(Evseenko et al., 2013). While the role of LPA in cardiac differentiation is not yet 
established, other similar bioactive lipids such as SPC and S1P both promote the 
differentiation of Sca1+ cardiac stem cells and umbilical cord mesenchymal stem cells 
respectively into cardiomyocytes (Li et al., 2016; Zhao et al., 2011).  
In addition to regulating pathways critical to cardiac differentiation discussed above, 
LPA modulates the Hippo pathway in both human ESCs and iPSCs. The Hippo 
pathway acts on the Yes-associated protein (YAP) and is fundamental in development 
but also a key regulator of stem cell pluripotency and differentiation (Lian et al., 2010; 
Meng, Moroishi, & Guan, 2016; Qin et al., 2016; Zhou et al., 2015a).  
1.5 Aim of the thesis 
Our group has demonstrated that LPA may act as an effective molecule for regulating 
the differentiation of P19 stem cells, a murine embryonal carcinoma cell line, into 
cardiomyocytes (Pradmod, 2017). This study reaffirmed this ability of LPA and 
examined the role of LPA receptors and downstream signalling molecules associated 
with the differentiation of stem cells into cardiomyocytes. Furthermore, the regulation 
of both cardiac specific and ubiquitous transcription factors has also been investigated. 
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2.1 Cell culture 
Mouse P19 embryonal carcinoma cells (ATCC CRL-1825) were used to carry out all 
experiments and were cultured in complete alpha-minimum essential medium 
(complete αMEM) containing 10% heat-inactivated foetal bovine serum with penicillin 
(100units/mL) and streptomycin (100µg/mL) and maintained in a humidified 5% CO2 
atmosphere at 37˚C. The cells were sub-cultured every 48 hours (cells ~70% 
confluent) using 0.05% trypsin-EDTA.  
All cell culture reagents were purchased from Gibco (Life Technologies) and warmed 
to 37˚C using a water bath before use. All centrifuge steps were carried out at 4˚C at 
1000rpm for 5 minutes unless otherwise specified.   
2.1.1 Recovery of P19 cells  
P19 cells at passage 2, cryopreserved in 5% DMSO, were received from ATCC. For 
removal of the cryopreservative, cells were rapidly thawed by repeated pipetting of 
1mL complete αMEM into the vial. The suspension was then transferred to a 15mL 
falcon tube containing 8mL complete αMEM and centrifuged. The medium was 
removed by aspiration, and the pellet was separated in 1mL of complete αMEM and 
added to a T25 flask containing 6mL of complete αMEM. The complete αMEM was 
changed every 48 hours until the cells were ~70% confluent. The pattern of cell growth 
during this period is shown in Figure 2.0.
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Figure 2.0. Growth of recovered P19 cells 
Cells were recovered and cultured as described in section 2.1.1 with the observation 
of growth after 24 (left), 72 (middle), and 96 (right) hours post recovery. Images are 
taken at 200x, 40x and 40x, respectively, using the inverted Olympus light microscope.
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2.1.2 Culturing of P19 cells 
The cells were maintained in exponential growth and sub-cultured by aspirating the 
medium and washing the cells twice with 1x PBS. 1ml of 0.05% trypsin-EDTA was 
used to detach the cells with 4mL of complete αMEM being added to stop the action 
of trypsin. The suspension was transferred to a 15mL falcon tube and centrifuged. The 
medium was aspirated and the pellet was resuspended in 5mL of complete αMEM. 
When sub-culturing cells from a T25 to a T75 flask, 1mL of the cell suspension was 
added to a T75 flask containing 12mL of αMEM. For future studies, the cell pellet was 
cryopreserved in 1mL of freezing medium containing 80% FBS, 10% glycerol, and 
10% complete αMEM. The cryovials were stored in a Mr. Frosty for 24 hours at -80˚C 
followed by storage in liquid nitrogen (-196˚C). The cells recovered thereafter were not 
centrifuged and were directly added to a T25 containing 6mL of complete αMEM as 
DMSO was not used as a cryopreservative.  
2.2 Differentiation Protocol   
2.2.1 Preparation of lysophosphatidic acid  
LPA (Oleoyl-L-α-lysophosphatidic acid sodium salt) was purchased from Sigma (UK) 
and prepared in a 5mM stock solution dissolved in 1x PBS containing 0.01% fatty acid-
free BSA. Aliquots of 10µL - 100µL were protected from light and stored at -20˚C. The 
final concentration of 5µM LPA was achieved by dilution in complete αMEM. 
2.2.2 Formation of embryoid bodies 
The differentiation model used required the formation of embryoid bodies (EBs) with 
an initial seeding density of 3.7x105 cells into bacterial grade 50mm Petri dishes with 
a total volume of 5mL complete αMEM. The cell count was determined using the 
Countess electronic cell counter. After separating the pellet in 5mL of complete αMEM, 
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20µL of the cell suspension was mixed with an equal volume of trypan blue and added 
to each of the two chambers of the cell countess slide. The volume of cell suspension 
containing 3.7x105 cells was determined from the average number of viable cells/mL 
as shown below.  
Chamber A: 
Total cells: 2.0X106/ml. 
Live cells: 1.8X106/ml 
Viability: 90% 
Chamber B: 
Total cells: 2.6X106/ml 
Live cells:  2.3X 106/ml 
Viability: 88% 
 
Average live cells =  
1.8𝑥106+2.3𝑥106
2
= 2.05𝑥106
𝑐𝑒𝑙𝑙𝑠
𝑚𝐿
 
Volume of cell suspension required for plating = 
3.7𝑥105𝐶𝑒𝑙𝑙𝑠
2.05𝑥106𝐶𝑒𝑙𝑙𝑠/𝑚𝐿 
= 0.180mL. 
Each Petri dish was plated with 0.180mL of cell suspension with the 
addition of 4.82mL of complete αMEM. 
  
2.2.3 Cardiac differentiation of P19 cells  
Differentiation was induced by supplementing the medium with 1% DMSO (positive 
control) or with LPA at the time of seeding. When used, EBs were incubated with LPA 
receptor antagonists or kinase-specific inhibitors for 60 minutes before the addition of 
LPA. An additional 2mL of complete αMEM was added 48 hours after seeding. The 
differentiation process was continued by transferring the EBs to a 15mL falcon tube 
96 hours after seeding and allowed to aggregate at the bottom of the tube before 
gently aspirating the medium. 12mL of complete αMEM was added, and the EBs were 
gently separated into a single EB suspension by repeated pipetting. 2mL of the 
suspension was added to each well of a 6-well tissue culture grade plate, and the 
medium was replaced every 48 hours.  The differentiation process is summarised in 
Figure 2.1.  
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2.2.4 Preparation of adherent cell cultures for ELISA analysis   
ELISA kits were used to study the early phosphorylation of specific kinases in the 
presence of LPA. Cells that were approximately 70% confluent were trypsinized and 
pelleted as described in section 2.1.2. The number of viable cells per mL was 
determined using the Countess cell counter as described in section 2.2.2 The cell 
suspension was diluted to obtain 100µL of cell suspension containing 1.5x104 cells. 
Each well of a 96-well plate was seeded with 100µL of cell suspension containing 
1.5x104 cells and incubated for 48 hours. Cells were then treated with LPA, diluted in 
serum-free αMEM, for 1, 5, 15, 30, 60 or 180 minutes. The cells were fixed and 
assayed as specified by the manufacturer’s instructions for each ELISA kit. The 
preparation of adherent cell cultures is summarised in Figure 2.2.  
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Figure 2.1. The differentiation of P19 cells into cardiomyocytes by the 
spontaneous formation of embryoid bodies in the presence of LPA  
P19 cells were cultured in a T75 flask until approximately 70% confluent and seeded 
(*) into non-tissue culture grade microbiological Petri dishes in the presence or 
absence of 5µM LPA over the course of four days (**). The embryoid bodies were 
cultured in tissue culture grade 6-well plates for further differentiation and lysates were 
generated on day 10 of the differentiation process (***).
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Figure 2.2. Preparation of adherent cell cultures for ELISA analysis 
P19 cells were cultured in a T75 flask until approximately 70% confluent and seeded into each well of a 96 well at a density of 1.5x104 
cells. After an incubation period of 48 hours, the cells were stimulated with 5µM LPA, diluted in serum free αMEM, for 1-180 minutes. 
The cells were fixed and the ELISA was performed according to the manufacturer’s instructions.  
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2.3 Protein quantification 
2.3.1 Cell lysis for the detection of MLC1v 
Lysates were generated on day 10 of the differentiation process. The 6-well plates 
were placed on ice, and after discarding the medium, each well was washed twice with 
cold 1X PBS followed by the addition of cold lysis buffer (10mM Tris-HCl, 1% SDS, pH 
7.4). The lysed cells were gathered using a cell scraper and transferred to a chilled 
Eppendorf. The lysates were processed by ultra-sonication for 90 seconds with 30-
second intervals and centrifuged for 20 minutes at 13000rpm. The supernatant was 
transferred to a chilled Eppendorf and stored at -80˚C until used. 
2.3.2 Cell lysis for the detection of total and phosphorylated proteins 
Lysates were generated at experiment-specific time points. For lysates generated on 
days 1-4 of the differentiation process, the EBs were transferred into 15mL falcon 
tubes and allowed to settle at the bottom before removing the medium. Cells were 
washed with 500µL of cold 1x PBS containing phosphatase and protease inhibitor 
cocktail (Sigma) at dilutions of 1:100 and 1:200 respectively and transferred to chilled 
1.5mL Eppendorf tubes. Tubes were centrifuged for 15 seconds at maximum speed 
in a microcentrifuge after which the PBS was removed and replaced with 1x RIPA 
buffer (Cell Signaling Technology). 1mM PMSF was added to the 1x RIPA buffer 
immediately before use. The tubes were kept on ice for 5 minutes followed by high-
speed vortex for 15 seconds and sonicated for 30 seconds in ice water. The lysates 
were then centrifuged at 13000rpm for 20 minutes at 4˚C. The supernatant was 
transferred to a chilled Eppendorf tube and stored at -80˚C until analysed. For lysates 
generated on days 6-10 of the differentiation process, each well of a 6-well plate was 
first washed with 1x PBS as described above followed by the addition of 1x RIPA buffer 
directly to the well. The plate was chilled on ice for 5 minutes, and the lysed cells were 
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scrapped using a cell scraper and transferred into a pre-chilled Eppendorf tube and 
processed in the same way as described above.   
2.3.3 The bicinchoninic acid assay (BCA) 
The Peirce BCA Protein Assay Kit was used to determine the total concentration of 
protein in the lysates. A stock of bovine serum albumin (BSA) was prepared at a 
concentration of 10mg/mL in double distilled water (DDW). Standards and a 96 well 
plate were prepared as shown in table 2.0 and 2.1 respectively. The plate was 
incubated for 60 minutes on an orbital shaker at room temperature. A reading at 
620nm was taken using the Labsystems Multiskan ascent or CLARIOstar plate reader. 
A protein standard curve was generated by plotting absorbance against protein 
concentration, and the amount of protein in the samples was calculated using the 
equation y=mx+b.
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Table 2.1. Preparation of a 96-well plate for protein quantification by BCA 
Well Double Distilled 
Water 
Standard Lysate Lysis Buffer (1x) BCA Solution 
Control 5µL  - - 5µL 100µL 
Standard - 5µL - 5µL 100µL 
Sample 5µL - 5µL - 100µL 
Table 2.0. Preparation of BSA standards 
BSA 
(10mg/mL)  
Double 
Distilled Water 
Final Concentration 
(µg/µL)  
 0µL  1000µL 0 
20µL  980µL  0.2 
40µL  960µL  0.4 
60µL  940µL  0.6 
100µL  900µL 1 
200µL  800µL 2 
300µL  700µL 3 
400µL 600µL 4 
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2.4 Protein analysis by western blot   
20µg of protein was mixed with an equal volume of 2x sample buffer and heated at 
95˚C for 5 minutes. Proteins were separated by 12% SDS-PAGE with a current of 
20mA and 25mA per gel, as the samples migrated through the stacking gel and 
resolving gel respectively, followed by transfer to a PVDF membrane with the Thermo 
G2 fast blotter using the pre-programmed method for mixed weight protein. The PVDF 
membrane was soaked in 100% methanol for 15 seconds and then in double distilled 
water for 2 minutes before transfer. Membranes were blocked with 5% non-fat milk for 
60 minutes at room temperature on a rocking platform. Primary antibody, anti-myosin 
light chain 3 (Abcam), was used at a dilution of 1:500 in blocking buffer with an 
overnight incubation at 4˚C with gentle agitation. The membrane was washed with 
TBS-T 3 times for 5 minutes each followed by a 60-minute incubation with agitation at 
room temperature with the secondary antibody, anti-mouse IgG, HRP-linked (Cell 
Signaling Technology), used at a dilution of 1:4500 in blocking buffer. The membrane 
was washed with TBS-T 3 times for 5 minutes each, and the Thermo ECL Reagent 
was used for protein detection with the Thermo myECL Imager. The compositions of 
the buffers can be found in tables 2.2 to 2.4. Expression of the protein of interest was 
normalised against the expression of the housekeeping protein β-actin (Cell Signaling 
Technology), used at a concentration of 1:10000 dilution in blocking buffer during 
secondary antibody incubation, in all experiments. The Restore Western Blot Stripping 
Buffer (Thermo Fisher) was used to detect other proteins of interest on the same 
membrane by incubating the blots for 20 minutes at room temperature followed by 
blocking as described earlier. 
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Table 2.2. Preparation of 2x sample buffer 
Reagent  2x Sample Buffer (10mL) 
Tris-HCl 0.5M pH 6.8 2500µL  
Glycerol 2000µL  
10% SDS 4000µL  
1% Bromophenol Blue 400µL  
2M Dithiothreitol 100µL  
Double distilled water 1000µL  
pH 6.8 
Storage Room Temperature 
 
 
Table 2.3. Preparation of resolving and stacking gel for SDS-PAGE 
Reagents 12% Resolving Gel (5mL) Stacking Gel (2mL) 
DDW  1655µL  1220µL  
30% Acrylamide  1995µL  260µL  
10% Ammonium persulfate 50µL  10µL  
10% SDS  50µL  20µL  
TEMED 3µL  2µL  
Tris-HCL 
1.5M pH 8.8 
0.5M pH 6.8 
 
1250µL  
- 
 
- 
500µL  
 
 
Table 2.4. Preparation of buffers 
Reagent  Electrophoresis Buffer Transfer Buffer TBS 
Tris-Base 250mM 480mM 200mM 
Glycine  1.92M 390mM - 
SDS 35mM 0.375% - 
NaCl - - 1.37M 
pH - 8.3 7.6 
Storage Room Temperature 4°C 4°C 
Concentration  10x 10x 10x 
Buffers were diluted to 1x in DDW before use.  
For TBS-T; 0.01% Tween-20 was added to TBS before use. 
For blocking buffer; 5% non-fat milk was added to TBS-T before use. 
For transfer buffer; 20% methanol was added before use.  
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2.5 Cell viability assay 
The MTT assay was used to determine the toxicity of the inhibitors used. 10x104 cells 
were seeded into each well of a 96-well plate. Once the cells were 60% confluent, the 
medium was removed and replaced with medium containing the inhibitor for 24 hours 
after which it was replaced with 200µL of medium containing 0.1mg of MTT for 4 hours. 
The MTT was discarded, and 100µL of isopropanol was added to each well. The plate 
was incubated at room temperature on an orbital shaker for 10 minutes. The plate was 
read at 540nm using the Labsystems Multiskan Ascent plate reader.  
2.6 Mycoplasma testing 
Mycoplasma testing was routinely carried out using the MycoAlert mycoplasma 
detection kit purchased from Lonza. P19 cells were cultured in a T75 flask containing 
12mL complete αMEM for 48 hours, and the cell supernatant was collected during 
passage of the cells. The complete αMEM was removed and transferred to a 15mL 
falcon tube and centrifuged for 5 minutes at 1500rpm. 100µL of the cleared 
supernatant was transferred to a 96 well clear bottom white polystyrene microplate 
and incubated at room temperature for 5 minutes with 100µL MycoAlert reagent. The 
luminescence was measured using the Promega Glomax multi-detection system 
followed by the addition of 100µL of MycoAlert substrate to the sample and incubated 
for a further 10 minutes at room temperature. Luminescence was measured again and 
reading 1 was divided by reading 2. A ratio of <0.9 was negative for mycoplasma 
whereas a ratio >1.2 was positive. Testing for mycoplasma was repeated 24 hours 
later if a ratio between 0.9-1.2 was calculated. Testing was carried out more frequently 
when cells exhibited changes in growth, morphology, or response to the positive 
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control (1% DMSO) and were not responsive to troubleshooting such as changes in 
serum, reagents, and cell culture conditions. 
2.7 Statistical analysis 
Densitometry was done using Image Studio Lite, and statistical analysis was done 
using GraphPad Prism 7. Statistical comparisons were performed by one-way and 
two-way analysis of variance (ANOVA) with Dunnett’s or Bonferroni post hoc test 
respectively. A value of p<0.05 was significant. The data are expressed as means ± 
S.E.M of at least three independent experiments unless otherwise noted.
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Chapter 3 
Establishment of the cardiac 
differentiation model  
&  
The role of LPA receptors and the 
PKC/PI3K pathway in LPA mediated 
cardiac differentiation of P19 cells 
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3.1 Introduction 
The murine P19 teratocarcinoma cell line (McBurney & Rogers, 1982) can be 
maintained in culture without the addition of LIF or a feeder layer and has been 
extensively studied as a model system for cardiomyogenic differentiation (Bradley et 
al., 1984; van der Hayden & Defize, 2003). During spontaneous EB formation, the 
organic solvent, dimethyl sulfoxide (DMSO) (Edwards, Harris, & McBurney, 1983; 
McBurney et al., 1982), has been widely used and led to invaluable insight into the 
mechanisms and signalling pathways that promote the differentiation to a cardiac fate 
(van der Hayden & Defize, 2003). Little was, however, known about the role 
endogenous biomolecules might play in generating cardiomyocytes from stem cells 
until recently when Pramod (2017) demonstrated that LPA has the potential to regulate 
the differentiation of P19 cells into cardiomyocytes. This occurred in a manner 
comparable to that of DMSO and established the upregulation of LPA receptors 
(LPARs) 1-4 in differentiating P19 cells. LPARs 1-4 signal through coupling with Gαi, 
Gαq, Gαs, and Gα12/13 proteins that regulate kinases including PI3K and PKC. The 
requirement of PI3K signalling in LPA mediated cell survival (Weiner & Chun, 1999) 
and hypertrophy (Chen et al., 2008b) and LPA mediated PKC activation in the 
presence of DAG, PS, and calcium (Sando & Chertihin, 1996) have been 
demonstrated and Pramod (2017) has also suggested that they may also regulate LPA 
induced differentiation of P19 cells to cardiomyocytes. The requirement of canonical 
Wnt signalling in DMSO treated P19CL6 cells was established by Nakamura et al. 
(2003) and Naito et al. (2005) demonstrated the importance of PI3K/AKT pathway 
signalling in maintaining canonical Wnt activity in these cells and as a required 
pathway for the further expression of GATA4 and NKX2.5 (Naito et al., 2003). Whether 
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this pathway also mediates effects on LPA in generating cardiomyocytes from P19 
stem cells remain to be established. 
Stimulation with insulin or insulin-like growth factors also prompts ESC differentiation 
towards a cardiac fate mediated in part by PI3K signalling (Engels et al., 2014). Bekhite 
et al. (2011) reported inhibition of the PI3K pathway impaired cardiac differentiation of 
ESCs and similar results were demonstrated by D’Amico et al. (2016) using H9C2 
cells. PKC upregulation has been studied for its role in ischemia, hypertrophy, and 
heart failure (Gray, Karliner, & Mochly-Rosen, 1997; Mizukima et al., 2000; Muth et 
al., 2001; Rouet-Benzineb et al., 1996), however, the combinatory effect of PKC 
isoforms makes it difficult to assess the precise role of PKC in in vitro cardiac 
differentiation, but Zhou, Quann, and Gallicano (2003) identified that the upregulation 
of the novel PKCε in co-operation with the downregulation of classic PKCβ and 
atypical PKCζ are critical in differentiating cardiomyocytes from ESCs. Further 
inhibition of both PKCβ and ζ in combination with PKG also enhances cardiac 
differentiation (Mobley et al., 2010). Other studies have shown while PKCζ is 
unchanged during cardiac differentiation of ESCs, PKCα, β, δ, and ε increase in 
nuclear expression (Ventura et al., 2003) however PKCα, ε, and ζ translocate to the 
cytosolic compartment in DMSO treated P19 cells (Xu et al., 1999). Bekhite et al. 
(2011) found little effect of PKC inhibition on cardiac differentiation of ESCs but studies 
within the group have found that inhibition of PKC abolishes DMSO induced cardiac 
differentiation in P19 cells (Humphrey, 2009).  
In this study, we aimed to validate the model developed by Pramod (2017) and confirm 
that LPA does indeed drive P19 stem cells down a cardiac lineage. In addition, the 
studies on LPARs conducted by Pramod were extended to establish the role of LPAR2 
in the differentiation process induced by LPA as this was not previously investigated.  
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3.2 Materials and Methods  
3.2.1 Determining the effect of LPA on P19 cells  
Differentiation of P19 cells was carried out as specified in chapter 2 section 2.2. EBs 
were seeded in medium containing 1, 5, 10, or 20µM LPA and lysates were generated 
on days 6, 8, 10, and 16 of the differentiation process as described in chapter 2 section 
2.3.1. Protein quantification and western blotting were performed as set out in chapter 
2 section 2.3.3 and section 2.4 respectively. Cell viability in the presence of 1, 5, 10, 
20, and 50µM LPA was determined using the MTT assay as described in chapter 2 
section 2.5. Statistical analysis was carried out as described in chapter 2 section 2.7. 
3.2.2 Determining the role of LPA receptors in LPA mediated cardiac 
differentiation of P19 cells 
Differentiation of P19 cells was carried out as specified in chapter 2 section 2.2. The 
LPA receptor 4 antagonist, Suramin, was purchased from Sigma and prepared in a 
1.43mg/mL stock solution dissolved in water. The antagonists of LPA receptor 1/3 and 
2, Ki16425 and H2L5186303, were purchased from Tocris and prepared in a 10mM 
and 1mM stock solution, respectively, dissolved in DMSO. Aliquots were protected 
from light and stored at -20˚C until used. Working concentrations were obtained by 
dilution in complete αMEM on the day of use. Lysates were generated on day 10 of 
the differentiation process as described in chapter 2 section 2.3.1. Protein 
quantification and western blotting were performed as set out in chapter 2 section 2.3.3 
and section 2.4 respectively. Cell viability in the presence of varying concentrations of 
each antagonist was determined using the MTT assay as described in chapter 2 
section 2.5. Statistical analysis was done as described in chapter 2 section 2.7. 
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3.2.3 Determining the role of PKC and PI3K in LPA mediated cardiac 
differentiation of P19 cells 
Differentiation of P19 cells was carried out as specified in chapter 2 section 2.2. In 
solution inhibitors for both PKC and PI3K were purchased from Merck Chemicals. The 
PKC inhibitor, Bisindolylmaleimide-1 (BIM-1), was received, dissolved in DMSO, at a 
concentration of 1mg/mL and the PI3K inhibitor, LY294002, was received, dissolved 
in DMSO, at a concentration of 10mM. Aliquots were protected from light and stored 
at -20˚C until use. Working concentrations were obtained by dilution in complete 
αMEM on the day of use. Lysates were generated on day 10 of the differentiation 
process as described in chapter 2 section 2.3.1. Protein quantification and western 
blotting were performed as set out in chapter 2 section 2.3.3 and section 2.4 
respectively. Cell viability in the presence of varying concentrations of each inhibitor 
was determined using the MTT assay as described in chapter 2 section 2.5. Statistical 
analysis was done as described in chapter 2 section 2.7.
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3.3 Results  
3.3.1 LPA induced differentiation of P19 cells into cardiomyocytes  
The number of cardiomyocytes derived spontaneously by the formation of EBs is very 
low but have been remarkably enhanced using chemical inducers. In establishing 
whether LPA is capable of inducing P19 cells into cardiomyocytes, the following 
studies were carried out. 
Firstly, tolerance to LPA (1, 5, 10, 20, and 50µM) by P19 cells was established. The 
lowest concentration of 1µM showed an increase in MTT metabolism of 17% 
compared to the control. Concentrations of 5-20µM LPA were also well tolerated by 
the cells and showed no significant differences in MTT metabolism when compared to 
the control. Cytotoxicity was observed at the highest concentration tested, 50µM, 
where viability decreased by 30% compared to the control (Figure 3.0).  
To examine the effects of LPA on the differentiation of cardiomyocytes, EBs were 
seeded in the absence and presence of LPA (1, 5, 10, 20µM). 1% DMSO was also 
used in parallel studies as a positive control.  As evidenced by the expression of the 
cardiac-specific marker MLC1v, cardiac differentiation was induced by all the tested 
concentrations of LPA compared to untreated cells, but maximum induction was 
achieved with 5µM LPA, and the effect was comparable to that seen with 1% DMSO 
on day 10.  Induction by concentrations of 1, 10 and 20µM LPA was approximately 20-
30% less than that seen by 5µM LPA (Figure 3.1A). 
As shown in Figure 3.1B, expression of MLC1v was sustained until day 16 of the 
differentiation process in cells treated with LPA compared to untreated cells. No 
significant difference between the lower concentrations of LPA was observed, 
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however, induction with the highest concentration of 20µM was approximately 20% 
less than the other concentrations of LPA tested.  
Next, to establish whether the expression of MLC1v induced by LPA was time-
dependent, EBs were treated with 5µM LPA, as maximum induction was achieved at 
this concentration. As shown in Figure 3.2, on days 6 and 8, MLC1v expression was 
near absent in cells seeded with or without LPA, establishing day 10 as the earliest 
expression of MLC1v in LPA treated cells.   
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Figure 3.0. The viability of P19 cells in the presence of LPA 
P19 cells were cultured in a 96 well plate until 60% confluent and incubated for 24 
hours with medium alone or with increasing concentrations of LPA. Cells were 
incubated with medium containing 0.1mg MTT for a further 4 hours before assessing 
viability as described in chapter 2 section 2.5. Statistical comparisons were performed 
by one-way ANOVA with Dunnett’s post hoc test (α=0.05). The data represent the 
means ± S.E.M. of 3 experiments.
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Figure 3.1. LPA induces the expression of MLC1v in P19 cells 
P19 cells were seeded in the presence of LPA, 1% DMSO, or without an inducing 
agent in non-tissue grade Petri dishes for 4 days. EBs were then transferred and 
cultured in 6-well tissue grade plates for a further 6 or 12 days. Lysates were generated 
on days 10(A) and 16(B) of the differentiation process for expression of MLC1v 
determined by western blot. Statistical comparisons were performed by one-way 
ANOVA with Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. 
of 6 experiments.
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Figure 3.2. LPA induces the expression of MLC1v in P19 cells in a time-
dependent manner 
P19 cells were seeded in the absence or presence of 5µM LPA in non-tissue grade 
Petri dishes for 4 days. EBs were then transferred and cultured in 6-well tissue grade 
plates for a further 6 days. Lysates were generated on days 6, 8, and 10 of the 
differentiation process for expression of MLC1v determined by western blot. Statistical 
comparisons were performed by two-way ANOVA with Bonferroni post hoc test 
(α=0.05). The data represent the means ± S.E.M. of 3 experiments.
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3.3.2 LPA receptors 1-4 mediate cardiac differentiation in LPA treated P19 
cells 
The concentrations used for each receptor antagonist were determined to be non-
cytotoxic using the MTT assay. Ki16425 (Figure 3.3A) and H2L5186303 (Figure 3.3B) 
were well tolerated by P19 cells even at high concentrations whereas concentrations 
of 1 and 2mg/mL of Suramin (Figure 3.3C) indicated cytotoxicity. 
To establish the importance of these receptors in LPA mediated cardiac differentiation, 
EBs were seeded in the presence of LPA receptor 1/3, 2, and 4 antagonists, Ki16425, 
H2L5186303, and Suramin respectively for 60 minutes before the addition of 5µM 
LPA. Treatment with each of the antagonists showed inhibition of MLC1v on day 10 in 
a concentration-dependent manner. Ki16425 reduced MLC1v expression by ~15, 35, 
and 85% using concentrations of 1, 10 and 20µM (Figure 3.4) whereas H2L5186303 
showed a reduction of ~25, 60, and 80% using a concentration of 1, 5, and 7.5nM 
compared to cells treated with 5µM LPA alone (Figure 3.5). Differentiation was not 
induced in cells treated with Ki16425 or H2L5186303 alone.  
Treatment with Suramin at 0.01, 0.05, and 0.1mg/mL concentrations decreased 
MLC1v expression by ~25, 40, and 90% respectively compared to cells treated with 
5µM LPA alone. However, at a concentration of 0.01mg/mL Suramin alone induced 
significant differentiation when compared to untreated cells. Compared to treatment 
with LPA alone, Suramin alone at 0.01mg/mL showed a mean difference of 15% in 
MLC1v expression (Figure 3.6). 
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Figure 3.3. The viability of P19 cells in the presence LPA receptor antagonists 
P19 cells were cultured in a 96 well plate until 60% confluent and incubated for 24 
hours with medium alone or with increasing concentrations of Ki16425 (A), 
H2L5186303 (B), or Suramin (C). Cells were incubated with medium containing 0.1mg 
MTT for a further 4 hours before assessing viability as described in chapter 2 section 
2.5. Statistical comparisons were performed by one-way ANOVA with Dunnett’s post 
hoc test (α=0.05). The data represent the means ± S.E.M. of 3 experiments.
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Figure 3.4. Ki16425 blocks LPA induced MLC1v expression in a concentration 
dependent manner 
P19 cells were seeded in the absence or presence of 5µM LPA after pre-treatment 
with Ki16425 for 60 minutes in non-tissue grade Petri dishes for 4 days. EBs were then 
transferred and cultured in 6-well tissue grade plates for a further 6 days. Lysates were 
generated on day 10 of the differentiation process for expression of MLC1v determined 
by western blot. Statistical comparisons were performed by one-way ANOVA with 
Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. of 3 
experiments. *represents significance relative to LPA treatment alone.
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Figure 3.5. H2L5186303 blocks LPA induced MLC1v expression in a 
concentration dependent manner 
P19 cells were seeded in the absence or presence of 5µM LPA after pre-treatment 
with H2L5186303 for 60 minutes in non-tissue grade Petri dishes for 4 days. EBs were 
then transferred and cultured in 6-well tissue grade plates for a further 6 days. Lysates 
were generated on day 10 of the differentiation process for expression of MLC1v 
determined by western blot. Statistical comparisons were performed by one-way 
ANOVA with Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. 
of 3 experiments. *represents significance relative to LPA treatment alone.
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Figure 3.6. Suramin blocks LPA induced MLC1v expression in a concentration 
dependent manner 
P19 cells were seeded in the absence or presence of 5µM LPA after pre-treatment 
with Suramin for 60 minutes in non-tissue grade Petri dishes for 4 days. EBs were 
then transferred and cultured in 6-well tissue grade plates for a further 6 days. Lysates 
were generated on day 10 of the differentiation process for expression of MLC1v 
determined by western blot. Statistical comparisons were performed by one-way 
ANOVA with Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. 
of 3 experiments. *represents significance relative to LPA treatment alone. #represents 
significance relative to without LPA treatment.
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3.3.3 PKC and PI3K signalling mediate cardiac differentiation in LPA 
treated P19 cells 
To establish whether PKC or PI3K was necessary to mediate the effects of LPA in 
cardiomyocyte differentiation, P19 cells were incubated during the EB forming stage 
with either BIM-1 or LY294002, inhibitors of PKC and PI3K respectively, for 60 minutes 
before the addition of 5µM LPA. The concentrations used for each inhibitor were 
determined to be non-cytotoxic using the MTT assay. BIM-1 was well tolerated by P19 
cells (Figure 3.7A), and LY294002 displayed reduced viability at 30µM and higher 
(Figure 3.7B). 
On day 10, neither of the inhibitors induced differentiation when used alone, and 
concentration-dependent inhibition of MLC1v was seen in cells treated with 5µM LPA 
following inhibitor treatment. 5µM BIM-1 treatment reduced MLC1v expression by half 
and abolished expression when treated with 10µM (Figure 3.8) compared to the 
treatment of 5µM LPA alone. LY294002 treatment of 1 and 10µM reduced expression 
by approximately 10%, and 40%, respectively, and abolished expression with 20µM 
treatment (Figure 3.9) compared to the treatment with 5µM LPA alone. 
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Figure 3.7. The viability of P19 cells in the presence of BIM-1 and LY294002   
P19 cells were cultured in a 96 well plate until 60% confluent and incubated for 24 
hours with medium alone or with increasing concentrations of BIM-1 (A), or LY294002 
(B). Cells were incubated with medium containing 0.1mg MTT for a further 4 hours 
before assessing viability as described in chapter 2 section 2.5. Statistical 
comparisons were performed by one-way ANOVA with Dunnett’s post hoc test 
(α=0.05). The data represent the means ± S.E.M. of 3 experiments.
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Figure 3.8. BIM-1 blocks LPA induced MLC1v expression in a concentration 
dependent manner 
P19 cells were seeded in the absence or presence of 5µM LPA after pre-treatment 
with BIM-1 for 60 minutes in non-tissue grade Petri dishes for 4 days. EBs were then 
transferred and cultured in 6-well tissue grade plates for a further 6 days. Lysates were 
generated on day 10 of the differentiation process for expression of MLC1v determined 
by western blot. Statistical comparisons were performed by one-way ANOVA with 
Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. of 3 
experiments. *represents significance relative to LPA treatment alone.
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Figure 3.9. LY294002 blocks LPA induced MLC1v expression in a 
concentration dependent manner 
P19 cells were seeded in the absence or presence of 5µM LPA after pre-treatment 
with LY294002 for 60 minutes in non-tissue grade Petri dishes for 4 days. EBs were 
then transferred and cultured in 6-well tissue grade plates for a further 6 days. Lysates 
were generated on day 10 of the differentiation process for expression of MLC1v 
determined by western blot. Statistical comparisons were performed by one-way 
ANOVA with Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. 
of 3 experiments. *represents significance relative to LPA treatment alone.
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3.4 Discussion 
Several models are used to decipher the mechanisms mediating differentiation of stem 
cells into cardiomyocytes. Of these, the murine P19 teratocarcinoma cell line 
(McBurney & Rogers, 1982) has been extensively used for nearly 36 years and has 
established a foundation of signalling transduction mechanisms, although not entirely 
elucidated, that are involved in cardiac differentiation (van der Heyden & Defize, 2003). 
P19 cells are grown in culture medium containing foetal bovine or calf serum and 
maintained in an undifferentiated state, without the addition of leukaemia inhibitory 
factor (LIF) or a feeder layer, for prolonged period whereas culture in suspension 
initiates differentiation into multiple cell types (Edwards, Harris, & McBurney, 1983; 
McBurney et al., 1982). Although the differentiation efficacy of these cells to develop 
into cardiomyocytes during spontaneous EB formation is low, the relatively simple 
culture conditions permit exaggeration or manipulation of differentiation. Changes in 
the culture medium by the addition of various molecules allows easy evaluation of the 
effects on differentiation, not only in comparison to DMSO but also to determine if 
signalling transduction mechanisms are conserved in regulating cardiac 
differentiation. In this regard, we evaluated the ability of a biolipid, LPA, in mediating 
cardiac differentiation of P19 cells. 
Cardiac differentiation of P19 cells (Rudnicki et al., 1990; Rudnicki et al., 1989) in 
response to DMSO treatment is verified by the expression of several cardiac-specific 
proteins, including MHC and MLC, and with the occurrence of beating cells. Our initial 
studies assessed the effect of non-cytotoxic concentrations of 1, 5, 10, and 20µM LPA 
on cardiac differentiation compared to 1% DMSO. Findings determined that all 
concentrations induce differentiation as evidenced by the expression of cardiac-
specific ventricular myosin light chain (MLC1v) in a manner comparable to DMSO. 
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Consistent with the findings of Pramod (2017), maximum induction was achieved with 
5µM LPA at day 10 that was sustained until day 16. The expression of MLC1v in LPA 
treated cells was time-dependent and the earliest expression of MLC1v, determined 
to be day 10, corresponded to the earliest time point in which beating cells were 
routinely observed in both LPA and DMSO treated cells.  
The ability of LPA to induce cardiac differentiation may reflect the properties 
possessed by bioactive lipids as other closely related lipids, including S1P and SPC, 
have been reported to differentiate various cell lines into cardiomyocytes (Li et al., 
2016; Zhao et al., 2011). A concentration of 5µM LPA is within range of commonly 
used concentrations of LPA for in vitro studies (Evseenko et al., 2013; Fukushima et 
al., 2007; Liu et al., 2010; Shumay et al., 2007) but also within the physiological 
concentrations found under normal conditions (Gaits et al., 1997; Yung, Stoddard, & 
Chun, 2014). However, it is important to note that experiments were conducted in the 
presence of foetal bovine serum (FBS) containing culture medium. LPA and other 
lipids are constituents of FBS and vary in each batch. The concentration of LPA that 
resulted in enhanced cardiac differentiation of P19 cells was in addition to the 
unidentified concentration present in FBS. Very little cardiac differentiation was 
however observed in cells cultured without additional LPA treatment, suggesting that 
if LPA was present in FBS, it was at concentrations not sufficient to induce 
differentiation.   
Although beating cells were routinely observed in LPA treated cells, this was not 
uniform in the well or amongst experiments. Obtaining a homogenous population of a 
specific cardiomyocyte sub-type is a challenge in deriving cardiomyocytes from 
pluripotent cells. Our studies used only the ventricular MLC marker to verify cardiac 
differentiation, and the existence of other cell types was not addressed. 
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LPA acts via G-protein coupled receptors (GPCRs) to control multiple cell processes. 
LPA receptors are present in pluripotent and multipotent stem cells of both murine and 
human origin (Pebay, Bonder, & Pitson, 2007). The effect of LPA on differentiation 
through receptors 1 and 3 has been shown in neural stem cells to oligodendrocytes 
(Cui & Qiao, 2007). Liu et al. (2010) revealed that LPA receptor 1 signalling was 
required for osteoblastic differentiation of human mesenchymal stem cells and this 
process was negatively regulated by LPA receptor 4. The role of LPA receptor 1 in 
stimulating neuronal differentiation of neuroblasts (Fukushima et al., 2007) and 
myofibroblastic differentiation of mesenchymal stem cells (Tang et al., 2014) is also 
known whereas opposing roles for LPA receptor 2 and 3 in differentiating K562 cells 
have been shown (Ho et al., 2015; Lin et al., 2016).  
We next evaluated the role of LPA receptors 1-4 in mediating the action of LPA in 
differentiating P19 cells into cardiomyocytes. Pharmacological inhibitors were used to 
antagonise the action of LPA at receptors 1-3. Ki16425 selectively inhibits LPA 
receptor 1 and 3 with a slightly higher affinity for the former (Ohta et al., 2003) and 
H2L5186303 selectively inhibits LPA receptor 2 (Fells et al., 2008). Suramin is a non-
metallic compound that inhibits many cellular enzymes, growth factors, and cell 
surface receptors. It is a broad-spectrum antagonist of P2Y purinergic receptors and 
was used to antagonise LPA receptor 4 (Beindl et al., 1996; Charlton et al., 1996).  
Using RT-PCR, Pramod (2017) identified the expression of LPAR1-4 in P19 cells and 
found mRNA levels for LPARs 1-4 were upregulated in LPA treated P19 cells. A 1.25 
and 1-fold increase was observed in mRNA levels for LPAR1 and 3/4 respectively 
whereas LPAR2 had a 3-fold increase compared to untreated cells. Pramod (2017) 
further established the role of LPARs 1/3 and 4 using receptor antagonists Ki16425 
(1-50µM) and Suramin (0.001-0.5mg/mL) respectively which decreased MLC1v in a 
74 
 
concentration dependent manner. These findings were replicated in this study using 
the same receptor antagonists within the same concentration range.  
LPA was unable to induce the same differentiation response in the presence of 
antagonists for LPA receptors 1-4 and this effect was concentration dependent for 
each antagonist used. Ki16425 decreased the expression of MLC1-v with 10µM 
treatment, but this effect was far more prominent with 20µM treatment. Other studies 
have used 10µM Ki16425 (Fukushima et al., 2007; Li et al., 2017; Liu et al., 2010; Wu 
et al., 2015) but treatment with 5µM and 20µM are also reported (Evseenko et al., 
2013; Tsutsumi et al., 2015). Ki16425 has an IC50 of 0.34µM, 0.93µM, and 6.5µM for 
LPAR 1, 3, and 2 respectively, therefore, it is important to highlight the possible 
inhibition of all three receptors at the concentrations used in this study. Inhibition of 
each receptor individually would be required to establish whether the effects observed 
are due to compounded inhibition of the receptors or if cardiac differentiation can be 
abolished by inhibition of either receptor.  
Pramod (2017) identified that mRNA levels for LPAR2 had the greatest fold increase 
in LPA treated cells, however, did not establish a role for LPAR2. To address this, we 
have now demonstrated that treatment with 7.5nM H2L5186303 for 60 minutes before 
the addition of LPA abolishes differentiation. The concentration range used is 
consistent with at least one other study by McArthur et al. (2015) whereas Wu et al. 
(2015) used higher concentrations of 1µM. H2L5186303 has an IC50 of 8.9, 1230, and 
27354nM for LPA receptors 2, 3, and 1. As we used concentrations of 1-7.5nM in our 
studies, we can conclude that LPA receptor 2 is required for LPA mediated cardiac 
differentiation of P19 cells.  
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Suramin blocked LPA induced differentiation in a concentration-dependent manner, 
however, also induced expression of MLC1-v with a treatment of 0.01mg/mL alone. 
This may be due to the ability of Suramin to inhibit the binding of FGF, TGF-β, and 
Wnt proteins (Coffrey et al., 1987; Kathir et al., 2006; Smolich et al., 1993). Modulation 
of these proteins in the culture medium alone has shown to impact cardiac 
differentiation (Laflamme et al., 2007; Lian et al., 2012; Mehta et al., 2014; Monzen et 
al., 1999; Yang et al., 2008). Suramin has also been shown to differentiate cells into a 
sinus node phenotype (Wiese et al., 2011). In this study, mesendoderm and cardiac-
specific transcription factors were initially downregulated and later sinus node markers 
were upregulated. An established and selective LPA receptor 4 antagonist was not 
available at the time these studies were initiated, and as Suramin is a broad-spectrum 
antagonist, we can only conclude that LPA receptor 4 may be involved in LPA 
mediated cardiac differentiation of P19 cells.   
We next set out to confirm the role of PKC and PI3K in mediating the actions of LPA 
in differentiating P19 cells into cardiomyocytes as established by Pramod (2017) 
wherein BIM-1 (0.1-10µM) and LY294002 (1-20µM) were used. The PKC inhibitor, 
BIM-1, is selective for PKCα, β, γ, δ, and ε isozymes with an IC50 of 10nM but may 
also inhibit GSK3/GSK3β and PKA at concentrations 30 and 200-fold higher 
respectively (Toullec et al., 1991). The PI3K inhibitor, LY294002, is selective for PI3K 
in the order of α > δ > β with an IC50 of 0.5µM, 0.57µM, and 0.97µM respectively 
(Vlahos et al., 1994).  
Consistent with the data produced by Pramod (2017), BIM-1 inhibited the response 
produced by LPA in a concentration-dependent manner. Identifying the exact role of 
PKC in cardiac differentiation has been difficult as PKC isoforms have opposing and 
combinatory effects resulting in contradicting studies (Bekhite et al., 2011; Ventura et 
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al., 2003; Xu et al., 1999; Zhou et al., 2003). Our results are consistent with other 
studies concluding that PKC was essential for cardiomyocyte differentiation from 
mESCs or circulating progenitor cells (Koyanagi et al., 2005; Ronca et al., 2009). 
Previous studies within our group also achieved concentration-dependent disruption 
of DMSO induced cardiac differentiation of P19 cells within the same concentration 
range of 1-10µM BIM-1 (Humphrey, 2009).  
Similar to the data produced by Pramod (2017), LY294002 also inhibited the response 
produced by LPA in a concentration-dependent manner. The importance of PI3K 
signalling in cardiomyocyte differentiation has been documented by several groups 
(Bekhite et al., 2011; Klinz et al., 1999; Naito et al., 2005; Sauer et al., 2000). 20µM 
LY294002 abolished differentiation in our model which is consistent with the study by 
Naito et al. (2005) in which the use of 20µM LY294002 disrupted DMSO induced 
cardiac differentiation of P19CL6 cells.  
In conclusion, the data generated in this study is consistent with that of Pramod (2017) 
in which LPA induced cardiac differentiation of P19 cells, most effectively when used 
at a concentration of 5µM. The effect is mediated through LPAR1/3 and 4, and both 
PKC and PI3K signalling pathways. We further established the critical role of LPAR2 
in this study which was previously unknown. Although treatment with Ki16425 
decreased the expression of MLC1v in LPA treated cells, the selectivity of the 
antagonist merits further assessment to establish the critical receptor in this 
experimental model. Similarly, the requirement of LPAR4 requires further evaluation 
as Suramin is a broad-spectrum antagonist.
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Chapter 4 
The role and regulation of the MAPKs 
in LPA mediated cardiac differentiation 
of P19 cells
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4.1 Introduction 
Response to signals from both intra- and extra-cellular stimuli including physical or 
chemical stress creates a portfolio of diverse cellular events mediated by the MAPKs. 
Cross-talk and feedback amongst MAPKs are partially owing to shared upstream 
activators and downstream targets but have been individually studied for their role in 
proliferation, survival, apoptosis, and differentiation (Binetruy et al., 2007; Rose, Force, 
& Wang, 2010; Wada & Penninger, 2004; Wang, 2007). MAPKs are capable of 
signalling independently and are targets of several identified regulators of cardiac 
lineage specification in ESCs.  
Activation of the ERK pathway by FGF effects many cellular processes including 
differentiation. ESCs isolated from fgfr+/- mice formed beating myocytes which was 
blocked with the inhibition of MEK1/2 but not MEK1 alone (Dell’Era et al., 2003). Other 
growth factors such as VEGF have also been shown to mediate cardiac differentiation 
of mESCs in an ERK-dependent manner (Chen et al., 2006b). Inhibition of the ERK 
pathway has also been reported to maintain ESC pluripotency (Force & Woodgett, 
2009). Findings in P19CL6 cells have been inconclusive as studies have shown no 
role for ERK in cardiac differentiation (Davidson & Morange, 2000) or a partial role in 
the presence of DMSO (Eriksson & Leppa, 2002). However, Pramod (2017) identified 
ERK as a critical signalling kinase in LPA induced cardiac differentiation of P19 cells. 
In differentiating P19 cells, the proliferative capacity of cells has been attributed mainly 
to JNK in the presence of DMSO (Eriksson & Leppa, 2002). This was challenged by 
Xu & Davis (2010) by demonstrating the requirement of JNK for ESC differentiation 
and not proliferation with other studies reporting similar findings (Byun et al., 2013; 
Yao et al., 2014). For the differentiation of ESCs, JNK1 and 2 is required for 
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establishing mesodermal and ectodermal lineages (Xu & Davis, 2010). JNK can be 
activated by numerous signals and factors including Wnt and TGF-β signalling. Wnt11 
induction of the cardiac fate has reportedly been prevented with the inhibition of the 
JNK pathway (Chen et al., 2015). Impaired cardiac differentiation was also observed 
in JSAP null ESCs with a decrease in NKX2.5 activity (Sato et al., 2005). There are 
approximately 90 well-validated targets of JNK, and several have been identified as 
regulators of cardiomyocyte differentiation of ESCs including, but not limited to, β-
catenin, ATF, Jun proteins, and YAP (Zeke et al., 2016).  
A study by Aouadi et al. (2006) suggested p38 activity may be critical in the promotion 
of a cardiac fate over a neural and is supported by p38 inhibition in DMSO treated P19 
cells abolishing cardiomyocyte differentiation (Eriksson & Leppa, 2002). p38 may be 
acting through BMP activated TAK1 signalling which has been shown to regulate 
multiple transcription factors, including cardiac specific transcription factors, GATA4 
and MEF2c, and ATF-2 (Hanafuse et al., 1999; Monzen et al., 2001; Sano et al., 1999). 
In contrast, Pramod (2017) found inhibiting p38 did not impact LPA induced cardiac 
differentiation of P19 cells. 
Pramod (2017) recently identified the role of ERK and p38 in LPA induced cardiac 
differentiation of P19 cells. We extended these studies to further establish the role of 
JNK which was previously not investigated. Furthermore, we aimed to determine the 
regulation of the three MAPKs by LPA receptors 1-4 and PKC/PI3K. 
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4.2 Materials and Methods 
4.2.1 Determining the role of MAPKs in LPA mediated cardiac 
differentiation of P19 cells 
Differentiation of P19 cells was carried out as specified in chapter 2 section 2.2. 
Inhibitors for ERK, p38, and JNK were purchased from Merck Chemicals. The ERK 
inhibitor, PD98059, was received in DMSO at a concentration of 5mg/mL. The p38 
inhibitor, SB203580, was received in DMSO at a concentration of 1mg/mL and the 
JNK inhibitor, SP600125, was received in DMSO at a concentration of 50mM. Aliquots 
were protected from light and stored at -20˚C until use. Working concentrations were 
obtained by dilution in complete αMEM on the day of use. Lysates were generated on 
day 10 of the differentiation process as described in chapter 2 section 2.3.1. Protein 
quantification and western blotting were performed as set out in chapter 2 section 2.3.3 
and section 2.4 respectively. Cell viability in the presence of varying concentrations of 
each inhibitor was determined using the MTT assay as described in chapter 2 section 
2.5. Statistical analysis was done as described in chapter 2 section 2.7. 
4.2.2 Determining the effect of 20µM SP600125 on the aggregation and 
proliferation of EBs 
Differentiation was carried out as described in chapter 2 section 2.2 with the following 
modifications: EBs were seeded in the presence or absence of 5µM LPA with 20µM 
SP600125 treatment at the same time, 24 hours, or 48 hours after initial seeding. The 
lysates were generated at day 10 as described in chapter 2 section 2.3.1. Protein 
quantification was carried out as specified in chapter 2 section 2.3.3. Statistical 
analysis was done as described in chapter 2 section 2.7. 
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4.2.3 Determining the phosphorylation of JNK during EB formation   
EBs were formed as described in chapter 2 section 2.2 and seeded in the absence or 
presence of 5µM LPA for 18, 24, 48 and 72 hours. Lysates were generated at 18, 24, 
48, and 72 hours as described in chapter 2 section 2.3.2 and protein quantification 
was carried out as described in chapter 2 section 2.3.3. Western blot was carried out 
as specified in chapter 2 section 2.4 with the following modifications: Blocking buffer 
was made with 5% BSA in TBS-T, phospho-SAPK/JNK (Thr183/Tyr185) mouse 
primary antibody (Cell Signaling Technology) was used at a dilution of 1:3000, and 
SuperSignal West Dura Substrate (Thermo Fisher) was used for protein detection. 
Statistical analysis was done as described in chapter 2 section 2.7. 
4.2.4 Determining the effect of delayed inhibition of the JNK pathway in 
differentiating P19 cells 
Differentiation was carried out as described in chapter 2 section 2.2 with the following 
modifications: EBs were seeded in the presence of 5µM LPA with 10µM SP600125 
treatment at the same time, 1, 3, 24, or 48 hours after initial seeding, or with 20µM 
SP600125 treatment 48 hours after initial seeding. Lysates were generated on day 10 
as described in chapter 2 section 2.3.1. Protein quantification was done as set out in 
chapter 2 section 2.3.3 followed by western blotting as described in chapter 2 section 
2.4. Statistical analysis was done as described in chapter 2 section 2.7. 
4.2.5 Determining the regulation of JNK by LPA receptors 
The regulation of JNK by LPA receptors 1-4 during EB formation was determined by 
forming EBs as described in chapter 2 section 2.2. EBs were seeded in the absence 
or presence of LPA after a 60-minute pre-treatment with LPA receptor antagonists, 
Suramin (LPAR4), Ki16425 (LPAR1 and 3), and H2L5186303 (LPAR2) or the JNK 
inhibitor, SP600125. Lysates were generated 48 hours after initial seeding as 
82 
 
described in chapter 2 section 2.3.2. Protein quantification and western blot were 
carried out as described in chapter 2 section 2.3.3 and section 2.4 with the following 
modifications: blocking buffer was made with 5% BSA in TBS-T, phospho-SAPK/JNK 
(Thr183/Tyr185) mouse primary antibody (Cell Signaling Technology) was used at a 
dilution of 1:3000, and SuperSignal West Dura Substrate (Thermo Fisher) was used 
for protein detection. Statistical analysis was done as described in chapter 2 section 
2.7. 
4.2.6 Determining the phosphorylation of MAPKs by LPA  
A cell-based ELISA kit (Sigma: product RAB0352) was used for detecting 
phosphorylated and total ERK, p38, and JNK in LPA treated cells. Buffers were 
supplied with the kit and prepared according to the manufacturer instructions. P19 
cells were prepared for the ELISA analysis as described in chapter 2 section 2.2.4. 
After treatment with LPA the medium was removed, and wells were washed three 
times with 1x wash buffer, and fixing solution was added. The plate was incubated for 
20 minutes at room temperature with gentle shaking and washed three times. 
Quenching buffer was added and the plate was incubated for 20 minutes without 
shaking followed by four washes. Wells were then incubated with 50µL of the 
appropriate primary antibody and incubated for 2 hours at room temperature with 
gentle shaking. The plate was washed four times followed by incubation with 50µL/well 
of secondary antibody for 1 hour at room temperature. The plate was washed four 
times before the addition of TMB substrate reagent. The plate was incubated for 30 
minutes in the dark with gentle shaking after which stop solution was added, and the 
plate was read at 450nm using the CLARIOstar plate reader. As multiple wash steps 
were carried out, resulting in the possible loss of cells, crystal violet solution was used 
to estimate the relative number of cells in each well. After reading the plate, cells were 
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washed twice with the buffer supplied and twice with 1x PBS. The plate was air dried 
for 10 minutes and 100µL of crystal violet solution was added to each well and left to 
incubate at room temperature for 30 minutes. The plate was washed using 1x PBS for 
5 minutes, repeated three times, before incubation with 1% SDS solution for 1 hour 
with gentle shaking. The absorbance was read at 595nm using the CLARIOstar plate 
reader. The MAPK phospho- and total signals were then normalized for cell number 
and data expressed as a percentage of non-treated cells (basal expression). Statistical 
analysis was done as described in chapter 2 section 2.7. 
4.2.7 Determining the cross-talk between MAPKs, and the regulation of 
MAPKs by LPA receptors 1-4, PKC, and PI3K 
A cell-based ELISA kit (Sigma: product RAB0352) was used to determine the effects 
of the inhibition of LPA receptors 1-4, PI3K, and PKC on the phosphorylation of ERK, 
p38, and JNK in the presence of LPA. Compensation by other MAPKs when a single 
subfamily was inhibited was also determined. Antagonists for LPA receptor 1/3 (20µM 
Ki16425), 2 (7.5nM H2L5186303), and 4 (0.1mg/mL Suramin) were prepared in 
serum-free αMEM as were inhibitors for PI3K (20µM LY294002), PKC (10µM BIM-1), 
ERK (20µM PD98059), p38 (10µM SB203580) and JNK (10µM SP600125). Cells were 
prepared as described in chapter 2 section 2.2.4 but were treated with the antagonists 
for 60 minutes before stimulation with 5µM LPA, prepared in serum-free αMEM, for 15 
minutes. The steps carried out next are the same as specified above in section 4.2.6. 
The MAPK phospho- signals were then normalized for cell number and data 
expressed as a percentage of LPA treated cells. As limited reagents were available, 
the treatments were repeated twice and presented as mean data. 
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4.3 Results 
4.3.1 ERK and JNK signalling mediate cardiac differentiation in LPA 
treated P19 cells 
To establish whether any of the MAPK subgroups were required in mediating LPA 
induced cardiomyocyte differentiation of P19 cells, the series of studies described 
were carried out.  
The concentrations used to inhibit each of the MAPKs were determined to be non-
cytotoxic using the MTT assay (Figure 4.0). Inhibition of MLC1v was achieved using 
20µM of the ERK inhibitor, PD98059 (Figure 4.1), whereas concentrations of 1-10µM 
of the p38 inhibitor, SB203580, did not affect the expression of MLC1v in LPA treated 
cells (Figure 4.2). Neither inhibitor induced the expression of MLC1v in cells when 
used alone. The JNK inhibitor, SP600125, decreased MLC1v by a third when used at 
a concentration of 1µM followed by 5µM LPA treatment and 10µM SP600125 
abolished the expression of MLC1v in the same conditions (Figure 4.3). Treatment 
with 20µM of SP600125 in the absence or presence of LPA resulted in significantly 
less protein being extracted from lysates generated at day 10 even though cytotoxicity 
was not observed when determined using the MTT assay (Figure 4.0C). The EBs 
treated with 20µM SP600125 displayed disrupted aggregation, and the aggregates did 
not demonstrate growth. Upon transfer to 6-well plates, the surviving EB's also failed 
to adhere.
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Figure 4.0. The viability of P19 cells in the presence of MAPK inhibitors 
P19 cells were cultured in a 96 well plate until 60% confluent and incubated for 24 
hours with medium alone or with increasing concentrations of PD98059 (A), SB203580 
(B), or SP600125 (C). Cells were incubated with medium containing 0.1mg MTT for a 
further 4 hours before assessing viability as described in chapter 2 section 2.5. 
Statistical comparisons were performed by one-way ANOVA with Dunnett’s post hoc 
test (α=0.05). The data represent the means ± S.E.M. of 3 experiments.
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Figure 4.1. 20µM PD98059 blocks LPA induced MLC1v expression 
P19 cells were seeded in the absence or presence of 5µM LPA after pre-treatment 
with PD98059 for 60 minutes in non-tissue grade Petri dishes for 4 days. EBs were 
then transferred and cultured in 6-well tissue grade plates for a further 6 days. Lysates 
were generated on day 10 of the differentiation process for expression of MLC1v 
determined by western blot. Statistical comparisons were performed by one-way 
ANOVA with Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. 
of 3 experiments. *represents significance relative to LPA treatment alone.
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Figure 4.2. SB203580 does not block LPA induced MLC1v expression 
P19 cells were seeded in the absence or presence of 5µM LPA after pre-treatment 
with SB203580 for 60 minutes in non-tissue grade Petri dishes for 4 days. EBs were 
then transferred and cultured in 6-well tissue grade plates for a further 6 days. Lysates 
were generated on day 10 of the differentiation process for expression of MLC1v 
determined by western blot. Statistical comparisons were performed by one-way 
ANOVA with Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. 
of 3 experiments. *represents significance relative to LPA treatment alone.
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Figure 4.3. SP600125 blocks LPA induced MLC1v expression in a 
concentration dependent manner 
P19 cells were seeded in the absence or presence of 5µM LPA after pre-treatment 
with SP600125 for 60 minutes in non-tissue grade Petri dishes for 4 days. EBs were 
then transferred and cultured in 6-well tissue grade plates for a further 6 days. Lysates 
were generated on day 10 of the differentiation process for expression of MLC1v 
determined by western blot. Statistical comparisons were performed by one-way 
ANOVA with Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. 
of 3 experiments. *represents significance relative to LPA treatment alone.
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4.3.2 The time-dependent effect of 20µM SP600125 on the aggregation 
and size of EBs 
From the observations and results above, we next set out to determine if delayed 
inhibition of JNK using 20µM SP600125 would yield a similar effect. EBs were seeded 
in the absence or presence of 5µM LPA with the addition of 20µM SP600125 at the 
time of seeding, 24 hours, or 48 hours after initial seeding. Photographs were taken 
96 hours after initial seeding (Figure 4.4A). 
The cells seeded without (Figure 4.4A1) or with 5µM LPA (Figure 4.4A2) exhibited 
normal EB aggregation, growth, adhered once transferred to 6-well plates, and 
resulted in normal protein content of lysates generated on day 10 (Figure 4.4B). Cells 
treated with 20µM SP600125 at the same time as 5µM LPA (Figure 4.4A4) or without 
LPA (Figure 4.4A3) exhibited disrupted EB aggregation and growth and did not adhere 
once transferred to 6-well plates which resulted in low protein content of lysates 
generated on day 10. The addition of 20µM SP600125 24 hours after initial seeding 
without (Figure 4.4A5) or with 5µM LPA (Figure 4.4A6) yielded similar results but the 
EBs were slightly larger. Treatment with 20µM SP600125 48 hours after initial seeding 
without (Figure 4.4A7) or with 5µM LPA (Figure 4.4A8) yielded results similar to 
treatment with lower concentrations of SP600125 and the EBs exhibited normal 
aggregation, growth, and adhered once transferred to 6-well plates. Protein 
quantification of lysates generated at day 10 showed that treatment with 20µM 
SP600125 after 48 hours of initial seeding was comparable to EBs seeded in the 
absence of SP600125 with or without LPA treatment (Figure 4.4B).
90 
 
 
B 
 
Figure 4.4. Time-dependent effects of 20µM SP600125 on aggregating P19 cells 
P19 cells were seeded in the absence or presence of 5µM LPA with a 20µM SP600125 treatment 
at the same time, 24 hours, or 48 hours after initial seeding in non-tissue grade Petri dishes for 4 
days. Photographs (A) were taken and EBs were then transferred and cultured in 6-well tissue grade 
plates for a further 6 days. Lysates were generated on day 10 of the differentiation process for 
protein quantification using the BCA assay (B) as specified in chapter 2 section 2.3.3. Statistical 
comparisons were performed by two-way ANOVA with Bonferroni post hoc test (α=0.05). The data 
represent the means ± S.E.M. of 3 experiments.
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4.3.3 Phosphorylation of JNK during EB formation 
The above experiments were followed by studies examining the phosphorylation of 
JNK (p46 and p54) during EB formation. 
As seen in Figure 4.5A, phosphorylation of p46 was gradual, peaking at 48 hours, and 
comparable in both LPA treated and untreated cells. Phosphorylation of both groups 
decreased at 72 hours to levels slightly less than at 18 hours. Phosphorylation of p54 
(Figure 4.5B) was barely detectable at 18 hours but steeply increased at 24 hours and 
was maintained at 48 hours. A sharp decrease at 72 hours was comparable to 
phosphorylation at 18 hours suggesting a transient activation between 24 and 48 
hours. No significant difference in phosphorylation between LPA treated and untreated 
cells was observed in any of the lysates generated.  
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Figure 4.5. Phosphorylation of JNK during EB formation of P19 cells 
P19 cells were seeded in the absence or presence of 5µM LPA in non-tissue grade 
Petri dishes for 18, 24, 48 and 72 hours. Lysates were generated using 1x RIPA buffer, 
as described in chapter 2 section 2.3.2, for expression of phospho-SAPK/JNK 
(Thr183/Tyr185) determined by western blot. Statistical comparisons were performed 
by two-way ANOVA with Bonferroni post hoc test (α=0.05). The data represent the 
means ± S.E.M. of 3 experiments.
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4.3.4 The effect of delayed inhibition of the JNK pathway on the 
expression of MLC1v 
From the experiment above, we next set to establish the effect of delayed inhibition of 
the JNK pathway in differentiating P19 cells.  
Differentiation into cardiomyocytes was inhibited as evidenced by the abolishment of 
MLC1v expression at day 10 with the addition of 10µM SP600125 at the same time as 
5µM LPA and 1, 3, 24, or 48 hours after initial seeding. Although, treatment with both 
10µM and 20µM SP600125 48 hours after LPA treatment inhibited the expression of 
MLC1v, a greater reduction in MLC1v was seen with 20µM SP600125 treatment 
(Figure 4.6)
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Figure 4.6. Delayed inhibition of the JNK pathway blocks LPA induced MLC1v 
expression 
P19 cells were seeded in the presence of 5µM LPA in non-tissue grade Petri dishes. 
Addition of 10µM SP600125 was concurrent with LPA treatment or 1, 3, 24, or 48 
hours after initial seeding. Treatment with 20µM SP600125 was 48 hours after initial 
seeding. Cells were cultured in suspension for 4 days and were then transferred and 
cultured in 6-well tissue grade plates for a further 6 days. Lysates were generated on 
day 10 of the differentiation process for expression of MLC1v determined by western 
blot. Statistical comparisons were performed by one-way ANOVA with Dunnett’s post 
hoc test (α=0.05). The data represent the means ± S.E.M. of 3 experiments.
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4.3.5 LPA receptor mediated regulation of JNK 
As seen in Figure 4.7, in EBs collected at 48 hours after initial seeding, the 
phosphorylation of both p54 and p46 JNK did not significantly differ with LPA 
treatment. In the presence of SP600125, 10µM of the inhibitor affected p46 JNK 
phosphorylation more drastically than p54 JNK, both of which were significantly 
inhibited irrespective of LPA treatment as did 20µM SP600125 treatment but affected 
both p46 and p54 JNK phosphorylation comparably. No change in JNK 
phosphorylation was detected with LPA receptor antagonist treatment alone. LPAR4 
inhibition by 0.1mg/mL Suramin did not affect JNK phosphorylation whereas LPAR2 
inhibition by 7.5nM H2L5186303 decreased both p46 and p54 mean phosphorylation 
by approximately 40% compared to LPA treatment alone. Phosphorylation of JNK was 
most drastically affected by LPAR1/3 inhibition by 20µM Ki16425, resulting in a mean 
decrease of both p46 and p54 by approximately 80% compared to LPA treatment 
alone.
96 
 
 
 
Figure 4.7. Ki16425 and H2L5186303 block JNK phosphorylation in LPA treated 
cells 
P19 cells were seeded in the absence or presence of 5µM LPA after pre-treatment 
with LPA receptor 1/3 (20µM Ki16425), receptor 2 (7.5nM H2L5186303), receptor 4 
(0.1mg/mL Suramin) antagonist, or JNK inhibitor (*10µM or **20µM SP600125) for 60 
minutes in non-tissue grade Petri dishes for 48 hours. Lysates were generated using 
1x RIPA buffer as described in chapter 2, section 2.3.2, for expression of phospho-
SAPK/JNK (Thr183/Tyr185) by western blot. Statistical comparisons were performed 
by one-way ANOVA with Dunnett’s post hoc test (α=0.05). The data represent the 
means ± S.E.M. of 3 experiments. *represents significance relative to LPA treatment 
alone. #represents significance relative to without LPA treatment.
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4.3.6 Phosphorylation of the MAPKs by LPA 
A cell-based ELISA was used to investigate the effects of LPA treatment on early 
phosphorylation of the MAPKs. Basal expression was determined by untreated cells, 
marked at time 0. Change in expression by LPA treatment over the course of 180 
minutes was compared to this. Total protein expression was unchanged in cells 
treated with LPA over the course of 180 minutes for all three MAPKs. Phosphorylation 
of each MAPK occurred within the first minute but was not significantly elevated for 
the first 15 minutes. A steep decrease in phosphorylated ERK was observed at 30 
minutes that was sustained until 180 minutes (Figure 4.8). A reduction in p38 
phosphorylation was also observed at 180 minutes (Figure 4.9) whereas a 
considerable decrease in phosphorylation was seen at 60 minutes in JNK with a 
further reduction at 180 minutes (Figure 4.10).
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Figure 4.8. Phosphorylation of ERK by LPA in adherent P19 cells 
A cell-based ELISA kit (Sigma) was used for detecting phosphorylated and total ERK, 
in LPA (5µM) treated cells. 100µL of cell suspension containing 1.5x104 cells was 
seeded into each well of a 96-well plate and incubated for 48 hours. LPA was diluted 
in serum-free αMEM, and the cells were treated for 1, 5, 15, 30, 60 or 180 minutes. 
The assay was carried out as described in section 4.2.6. The ERK phospho- (A) and 
total (B) signals were normalised for cell number and data expressed as a percentage 
of non-treated cells (time 0). Statistical comparisons were performed by one-way 
ANOVA with Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. 
of 3 experiments.
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Figure 4.9. Phosphorylation of p38 by LPA in adherent P19 cells 
A cell-based ELISA kit (Sigma) was used for detecting phosphorylated and total p38, 
in LPA (5µM) treated cells. 100µL of cell suspension containing 1.5x104 cells was 
seeded into each well of a 96-well plate and incubated for 48 hours. LPA was diluted 
in serum-free αMEM, and the cells were treated for 1, 5, 15, 30, 60 or 180 minutes. 
The assay was carried out as described in section 4.2.6. The p38 phospho- (A) and 
total (B) signals were normalised for cell number and data expressed as a percentage 
of non-treated cells (time 0). Statistical comparisons were performed by one-way 
ANOVA with Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. 
of 3 experiments.
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Figure 4.10. Phosphorylation of JNK by LPA in adherent P19 cells 
A cell-based ELISA kit (Sigma) was used for detecting phosphorylated and total JNK, 
in LPA (5µM) treated cells. 100µL of cell suspension containing 1.5x104 cells was 
seeded into each well of a 96-well plate and incubated for 48 hours. LPA was diluted 
in serum-free αMEM, and the cells were treated for 1, 5, 15, 30, 60 or 180 minutes. 
The assay was carried out as described in section 4.2.6. The JNK phospho- (A) and 
total (B) signals were normalised for cell number and data expressed as a percentage 
of non-treated cells (time 0). Statistical comparisons were performed by one-way 
ANOVA with Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. 
of 3 experiments.
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4.3.7 Regulation of the MAPKs in LPA treated cells by LPA receptors 1-4, 
PKC, and PI3K 
For further investigation into whether there is cross-talk amongst MAPK or regulation 
by PKC, PI3K and LPA receptors 1-4, an ELISA kit was used. Basal expression was 
determined by stimulating the cells with 5µM LPA for 15 minutes and change in 
expression by LPA treatment for 15 minutes after an initial 60-minute incubation with 
the inhibitor was compared to this. As limited reagent was available, the treatments 
were repeated twice and presented as mean data.  
Phosphorylation of ERK appeared to be upregulated with the inhibition of the p38 
pathway whereas a minuscule decrease was observed with LPA receptor inhibition 
and inhibition of the JNK pathway. No change was seen in ERK phosphorylation with 
the inhibition of the PKC and PI3K kinases (Figure 4.11A). 
p38 phosphorylation appeared to be upregulated with LPA receptor 1-4 inhibition as 
with PKC. No noticeable difference in p38 phosphorylation was observed by the 
inhibition of PI3K, ERK, or JNK (Figure 4.11B).   
JNK phosphorylation did not appear to be affected by LPA receptor 4 and 1/3 
inhibition, but a slight decrease in phosphorylation with the inhibition of LPA receptor 
2 was detected. Inhibition of the PKC kinase showed an increase in JNK 
phosphorylation and inhibition of the PI3K kinase showed no change. A slight increase 
in JNK phosphorylation was detected upon inhibition of the ERK pathway; this result 
was more prominent with p38 inhibition (Figure 4.11C)
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Figure 4.11. Regulation of the MAPKs in LPA treated cells 
A cell-based ELISA kit (Sigma) was used to determine the regulation and cross-talk 
between MAPK subgroups. 100µL of cell suspension containing 1.5x104 cells was 
seeded into each well of a 96-well plate and incubated for 48 hours. Basal expression 
was determined by stimulating the cells with 5µM LPA, prepared in serum-free αMEM, 
for 15 minutes. Changes in basal expression after an initial 60-minute incubation with 
the inhibitors for LPA receptors (LPAR 1/3 antagonized with 20µM Ki16425, LPAR 4 
antagonized with 0.1mg/mL Suramin, LPAR2 antagonized with 7.5nM H2L5186303) 
or kinase inhibitors (ERK pathway inhibited with 20µM PD98059, p38 pathway 
inhibited with 10µM SB203580, JNK pathway inhibited with 10µM SP600125, PI3K 
inhibited with 20µM LY294002, PKC inhibited with 10µM BIM-1) followed by 
stimulation with LPA for 15 minutes was compared to basal expression. The assay 
was carried out as described in section 4.2.7. The phospho-signals for ERK (A), p38 
(B), and JNK (C) were normalised for cell number and the data expressed as a 
percentage of basal expression. As limited wells were available, the treatments were 
repeated twice and presented as mean data.
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4.4 Discussion  
The mitogen-activated kinases are activated by multiple stimuli and receptor families 
including GPCRs. LPA signalling, via the MAPKs, regulates proliferation, survival, 
migration, and differentiation (Du et al., 2010; Hayashi et al., 2001; Kostic et al., 2015; 
Malchinkhuu et al., 2005; Schuck et al., 2003; Sorensen et al., 2003). The requirement 
of the MAPKs for LPA signal transduction and evidence of PKC and PI3K regulation 
of the MAPKs in other models, in conjunction with our findings highlighted in chapter 
3, prompted us to extend our studies to examine the involvement of the MAPKs in LPA 
mediated cardiac differentiation of P19 cells.   
Commercially available and widely used inhibitors were used to determine the role of 
each MAPK subfamily. ERK inhibition was achieved using PD98059, a selective 
inhibitor of MEK1 (Dudley et al., 1995). Inhibition of p38 was achieved using 
SB203580, a selective inhibitor of p38α and β with slightly more affinity for the former. 
SB203580 has an IC50 of 0.6µM but also shown to inhibit Akt at 10-fold higher 
concentrations (Cuenda et al., 1995; Lali et al., 2000). JNK inhibition was achieved 
using SP600125, a selective inhibitor for JNK1> JNK2>JNK3 with an IC50 of 40nM, 
40nM, and 90nM respectively but also MKK4 at 10-fold higher concentrations and 
MKK3/6, Akt, and PKCα at 25-fold higher concentrations (Bennett et al., 2001).  
Pramod (2017) established the role of ERK and p38 using 1-20µM of PD98059 and 1-
10µM of SB203580 respectively and found while ERK was a required signalling target 
of LPA, inhibition of p38 did not result in the decrease of MLC1v in LPA treated cells. 
The current thesis has confirmed that LPA induced cardiac differentiation of P19 cells 
could be inhibited with the treatment of 20µM PD98059. The importance of ERK in 
cardiac differentiation is supported by several recent studies (Abbey and Seshagiri, 
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2013; Qian et al., 2012; Wang et al., 2017; Wu et al., 2013), however, studies in P19 
cells have not fully supported this (Davidson & Morange, 2000; Eriksson & Leppa, 
2002). Dell’Era et al. (2003) shed light on this contradiction by treating fgfr+/- EBs with 
both PD98059 and U0126, the latter is an inhibitor of both MEK1 and MEK2. Only 
inhibition of MEK1/2 inhibited cardiac differentiation whereas inhibition of MEK1 alone 
did not. PD98059 is highly selective for MEK1, and the concentration of 20µM used in 
our studies is supported by reports inhibiting the ERK pathway to evaluate the effect 
on cardiac differentiation (Ronca et al., 2009; Wu et al., 2013). 
Inhibition of p38 by 1, 5, and 10µM SB203580 did not affect LPA induced cardiac 
differentiation of P19 cells. This observation contradicts several reports that have 
implicated p38 in cardiac differentiation (Aoudi et al., 2006; Ding et al., 2008; Eriksson 
& Leppa, 2002; Li et al., 2006). However, others have suggested that the use of 
SB203580 at concentrations of less than 10µM promotes cardiac differentiation of 
hESCs whereas higher concentrations oppose this (Graichen et al., 2008; Kempf et 
al., 2011; Xu et al., 2008). Davidson and Morange (2000) and Gaur et al. (2010) also 
reported that effects are dependent on the stage of development in which p38 is 
inhibited.  
The expression of MLC1v was abolished by treatment of 10µM SP600125 before LPA 
treatment. Earlier studies implicated JNK in regulating proliferation (Eriksson & Leppa, 
2002) or differentiation by association to noncanonical Wnt signalling (Pandur et al., 
2002). However, recent reports indicate that JNK signalling is involved in cardiac 
differentiation induced by different stimuli and in multiple cell types (Li et al., 2016; Ou 
et al., 2016; Shi et al., 2017; Tanwar et al., 2014; Wu et al., 2013). This is supported 
by the negative regulation of JNK on pluripotent genes, OCT4 and Klf4 (Byun et al., 
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2013; Yao et al., 2014). SPC, a closely related lipid to LPA, also induced differentiation 
into cardiomyocytes through JNK signalling (Li et al., 2016). Supportive of our findings, 
both Li et al. (2016) and Tanwar et al. (2014) reported inhibition of cardiac 
differentiation upon 10µM SP600125 treatment. 
Treatment with 20µM SP600125 60 minutes before LPA treatment resulted in the 
formation of smaller EB aggregates that were unable to adhere once transferred to 
tissue grade 6-well plates. The same was observed in EBs seeded with the inhibitor 
without LPA. Cytotoxicity was not reported at this concentration. Therefore, we 
furthered our investigation to determine if the effect was time-dependent. EBs were 
seeded in the absence or presence of 5µM LPA and 20µM SP600125 treatment was 
administered at the same time or delayed by 24 and 48 hours. Treatment at the same 
time or 24 hours after initial seeding yielded similar results although some cells 
appeared to adhere after transfer in the latter. Treatment 48 hours after initial seeding 
resulted in normal EB aggregation and cells adhered once transferred to tissue grade 
6-well plates.  
Our observations are supported by many studies as JNK is known to regulate 
development and cell cycle progression. Nakaya et al. (2009) observed defective 
cytokinesis, in the context of neurogenesis, of P19 clone #3 cells that was SP600125 
concentration dependent; 2.5, 5, 10, and 20µM SP600125 concentrations were used. 
Zhou et al. (2013) reported that increasing concentrations of 5, 10, 15, 20, and 25µM 
SP600125 resulted in smaller and smaller sized ESC colonies. The same study also 
found that culturing mESCs for 24 hours followed by treatment with 25µM SP600125 
arrested over 60% of the cells in the G2/M phase. Ou et al. (2016) highlighted the 
requirement of JNK in cardiac differentiation of miPSCs but also found that 20µM 
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SP600125 treatment significantly affected proliferation of these cells. In the context of 
neurogenesis, Tiwari et al. (2011) demonstrated that the addition of SP600125 in the 
early stages of differentiation resulted in cell death, however, apoptosis was not 
apparent when differentiated neurons were treated with SP600125.  
In our studies, the effect of SP600125 was found to be time and dose-dependent, as 
highlighted above. Therefore, we next set out to determine the phosphorylation of JNK 
in aggregating EBs. The earliest collection of EBs was achievable 18 hours after initial 
seeding. Attempts were made to collect EBs 1-15 hours after initial seeding, however, 
the size of pelleted cells was too small making protein extraction difficult, and 
consistency could not be assured. The number of cells initially seeded could have 
been increased however this requires further optimisation as seeding density 
influences gene expression patterns (Chen et al., 2015).  
We examined JNK phosphorylation in EBs seeded in the absence and presence of 
5µM LPA for 18, 24, 48, and 72 hours and found a transient phosphorylation of JNK 
in both groups between 24 and 48 hours. The phosphorylation of p46 was more 
gradual between 18-48 hours whereas p54 phosphorylation was steep and sustained 
at 24 and 48 hours. Both p46 and p54 phosphorylation was decreased at 72 hours. 
From these findings, we next set out to determine if disruption of JNK signalling during 
the period of transient phosphorylation inhibited cardiac differentiation. Our previous 
findings demonstrated that pre-treatment of EBs for 60 minutes with 10µM SP600125 
was sufficient to block differentiation, however, whether JNK activation is a biphasic 
event, as JNK activation in EBs cultured for less than 18 hours was not determined, is 
unknown, therefore, we cultured EBs in the presence of 5µM LPA for 1 and 3 hours 
before the addition of 10µM SP600125. EBs were also cultured in the presence of LPA 
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for 24 and 48 hours before the addition of 10µM SP600125. It was determined from 
findings discussed above that treatment with 20µM SP600125 48 hours after initial 
seeding restored proliferation, however, the effect of this concentration on 
differentiation was unknown. Therefore, we treated EBs with 20µM SP600125 48 
hours after LPA treatment. Treatment of SP600125 1, 3, 24, or 48 hours after LPA 
treatment disrupted cardiac differentiation suggesting that commitment to the cardiac 
lineage in LPA treated cells occurs post 48 hours. Treatment of 20µM SP600125 also 
inhibited cardiac differentiation more strongly than 10µM SP600125. Taken together 
these results suggest that the gene program for proliferation that is regulated by JNK 
is switched off half way through EB formation, as evidenced by the normal growth in 
EBs treated with 20µM SP600125 48 hours after initial seeding, whereas the gene 
program for cardiac differentiation that is regulated by JNK occurs post 48 hours.  
Xu and Davis (2010) demonstrated something similar in ESCs derived from JNK 
deficient mice. They showed that compound JNK1-/- and JNK2-/- ES cells formed EBs 
but did not increase in number during culture suggesting that JNK is necessary for the 
proliferation of cells that have initiated a differentiation program. They further 
examined the effect of compound JNK1-/- and JNK2-/- ES cells on mesodermal lineage 
genes and found that Brachyury is poorly expressed in these cells as are cardiac 
progenitor genes, GATA4 and MEF2c, and MHC and MLC genes.  
From the results above, we next set out to determine if 10µM and 20µM SP600125 
were affecting p46 and p54 phosphorylation differently. We also furthered our studies 
to investigate the regulation of p46 and p54 by Ki16425, H2L5186303, and Suramin. 
EBs were seeded in the absence or presence of 5µM LPA after a 60-minute pre-
treatment with SP600125 (10µM and 20µM), Ki16425 (20µM), H2L5186303 (7.5nM), 
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and Suramin (0.1mg/mL). Phosphorylation of p46 and p54 JNK in the presence of 
SP600125 revealed that 10µM of the inhibitor effected p46 JNK phosphorylation more 
drastically than p54 JNK, but both were significantly inhibited irrespective of LPA 
treatment as did 20µM SP600125 treatment but affected both p46 and p54 JNK 
phosphorylation comparably. No change in JNK phosphorylation was detected with 
LPA receptor antagonist treatment alone. LPAR4 inhibition by 0.1mg/mL Suramin did 
not affect JNK phosphorylation whereas LPAR2 inhibition by 7.5nM H2L5186303 
decreased both p46 and p54 mean phosphorylation by approximately 40% compared 
to LPA treatment alone. The phosphorylation of JNK was most drastically affected by 
LPAR1/3 inhibition by 20µM Ki16425, resulting in a mean decrease of both p46 and 
p54 by approximately 80% compared to LPA treatment alone. A decrease in JNK 
signalling by interrupting LPAR2 (Saatian et al., 2006), LPAR1 and LPAR2 (Contos et 
al., 2002) and LPAR1 using Ki16425 (Iyoda et al., 2012) is also seen in studies 
evaluating other cellular processes.  
We evaluated the activation of each MAPK subfamily upon stimulation with LPA over 
the course of 180 minutes using the MAPK ELISA kit (Sigma). Cells were plated in 96 
well plates and cultured for 48 hours to allow serum depletion. Cells were then 
stimulated with 5µM LPA, prepared in serum-free αMEM. Phosphorylated and total 
ERK, p38, and JNK was measured after 1, 5, 15, 30, 60, and 180 minutes. LPA did 
not cause a significant spike in the phosphorylation of any of the kinases, but an 
upward trend for each was seen for 15-30 minutes followed by a decrease at 30 and 
60 minutes for ERK and p38/JNK respectively. Studies within the group have identified 
that EB formation is required for cardiac differentiation induction by LPA. It is possible 
that in EBs the upward trend initially seen in the phosphorylation of the kinases would 
continue, but as the cells were in adherent culture, LPA does not maintain their activity. 
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It is also possible that serum is required for the sustained activation of the MAPKs 
upon LPA treatment. 
We next evaluated the regulation of the MAPKs by LPA receptors 1-4 and PKC/PI3K, 
as the importance of these kinases was highlighted in chapter 3. We also investigated 
the possibility of cross-talk between the MAPKs. We stimulated the cells with LPA for 
15 minutes, where maximum activity was achieved as evidenced from the study 
above, after a 60-minute pre-treatment with inhibitors specific to the targets mentioned 
earlier. LPA and the inhibitors were prepared in serum-free αMEM and treatment was 
after cells were cultured for 48 hours in 96 well plates. The experiments were repeated 
twice as limited reagents were available. 
Phosphorylation of ERK was unchanged (within 2% range) by the inhibition of PKC 
and PI3K by BIM-1 and LY294002 respectively. A minor decrease of 8-14% was seen 
in cells treated with Ki16425 (LPAR 1/3 antagonist), H2L5186303 (LPAR 2 
antagonist), Suramin (LPAR 4 antagonist), and SP600125 (JNK inhibitor) whereas an 
increase of 30% occurred in cells treated with SB203580 (p38 inhibitor).  
Phosphorylation of p38 was unchanged (within 5% range) by the inhibition of ERK by 
PD98059, JNK by SP600125, and PI3K by LY294002. Treatment with Suramin (LPAR 
4 antagonist) and Ki16425 (LPAR 1/3 antagonist) increased phosphorylation by 
approximately 10% whereas targeting LPAR2 with H2L5186303 and PKC with BIM-1 
resulted in a 16-17% increase.  
Phosphorylation of JNK was unchanged (within 2% range) with the inhibition of PI3K 
by LY294002, LPAR4 by Suramin and LPAR1/3 by Ki16425. Phosphorylation 
increased by 8-12% in response to the inhibition of ERK by PD98059 and PKC by 
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BIM-1, and a 30% increase was seen in cells treated with SB203580 (p38 inhibitor). 
Inhibition of LPAR2 by H2L5186303 decreased phosphorylation by 10%. 
In conclusion, LPA mediated cardiac differentiation of P19 cells requires both ERK 
and JNK signalling. JNK signalling is regulated by LPA receptors 1/3 and partially 
through LPA receptor 2. Disruption in JNK signalling using 20µM SP600125 suggests 
that early JNK signalling is required for the proper aggregation and growth of EBs 
whereas late signalling is required for LPA induced cardiac differentiation. However, 
the latter was also achieved with the treatment of 10µM SP600125. Therefore, the 
selectivity of SP600125 when used at a concentration of 20µM requires further 
evaluation.
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Chapter 5 
The role and regulation of ubiquitous 
transcription factors in LPA mediated 
cardiac differentiation of P19 cells
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5.1 Introduction 
Activator protein 1 (AP-1) is involved in cell regulation, apoptosis, development, and 
differentiation (Hess, Angel, & Schorpp-Kistner, 2004). It also impacts on gene 
expression through the dimerization of members of the Jun and Fos families. Members 
of the Jun family form both homo- and heterodimers with other Jun and Fos members 
whereas members of the Fos family do not form dimers with other Fos proteins (Deng 
& Karin, 1993; Whitmarsh & Davis, 1996). Disruption in the c-Jun protein is embryonic 
lethal at E12.5 due to defects in the heart outflow tract (Eferl et al., 1999) and disruption 
in the JunB protein is embryonic lethal at E8.5-10 due to defects in extra-embryonic 
tissues (Schorpp-Kistner et al., 1999). Fra-1 is also embryonic lethal at E9.5 (Schreiber 
et a., 2000) whereas Fra-2 knockout results in inadequate cartilage and spinal 
development (Karreth et al., 2004). Disruption in JunD results in cardiac hypertrophy 
(Ricci et al., 2005), while disruption in c-Fos affects bone development (Johnson, 
Spiegelman, & Papaioannou, 1992). AP-1 has been reported to be vital for the cardiac 
differentiation of P19 cells in the presence of DMSO (Eriksson & Leppa, 2002) and in 
icariin induced cardiac differentiation of mESCs (Wo et al., 2008). Other transcription 
factors such as ATF also dimerize with Jun and Fos proteins (Angel & Karin, 1991; 
Fuchs & Ronai, 1999; Mechta-Grigoriou, Gerald, & Yaniv, 2001; Vogt & Bos, 1990). 
ATF and c-Jun are well-studied substrates of JNK as is c-Fos as an ERK substrate, 
however, other transcription factors and signalling pathways also converge on the 
regulation of AP-1 including NF-κB (Kracht, 2007; Whitmarsh & Davis, 1996). 
The ubiquitous NF-κB transcription factor (Ghosh & Hayden, 2012) contains the Rel 
homology domain and is subdivided into five subunits, p100/p52, p105/p50, RelA 
(p65), RelB, and c-Rel. These subunits produce homo- and hetero-dimers forming 
inactive or active NF-κB complexes with different DNA binding affinities. IκB proteins 
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bind and retain NF-κB in the cytoplasm preventing translocation into the nucleus. 
Translocation can be mediated by events such as proteasomal degradation of IκB 
proteins or DNA damage. p38 is known to regulate NF-κB (Wagley et al., 2013) and 
the most active p65 subunit has also been shown to be phosphorylated by the MAPK 
activated protein kinases, RSK1 and MSK1/2, amongst other non-MAPK mediated 
kinases (Buss et al., 2004a; Buss et al., 2004b; Schmitz et al., 2004; Viatour et al., 
2005).  
In this study, we aim to investigate the activation and regulation of AP-1 in 
differentiating P19 cells. Both the MAPKs and NF-κB are critical regulators of AP-1, 
and the importance of MAPK signalling in our model has already been established in 
chapter 4. Therefore, the role and regulation of NF-κB will also be evaluated here.
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5.2 Materials and Methods 
5.2.1 Determining the role of NF-κB in LPA mediated cardiac 
differentiation of P19 cells 
Differentiation of P19 cells was carried out as specified in chapter 2 section 2.2. The 
inhibitor for NF-κB, CAY10470, was purchased from Merck Chemicals and received 
in a DMSO solution at a concentration of 10mM. Aliquots were protected from light 
and stored at -20˚C until use. Working concentrations were obtained by dilution in 
complete αMEM on the day of use. Lysates were generated on day 10 of the 
differentiation process as described in chapter 2 section 2.3.1. Protein quantification 
and western blotting were performed as set out in chapter 2 section 2.3.3 and section 
2.4 respectively. Cell viability in the presence of varying concentrations of the inhibitor 
was determined using the MTT assay as described in chapter 2 section 2.5. Statistical 
analysis was done as described in chapter 2 section 2.7. 
5.2.2 Determining the phosphorylation of NF-κB by LPA 
The differentiation process was carried out as described in chapter 2 section 2.2. 
Lysates were generated on day 1, 2, 3, 4, 6, 8, and 10 of the differentiation process 
as described in chapter 2 section 2.3.2. Protein quantification and western blot were 
carried out as described in chapter 2 section 2.3.3 and section 2.4 respectively with 
the following modifications: the membrane was blocked using 1x TBS-T containing 5% 
BSA. The phospho-NF-κB p65 (Ser536) (Cell Signaling Technology) primary antibody 
was used at a dilution of 1:1000 and the anti-rabbit IgG, an HRP-linked secondary 
antibody was used at a dilution of 1/4000. SuperSignal West Dura Substrate (Thermo 
Fisher) was used for protein detection. Statistical analysis was done as described in 
chapter 2 section 2.7. 
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5.2.3 Determining the early phosphorylation of NF-κB by LPA in adherent 
P19 cells 
The FACE NF-κB p65 Profiler Kit was purchased from Active Motif (product 48400) to 
detect the phosphorylation of NF-κB p65 at serine residues 536 and 468, and total p65 
in LPA treated cells. Buffers were supplied with the kit and prepared according to the 
manufacturer instructions. P19 cells were prepared for analysis as described in 
chapter 2 section 2.2.4. After treatment with LPA the cells were fixed with 4% 
formaldehyde for 20 minutes at room temperature, washed 3 times with wash buffer 
for 5 minutes with gentle shaking, followed by incubation with quenching buffer for 20 
minutes at room temperature. The wells were washed twice, incubated with blocking 
buffer for 1 hour, and washed twice before overnight incubation at 4˚C with primary 
antibody. The wells were washed three times before adding the secondary antibody 
for 1 hour and then washed three times with wash buffer and twice with 1x PBS. A 
chemiluminescent working solution was added to each well and read using the CCD 
camera equipped Thermo myECL Imager. As multiple wash steps were carried out, 
resulting in the possible loss of cells, crystal violet solution was used to estimate the 
relative number of cells in each well. After reading the plate, cells were washed twice 
with the buffer supplied and twice with 1x PBS. The plate was air dried for 10 minutes, 
and 100µL of crystal violet solution was added to each well and left to incubate at room 
temperature for 30 minutes. Each plate was washed using 1x PBS for 5 minutes, 
repeated three times, before incubation with 1% SDS solution for 1 hour with gentle 
shaking. The absorbance was read at 595nm using the CLARIOstar plate reader. The 
total and phospho- NF-κB signals were then normalised for cell number and data 
expressed as a percentage of non-treated cells (basal expression). Statistical analysis 
was done as described in chapter 2 section 2.7. 
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5.2.4 Determining the regulation of NF-κB in LPA treated cells by LPA 
receptors, MAPKs, PKC and PI3K 
The FACE NF-κB p65 Profiler kit (Active Motif: product 48400) was used to determine 
the effects of LPA receptor, MAPKs, PKC, and PI3K inhibition on the phosphorylation 
of NF-κB in the presence of LPA. Antagonists for LPA receptor 1/3 (20µM Ki16425), 2 
(7.5nM H2L5186303), and 4 (0.1mg/mL Suramin) were prepared in serum-free αMEM 
as were inhibitors for PI3K (20µM LY294002), PKC (10µM BIM-1), ERK (20µM 
PD98059), and JNK (10µM SP600125). P19 cells were prepared for analysis as 
described in chapter 2 section 2.2.4. but were treated with the antagonists for 60 
minutes before stimulation with 5µM LPA, prepared in serum-free αMEM, for 15 
minutes. The steps carried out next were the same as specified in section 5.2.3. The 
NF-κB phospho- signals were then normalised for cell number and data expressed as 
a percentage of LPA only treated cells. Statistical analysis was done as described in 
chapter 2 section 2.7. 
5.2.5 Determining the phosphorylation of AP-1 subunits by LPA 
The TransAM AP-1 family transcription factor assay kit was purchased from Active 
Motif (product 44296) to evaluate the activation of AP-1 subunits, c-Jun, JunD, FosB, 
and c-Fos. Buffers were supplied with the kit and prepared according to the 
manufacturer instructions. 
5.2.5.1 Preparation of nuclear extract  
Cardiac differentiation was carried out as described in chapter 2 section 2.2 and 
lysates were generated on day 1, 2, 3, 4, 6, 8, and 10 of the differentiation process. 
For the generation of lysates on days 1-4 of the differentiation process, EBs were 
transferred to falcon tubes as described in chapter 2 section 2.2.3 with the following 
modifications: cold 1x PBS containing phosphatase and protease inhibitor cocktails 
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(Sigma) (1:100 and 1:200 respectively) was added to the tubes instead of complete 
αMEM. The cells were transferred to a pre-chilled 1.5mL Eppendorf and centrifuged 
for 15 seconds at 13000rpm. The PBS was removed, and 150µL-350µL of hypotonic 
buffer (20mM Hepes pH 7.5, 5mM NaF, 0.1mM EDTA, and 10µM Na2MoO4) was 
added. The cells were gently broken into a single cell suspension by repeated pipetting 
and allowed to swell on ice for 15 minutes. Nonidet P-40 (final concentration of 0.5%) 
was added to the tube and vortexed for 10 seconds. The cells were then centrifuged 
for 60 seconds at 4˚C. The cytoplasmic fraction (supernatant) was removed, and the 
pellet was resuspended in 50µL of complete lysis buffer (provided with the kit). The 
tube was rocked on ice for 30 minutes and then centrifuged for 15 minutes at 
13000rpm at 4˚C. The nuclear fraction (supernatant) was transferred to a chilled tube 
and stored at -80˚C until required. Lysates generated on days 6, 8, and 10 of the 
differentiation process were washed with 1x PBS containing phosphatase and 
protease inhibitors, and the hypotonic buffer was added to each well. The cells were 
scraped using a cell scraper and transferred to a pre-chilled Eppendorf before the 
addition of Nonidet P-40 and processed as described above.  
5.2.5.2 Protein quantification  
The Bradford-based assay was used to determine the total concentration of protein in 
the nuclear lysates. The Bradford reagent was made by first dissolving 100mg of 
Coomassie brilliant blue G-250 in 50mL of 95% ethanol followed by the addition of 
100mL of 85% w/v orthophosphoric acid. The final volume was made to 1L using 
double distilled water. The reagent was filtered using Whatman filter paper and stored 
at room temperature. BSA standards were prepared as set out in table 2.0. A 96 well 
plate was used to carry out the assay. 300µL of Bradford reagent was added to 10µL 
of each standard or unknown sample and mixed for 30 seconds using a plate shaker 
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followed by a 10-minute incubation at room temperature. Absorbance was read at 
595nm using the CLARIOstar plate reader. A standard curve was prepared by plotting 
the average of each BSA standard measurement against the concentration in µg/µL, 
and the protein concentration of each unknown sample was determined using the 
standard curve. 
5.2.5.3 AP-1 assay 
All buffers and antibodies were supplied with the kit and prepared according to the 
manufacturer’s instructions. 30µL of complete binding buffer was added to each well 
followed by 20µg of sample diluted in 20µL of complete lysis buffer and incubated for 
60 minutes at room temperature with mild agitation. The K-562 nuclear extract was 
provided with the kit and used as a positive control. The wells were washed three times 
with wash buffer, and 100µL of the primary antibody was added to each well. The plate 
was incubated for 60 minutes at room temperature, and each well was washed three 
times using wash buffer. 100µL of secondary antibody was added to each well and 
incubated for 60 minutes at room temperature. Wells were washed four times with 
wash buffer and then incubated with developing solution until the positive control wells 
turned dark blue. The plate was protected from light during this incubation. 100µL of 
stop solution was added to each well, and the absorbance was read at 450nm using 
the CLARIOstar plate reader. Statistical analysis was done as described in chapter 2 
section 2.7.   
5.2.6 Determining the regulation of AP-1 subunits in LPA treated cells by 
LPAR1-4, MAPKs, PKC, PI3K, and NF-κB. 
The TransAM AP-1 family transcription factor assay kit (Active Motif: product 44296) 
was used to determine the role of LPA receptors, MAPKs, PKC, PI3K, and NF-κB 
inhibition on the activation of AP-1 subunits in the presence of LPA. Differentiation was 
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carried out as described in chapter 2 section 2.2 in the presence of antagonists for 
LPA receptor 1/3 (20µM Ki16425), 2 (7.5nM H2L5186303), and 4 (0.1mg/mL Suramin) 
and inhibitors for PI3K (20µM LY294002), PKC (10µM BIM-1), ERK (20µM PD98059), 
JNK (10µM SP600125) and NF-κB (0.01nM CAY10470) for 60 minutes prior to 
treatment with 5µM LPA. Preparation of nuclear extracts on day 10 of the 
differentiation process was completed as described in section 4.2.5.1. Protein 
quantification and the AP-1 assay were carried out as described in section 4.2.5.2 and 
4.2.5.3 respectively. Statistical analysis was done as described in chapter 2 section 
2.7. 
5.2.7 Determining the phosphorylation of ATF2 by LPA 
The differentiation process was carried out as described in chapter 2 section 2.2. 
Lysates were generated on day 1, 2, 3, 4, 6, 8, and 10 of the differentiation process 
as described in chapter 2 section 2.3.2. Protein quantification and western blot were 
carried out as described in chapter 2 section 2.3.3 and 2.4 respectively with the 
following modifications: the membrane was blocked using 1x TBS-T containing 5% 
BSA. The phospho-ATF2 (Thr71) primary antibody (Cell Signaling Technology) was 
used at a dilution of 1:1000, the anti-rabbit IgG, HRP-linked secondary antibody (Cell 
Signaling Technology) was used at a dilution of 1:4000, and SuperSignal West Dura 
Substrate (Thermo Fisher) was used for protein detection. Statistical analysis was 
done as described in chapter 2 section 2.7. 
5.2.8 Determining the regulation of ATF2 in LPA treated cells by LPAR1-4, 
MAPKs, PKC, PI3K, and NF-κB. 
The differentiation process was carried out as described in chapter 2 section 2.2. Cells 
were seeded in the presence of antagonists for LPA receptor 1/3 (20µM Ki16425), 2 
(7.5nM H2L5186303), and 4 (0.1mg/mL Suramin) and inhibitors for PI3K (20µM 
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LY294002), PKC (10µM BIM-1), ERK (20µM PD98059), JNK (10µM SP600125) and 
NF-κB (0.01nM CAY10470) for 60 minutes before treatment with 5µM LPA. Lysates 
were generated on day 10 of the differentiation process as described in chapter 2 
section 2.3.2. Protein quantification and western blot were carried out as described in 
chapter 2 section 2.3.3 and section 2.4 respectively with the following modifications: 
the membrane was blocked using 1x TBS-T containing 5% BSA. The phospho-ATF2 
(Thr71) primary antibody (Cell Signaling Technology) was used at a dilution of 1:1000, 
the anti-rabbit IgG, HRP-linked secondary antibody (Cell Signaling Technology) was 
used at a dilution of 1:4000, and SuperSignal West Dura Substrate (Thermo Fisher) 
was used for protein detection. Statistical analysis was done as described in chapter 
2 section 2.7.
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5.3 Results  
5.3.1 NF-κB signalling mediates cardiac differentiation in LPA treated P19 
cells 
To establish whether LPA was acting through the NF-κB transcription factor in 
mediating cardiac differentiation of P19 cells, NF-κB was inhibited during EB formation 
using CAY10470. No cytotoxicity was reported with the concentrations used. A higher 
concentration of 1nM, not used in experimental studies, showed a slight decrease in 
the viability of P19 cells (Figure 5.0). In lysates generated on day 10, the inhibitor of 
NF-κB did not induce differentiation when used alone (Figure 5.1). When used in 
conjunction with LPA treatment, concentrations of 0.01nM and 0.05nM of CAY10470 
returned MLC1v expression to basal level while the lowest concentration of 0.001nM 
had no significant effect
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Figure 5.0. The viability of P19 cells in the presence of CAY10470  
P19 cells were cultured in a 96 well plate until 60% confluent and incubated for 24 
hours with medium alone or with increasing concentrations of CAY10470. Cells were 
incubated with medium containing 0.1mg MTT for a further 4 hours before assessing 
viability as described in chapter 2 section 2.5. Statistical comparisons were performed 
by one-way ANOVA with Dunnett’s post hoc test (α=0.05). The data represent the 
means ± S.E.M. of 3 experiments.
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Figure 5.1. CAY10470 blocks LPA induced MLC1v expression in a concentration 
dependent manner 
P19 cells were seeded in the absence or presence of 5µM LPA after pre-treatment 
with CAY10470 for 60 minutes in non-tissue grade Petri dishes for 4 days. EBs were 
then transferred and cultured in 6-well tissue grade plates for a further 6 days. Lysates 
were generated on day 10 of the differentiation process for expression of MLC1v 
determined by western blot. Statistical comparisons were performed by one-way 
ANOVA with Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. 
of 3 experiments. *represents significance relative to LPA treatment alone. 
124 
 
5.3.2 Phosphorylation of NF-κB by LPA 
To determine whether the phosphorylation of NF-κB by LPA is an early or late event 
the following studies were carried out. Lysates were generated on days 1, 2, 3, 4, 6, 
8, and 10 of the differentiation process and as seen in Figure 5.2, NF-κB 
phosphorylation at the serine 536 residue was detectable on days 1 and 2 in both LPA 
treated and untreated cells and undetected afterwards. No difference in expression 
between LPA treated and untreated cells was seen throughout the differentiation 
process. 
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Figure 5.2. p65 at serine 536 is phosphorylated during early EB formation  
P19 cells were seeded in the absence or presence of 5µM LPA in non-tissue grade 
Petri dishes for 4 days. EBs were then transferred and cultured in 6-well tissue grade 
plates for a further 6 days. Lysates were generated on day 1, 2, 3, 4, 6, 8, and 10 of 
the differentiation process using 1x RIPA buffer, as described in chapter 2 section 
2.3.2, for expression of phospho-NF-κB p65 (Ser536) determined by western blot. 
Statistical comparisons were performed by two-way ANOVA with Bonferroni post hoc 
test (α=0.05). The data represent the means ± S.E.M. of 3 experiments.
126 
 
5.3.3 Early phosphorylation of NF-κB by LPA 
As very early activation of NF-κB at the serine 536 residue was detected in the study 
above, we next set out to determine if LPA activates NF-κB at serine 536 and 468 
within 180 minutes of LPA stimulation. Early activation of NF-κB at both serine 536 
and serine 468 residues by LPA was determined using the FACE NF-κB kit. As seen 
in Figure 5.3A and B, stimulation with 5µM LPA for up to 180 minutes did not 
significantly change the activation of NF-κB at either serine residue. Total NF-κB 
activity was also stable over the course of 180 minutes (Figure 5.3C). Although there 
was no significant change upon LPA stimulation, there was higher basal activity at the 
serine 468 residue compared to the serine 536 residue as seen in Figure 5.3D.  
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Figure 5.3. Effect of LPA on NF-κB activation in adherent P19 cells 
A cell-based ELISA kit (Active Motif) was used for detecting phosphorylated and total 
NF-κB in LPA treated cells. 100µL of cell suspension containing 1.5x104 cells was 
seeded into each well of a 96-well plate and incubated for 48 hours. LPA was diluted 
in serum-free αMEM, and the cells were treated for 1, 5, 15, 30, 60 or 180 minutes. 
The assay was carried out as described in section 5.2.3. Chemiluminescence was 
read using the CCD camera equipped Thermo myECL Imager (D). The NF-κB 
activation signal at Ser536 (A), Ser468 (B), or total (C), was normalised for cell number 
and data expressed as a percentage of basal expression (time 0). Statistical 
comparisons were performed by one-way ANOVA with Dunnett's post hoc test 
(α=0.05). The data represent the means ± S.E.M. of 3 experiments. 
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5.3.4 The regulation of NF-κB in LPA treated cells by LPAR1-4, MAPKs, 
PKC and PI3K. 
LPA receptors and specific kinases were inhibited by treating the cells with antagonists 
60 minutes before stimulation with 5µM LPA for 15 minutes. As seen in Figure 5.4, the 
LPA receptor 4 antagonist, Suramin, increased the expression of both serine 536 (A) 
and serine 468 (B) residues compared to LPA treatment alone. The serine 536 residue 
was more sensitive to this inhibition and showed a much greater increase than the 
serine 468 residue which was evident but not significant. Inhibition of LPA receptors 
1/3 and 2 using Ki16425 and H2L5186303 respectively resulted in approximately 30% 
decrease in mean phosphorylation at serine 468 (Figure 5.4B) but was without 
significant effect on serine 536 (Figure 5.4A). The same was observed with PD98059 
and BIM-1 treatment. Inhibition of PI3K using the inhibitor LY294002 had no significant 
effect on either residue. The greatest effect at both residues was observed with JNK 
inhibition, reducing phosphorylation to ~50%. Expression of total NF-κB (Figure 5.4C) 
was unchanged by treatment with the inhibitors and LPA receptor antagonists. 
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Figure 5.4. Regulation of NF-κB in LPA treated P19 cells 
A cell-based ELISA kit (Active Motif) was used to determine the regulation of 
phosphorylated and total NF-κB in LPA treated cells. 100µL of cell suspension 
containing 1.5x104 cells was seeded into each well of a 96-well plate and incubated 
for 48 hours. Basal expression was determined by stimulating the cells with 5µM LPA, 
prepared in serum-free αMEM, for 15 minutes. Changes in basal expression after an 
initial 60-minute incubation with the inhibitors for LPA receptors (LPAR 1/3 
antagonized with 20µM Ki16425, LPAR 4 antagonized with 0.1mg/mL Suramin, 
LPAR2 antagonized with 7.5nM H2L5186303) or kinase inhibitors (ERK pathway 
inhibited with 20µM PD98059, JNK pathway inhibited with 10µM SP600125, PI3K 
inhibited with 20µM LY294002, PKC inhibited with 10µM BIM-1) followed by 
stimulation with LPA for 15 minutes was compared to basal expression. The assay 
was carried out as described in section 5.2.4. The NF-κB activation signal at Ser536 
(A), Ser468 (B), or total (C) was normalised for cell number and data expressed as a 
percentage of basal expression. Statistical comparisons were performed by one-way 
ANOVA with Dunnett's post hoc test (α=0.05). The data represent the means ± S.E.M. 
of 3 experiments. 
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5.3.5 Phosphorylation of AP-1 subunits by LPA 
To determine the activation of c-Fos, JunD, FosB, and c-Jun in LPA treated cells, the 
TransAm AP-1 family ELISA kit was used.  
The phosphorylation of c-Fos (Figure 5.5) was relatively low and unchanged in cells 
seeded with or without 5µM LPA during EB formation. Maximum expression was seen 
on day 10 in both treated and untreated cells. Similarly, the phosphorylation of FosB 
(Figure 5.6) was also unchanged in cells seeded with or without 5µM LPA during EB 
formation. Expression in both treated and untreated cells was near constant until day 
6 with a sustained peak on day 8 and 10. Although not statistically different, the 
untreated cells showed a higher FosB expression from day 6 to 10. JunD expression 
(Figure 5.6) was also relatively unchanged between treated and untreated cells from 
days 1-4. An increase in JunD phosphorylation in LPA treated cells was seen on day 
6 and onwards compared to the untreated cells with a significant difference seen on 
day 10. Maximum activity of JunD in LPA treated cells was also seen on day 10. 
Phosphorylation of c-Jun (Figure 5.7) was also comparable in both treated and 
untreated cells on days 1-4. On day 6 a spike in cJun activity in both untreated and 
treated cells was seen with the latter being slightly greater. This decreased on day 8, 
and the decrease continued to day 10 in untreated cells but significantly increased in 
LPA treated cells.
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Figure 5.5. The effect of LPA on the activation of c-Fos 
P19 cells were seeded in the absence or presence of 5µM LPA in non-tissue grade 
Petri dishes for 4 days. EBs were then transferred and cultured in 6-well tissue grade 
plates for a further 6 days. Nuclear lysates were generated on day 1, 2, 3, 4, 6, 8, and 
10 of the differentiation process and activation of c-Fos was determined using the 
TransAM AP-1 family transcription factor assay kit (Active Motif) as described in 
section 5.2.5. Statistical comparisons were performed by two-way ANOVA with 
Bonferroni post hoc test (α=0.05). The data represent the means ± S.E.M. of 3 
experiments. 
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Figure 5.6. The effect of LPA on the activation of FosB 
P19 cells were seeded in the absence or presence of 5µM LPA in non-tissue grade 
Petri dishes for 4 days. EBs were then transferred and cultured in 6-well tissue grade 
plates for a further 6 days. Nuclear lysates were generated on day 1, 2, 3, 4, 6, 8, and 
10 of the differentiation process and activation of FosB was determined using the 
TransAM AP-1 family transcription factor assay kit (Active Motif) as described in 
section 5.2.5. Statistical comparisons were performed by two-way ANOVA with 
Bonferroni post hoc test (α=0.05). The data represent the means ± S.E.M. of 3 
experiments.
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Figure 5.7. The effect of LPA on the activation of JunD 
P19 cells were seeded in the absence or presence of 5µM LPA in non-tissue grade 
Petri dishes for 4 days. EBs were then transferred and cultured in 6-well tissue grade 
plates for a further 6 days. Nuclear lysates were generated on day 1, 2, 3, 4, 6, 8, and 
10 of the differentiation process and activation of JunD was determined using the 
TransAM AP-1 family transcription factor assay kit (Active Motif) as described in 
section 5.2.5. Statistical comparisons were performed by two-way ANOVA with 
Bonferroni post hoc test (α=0.05). The data represent the means ± S.E.M. of 3 
experiments.
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Figure 5.8. The effect of LPA on the activation of c-Jun 
P19 cells were seeded in the absence or presence of 5µM LPA in non-tissue grade 
Petri dishes for 4 days. EBs were then transferred and cultured in 6-well tissue grade 
plates for a further 6 days. Nuclear lysates were generated on day 1, 2, 3, 4, 6, 8, and 
10 of the differentiation process and activation of c-Jun was determined using the 
TransAM AP-1 family transcription factor assay kit (Active Motif) as described in 
section 5.2.5. Statistical comparisons were performed by two-way ANOVA with 
Bonferroni post hoc test (α=0.05). The data represent the means ± S.E.M. of 3 
experiments. 
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5.3.6 Regulation of AP-1 subunits in LPA treated cells by LPAR1-4, 
MAPKs, PKC, PI3K, and NF-κB 
5.3.6.1 c-Fos 
As seen in Figure 5.9, inhibition of LPA receptor 4, 1/3, and 2 using Suramin, Ki16425, 
and H2L5186303 respectively did not significantly affect the activation of c-Fos. 
Inhibition of the PKC and PI3K kinases by BIM-1 and LY294002 respectively also did 
not affect the activation of c-Fos. The AP-1 subunits are well-established targets of the 
MAPKs and NF-κB, however, inhibition of JNK, ERK, and NF-κB by SP600125, 
PD98059, and CAY10470 respectively did not change the activity of c-Fos.
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Figure 5.9. Regulation of c-Fos in LPA treated P19 cells  
P19 cells were seeded in the presence of 5µM LPA after a 60-minute pre-treatment 
with antagonists for LPA receptor 1/3 (20µM Ki16425), 2 (7.5nM H2L5186303), and 4 
(0.1mg/mL Suramin) and inhibitors for PI3K (20µM LY294002), PKC (10µM BIM-1), 
ERK (20µM PD98059), JNK (10µM SP600125) and NF-κB (0.01nM CAY10470) in 
non-tissue grade Petri dishes for 4 days. EBs were then transferred and cultured in 6-
well tissue grade plates for a further 6 days. Nuclear lysates were generated on day 
10 of the differentiation process, and activation of c-Fos was determined using the 
TransAM AP-1 family transcription factor assay kit (Active Motif) as described in 
section 5.2.6. Statistical comparisons were performed by one-way ANOVA with 
Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. of 3 
experiments. 
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5.3.6.2 FosB 
As seen in Figure 5.10, inhibition of LPA receptor 4, 1/3, and 2 using Suramin, 
Ki16425, and H2L5186303 respectively did not significantly affect the activation of 
FosB. Inhibition of the PKC kinase by BIM-1 also did not change the activation of FosB. 
However, inhibition of PI3K by LY294002 significantly reduced the activity of FosB as 
did the inhibition of ERK by PD98059. Inhibition of JNK with SP600125 also left the 
activation of FosB unchanged. A slight decrease in FosB activation was observed with 
the inhibition of NF-κB by CAY10470, but this was not significant.
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Figure 5.10. Regulation of FosB in LPA treated P19 cells  
P19 cells were seeded in the presence of 5µM LPA after a 60-minute pre-treatment 
with antagonists for LPA receptor 1/3 (20µM Ki16425), 2 (7.5nM H2L5186303), and 4 
(0.1mg/mL Suramin) and inhibitors for PI3K (20µM LY294002), PKC (10µM BIM-1), 
ERK (20µM PD98059), JNK (10µM SP600125) and NF-κB (0.01nM CAY10470) in 
non-tissue grade Petri dishes for 4 days. EBs were then transferred and cultured in 6-
well tissue grade plates for a further 6 days. Nuclear lysates were generated on day 
10 of the differentiation process, and activation of FosB was determined using the 
TransAM AP-1 family transcription factor assay kit (Active Motif) as described in 
section 5.2.6. Statistical comparisons were performed by one-way ANOVA with 
Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. of 3 
experiments. 
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5.3.6.3 JunD 
As seen in Figure 5.11, inhibition of LPA receptor 4, and 1/3 using Suramin, and 
Ki16425 respectively noticeably decreased the activation of JunD as did the inhibition 
of JNK by SP600125 and PKC by BIM-1. A further decrease was seen with the 
inhibition of PI3K by LY294002 and NF-κB by CAY10470. The greatest decrease in 
the activation of JunD was achieved with the inhibition of ERK by PD98059. Inhibition 
of LRA receptor 2 using H2L5186303 was the only treatment that left JunD activation 
unchanged compared to LPA treatment alone. 
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Figure 5.11. Regulation of JunD in LPA treated P19 cells  
P19 cells were seeded in the presence of 5µM LPA after a 60-minute pre-treatment 
with antagonists for LPA receptor 1/3 (20µM Ki16425), 2 (7.5nM H2L5186303), and 4 
(0.1mg/mL Suramin) and inhibitors for PI3K (20µM LY294002), PKC (10µM BIM-1), 
ERK (20µM PD98059), JNK (10µM SP600125) and NF-κB (0.01nM CAY10470) in 
non-tissue grade Petri dishes for 4 days. EBs were then transferred and cultured in 6-
well tissue grade plates for a further 6 days. Nuclear lysates were generated on day 
10 of the differentiation process, and activation of JunD was determined using the 
TransAM AP-1 family transcription factor assay kit (Active Motif) as described in 
section 5.2.6. Statistical comparisons were performed by one-way ANOVA with 
Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. of 3 
experiments. 
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5.3.6.4 cJun 
As seen in Figure 5.12, each treatment inhibiting a specific kinase or LPA receptor 
significantly affected the activation of c-Jun compared to treatment with LPA alone. 
The decrease in cJun activation with the inhibition of LPA receptor 4, 1/3, and 2 was 
comparable amongst the group with the mean decrease between 25-35% when 
compared to LPA treatment alone. Inhibition of JNK also decreased cJun activation by 
a similar margin. A decrease of approximately 40% in the mean activation of cJun was 
achieved with the inhibition of PKC, PI3K, and NF-κB whereas the activation of cJun 
was reduced to ~50% with the inhibition of ERK. 
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Figure 5.12. Regulation of c-Jun in LPA treated P19 cells  
P19 cells were seeded in the presence of 5µM LPA after a 60-minute pre-treatment 
with antagonists for LPA receptor 1/3 (20µM Ki16425), 2 (7.5nM H2L5186303), and 4 
(0.1mg/mL Suramin) and inhibitors for PI3K (20µM LY294002), PKC (10µM BIM-1), 
ERK (20µM PD98059), JNK (10µM SP600125) and NF-κB (0.01nM CAY10470) in 
non-tissue grade Petri dishes for 4 days. EBs were then transferred and cultured in 6-
well tissue grade plates for a further 6 days. Nuclear lysates were generated on day 
10 of the differentiation process, and activation of c-Jun was determined using the 
TransAM AP-1 family transcription factor assay kit (Active Motif) as described in 
section 5.2.6. Statistical comparisons were performed by one-way ANOVA with 
Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. of 3 
experiments. 
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5.3.7 Phosphorylation of ATF2 by LPA  
The expression of pATF2 steadily increased in both LPA treated and untreated cells 
from day 1 until day 4 with comparable expression. Expression of pATF2 plateaued 
from day 4 until 8 in both treated and untreated cells with slightly greater pATF2 
expression in LPA treated cells on day 4 and 6. On day 10 the expression of pATF2 in 
untreated cells remained relatively the same as days 4-8 however the expression of 
pATF2 approximately doubled in LPA treated cells (Figure 5.13). 
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Figure 5.13. The effect of LPA on the expression of pATF2. 
P19 cells were seeded in the absence or presence of 5µM LPA in non-tissue grade 
Petri dishes for 4 days. EBs were then transferred and cultured in 6-well tissue grade 
plates for a further 6 days. Lysates were generated on day 1, 2, 3, 4, 6, 8, and 10 of 
the differentiation process using 1x RIPA buffer, as described in chapter 2 section 
2.3.2, for expression of phospho-ATF2 (Thr71) determined by western blot. Statistical 
comparisons were performed by two-way ANOVA with Bonferroni post hoc test 
(α=0.05). The data represent the means ± S.E.M. of 3 experiments.
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5.3.8 The regulation of pATF2 in LPA treated cells by LPAR1-4, MAPKs, 
PKC, PI3K, and NF-κB. 
As seen in Figure 5.14, each treatment inhibiting a specific kinase or LPA receptor 
significantly affected the phosphorylation of pATF2 compared to treatment with LPA 
alone. The decrease in phosphorylated pATF2 with the inhibition of LPA receptor 4, 
1/3, and 2 was comparable amongst the group with the mean decrease of 
approximately 80% when compared to LPA treatment alone. Inhibition of the MAPKs, 
JNK and ERK, reduced the mean expression of phosphorylated pATF2 by 
approximately 75% and 50% respectively. Inhibition of PKC also reduced mean 
expression by approximately 80% whereas inhibition of PI3K had no significant effect 
on the expression of phosphorylated pATF2. A decrease of approximately two thirds 
in the expression of phosphorylated pATF2 was achieved with the inhibition of NF-κB.  
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Figure 5.14. Regulation of pATF2 in LPA treated P19 cells  
P19 cells were seeded in the presence of 5µM LPA after a 60-minute pre-treatment 
with antagonists for LPA receptor 1/3 (20µM Ki16425), 2 (7.5nM H2L5186303), and 4 
(0.1mg/mL Suramin) and inhibitors for PI3K (20µM LY294002), PKC (10µM BIM-1), 
ERK (20µM PD98059), JNK (10µM SP600125) and NF-κB (0.01nM CAY10470) in 
non-tissue grade Petri dishes for 4 days. EBs were then transferred and cultured in 6-
well tissue grade plates for a further 6 days. Lysates were generated on day 10 of the 
differentiation process using 1x RIPA buffer, as described in chapter 2 section 2.3.2, 
for expression of phospho-ATF2 (Thr71) determined by western blot. Statistical 
comparisons were performed by one-way ANOVA with Dunnett’s post hoc test 
(α=0.05). The data represent the means ± S.E.M. of 3 experiments.
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5.4 Discussion 
Little is known about the role of NF-κB in heart development or in the differentiation of 
stem cells into cardiomyocytes, but it has a cardioprotective ability during acute 
hypoxia and reperfusion injury (Misra et al., 2003; Mustapha et al., 2000). NF-κB 
activation in cardiomyocytes is also necessary for regeneration after injury in the 
zebrafish (Karra et al., 2015). Although NF-κB subunits p50 and p65 are present 
throughout myocyte development (Norman, Yacoub, & Barton, 1998), studies in stem 
cells have been contradicting. NF-κB activity has been reported to maintain 
pluripotency of ihPSCs (Takase et al., 2013) and hESCs (Armstrong et al., 2006) while 
studies in mESCs suggest the up-regulation of NF-κB in differentiating cells (Kim et 
al., 2008; Torres & Watt, 2008).    
We evaluated the role of NF-κB in mediating the actions of LPA in P19 cells by blocking 
NF-κB activity using CAY10470 (Tobe et al., 2003). This inhibitor has an IC50 of 7-
11nM and has previously been used in the low nM range in P19 cells (Wagley et al., 
2013), and hiPSC derived neurons (Nekrasov et al., 2016). Possible mechanisms for 
NF-κB inactivation by this inhibitor include indirect inhibition by blocking store-operated 
calcium entry (Choi et al., 2006) or directly by blocking IκB-α phosphorylation (Bernard 
& Gallo, 2010).  
Inhibition of NF-κB using 0.01nM of the inhibitor effectively blocked LPA induced 
expression of MLC1v on day 10 of differentiation implying that NF-κB is necessary in 
our model. We furthered examined the phosphorylation profile of p65 at serine 536 on 
days 1, 2, 3, 4, 6, 8, and 10 of the differentiation process in response to LPA and found 
that p65 phosphorylation occurs in both untreated and untreated cells only for the first 
2 days. We next used the FACE NF-κB kit to examine the phosphorylation of p65 at 
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serine 536 and 468 in response to LPA over the course of 180 minutes to determine 
if NF-κB activation by LPA was an immediate event. Our findings indicate that, 
although activity is higher at serine 468, p65 activity does not increase in response to 
LPA. As discussed in chapter 4, this may be due to the adherent culture conditions in 
which the assay is conducted. We also evaluated the regulation of p65 using the same 
kit.  
The LPA receptor 4 antagonist, Suramin, increased the expression of both serine 468 
and 536 residues compared to LPA treatment alone. The serine 536 residue was more 
sensitive to this inhibition and showed a much greater increase than the serine 468 
residue which was evident but not significant. Aside from blocking P2Y receptors, 
Suramin is an agonist of ryanodine receptors (Emmick et al., 1994; Hohenegger et al., 
1996; Sitsapesan & Williams, 1996). These receptors activate NF-κB by mediating 
calcium release (Valdes et al., 2007) and are expressed in iPSCs exposed to DMSO 
to initiate cardiac differentiation (Iglesias-García et al., 2015).  
Inhibition of LPA receptors 1/3 and 2 using the Ki16425 and H2L5186303 antagonists 
respectively resulted in approximately 30% decrease in phosphorylation at serine 468 
but was without significant effect at serine 536. The same was observed with PD98059 
and BIM-1 treatment.  In the context of cardiac hypertrophy, LPAR 1/3 and ERK have 
been implicated in the induction of the NF-κB pathway (Chen et al., 2008b). LPA also 
requires PKC signalling to induce NF-κB signalling in MEFs (Klemm et al., 2007; Sun 
et al., 2009), bronchial epithelial cells (Cummings et al., 2004), and ovarian cancer 
cells (Mahanivong et al., 2008), whereas PI3K signalling is dispensable (Chen et al., 
2008b; Klemm et al., 2007) and is consistent with our results where inhibition of PI3K 
using the inhibitor LY294002 had no significant effect on either residue. The greatest 
effect at both residues was observed with JNK inhibition, reducing phosphorylation to 
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half. IκB proteins bind and retain NF-κB in the cytoplasm preventing translocation into 
the nucleus. Several kinase cascades including PKC, PKA, MAPKs, and Raf, can 
activate NF-κB for translocation into the nucleus (Valen, Yan, & Hansson, 2001). The 
upstream kinase TAK1 has been shown to regulate JNK and NF-κB, both of which 
cross-talk and converge on the regulation of AP-1 (Kracht, 2007).  
The effects of AP-1 signalling are multi-faceted and span multiple cellular processes. 
This is achieved by different compositions of dimerization of Jun and Fos, and with 
other transcription factors including ATF2. AP-1 also acts as a co-factor for other 
transcription factors including GATA4 (Martin et al., 2012; Schroder et al., 2006; 
Suzuki et al., 1999). c-Jun lacking murine embryos expressing the second heart field 
(SHF) marker IsI1 are reported to display multiple defects in cardiac development 
(Zhang et al., 2013) supported by earlier findings of Eferl et al. (1999) and a study by 
Jahangiri et al. (2016) that implicated Fos-like antigen 2 in the transition of SHF 
progenitors to cardiomyocytes. AP-1 has been reported to be vital for the cardiac 
differentiation of P19 cells in the presence of DMSO (Eriksson & Leppa, 2002) and in 
icariin induced cardiac differentiation of mESCs (Wo et al., 2008). Recently, Liu et al. 
(2017) also suggested Fos and Jun play important roles in cardiac differentiation by 
profiling both hiPSC and hESC cell lines during various stages of differentiation.   
Eriksson and Leppa (2002) examined the induction of AP-1 in P19 cells stimulated by 
DMSO and reported the upregulation of c-Jun and JunD during differentiation whereas 
c-Fos remained steady and that this activity was necessary for cardiac differentiation 
of P19 cells. LPA induces AP-1 (Cook, Aziz, & McMahon, 1999; Marinissen et al., 
2004) and, in our experimental model, JunD and c-Jun were also upregulated in 
differentiating cells while c-Fos and FosB were steadily expressed in both treated and 
untreated cells on days 1-6 with an increasing trend on days 8 and 10. Our studies 
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were not extended to examine the necessity of AP-1 activity in LPA induced cardiac 
differentiation of P19 cells but initiated studies to understand the regulation of the AP-
1 subunits in this model.  
As c-Fos expression was barely detectable compared to other AP-1 subunits in 
response to LPA stimulation, it is reasonable that phosphorylation levels of c-Fos were 
unaffected by treatment with antagonists for LPA receptors 1-4, the MAPKs, PKC, 
PI3K, and NF-κB. FosB phosphorylation was decreased only with PD98059 and 
LY294002. Phosphorylated levels of JunD were brought to basal by the inhibition of 
LPAR4, LPAR1/3, JNK, PKC, PI3K, and NF-κB, but inhibition of the ERK pathway 
reduced levels to below basal. Phosphorylated levels of c-Jun were similarly brought 
to basal with the inhibition of LPAR4, LPAR1/3, but also LPAR2. Inhibition of NF-κB, 
PI3K, and PKC reduced levels to below basal. Of the MAPKs, inhibition of JNK 
returned phosphorylated levels to basal and inhibition of ERK had the greatest effect 
amongst all pathways targeted.  
AP-1 forms complexes with ATF2 and is essential to cardiac differentiation in P19CL6 
cells (Eriksson & Leppa, 2002; Monzen et al., 2001). In our studies, the expression of 
phosphorylated ATF2 steadily increased during EB formation in both LPA treated and 
untreated cells and was sustained until day 10 in untreated cells but doubled in LPA 
treated cells on day 10. Phosphorylation of ATF2 was negatively affected by the 
inhibition of LPAR1-4 in a comparable manner, reducing the expression to 
approximately 20%. Inhibition of PKC, NF-κB, and JNK was slightly less effective and 
decreased phosphorylation by two thirds whereas inhibition of ERK only reduced 
expression by half. Inhibition of PI3K was without effect. Multiple pathways converge 
on ATF2 regulation as it is a target of SMAD and TAK1 pathways in TGF-β signalling 
(Sano et al.,1999). In mECCs, the overexpression of Noggin antagonized cardiac 
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differentiation in the presence of DMSO which was rescued by the addition of BMP to 
the culture medium as did the downstream targets of BMP signalling, SMAD 1/4 
(Monzen et al., 2001), and TAK1 (Monzen et al., 1999).  
In conclusion, NF-κB signalling is required in LPA mediated cardiac differentiation of 
P19 cells however p65 phosphorylation at serine 468 and 536 was unchanged in 
response to LPA treatment therefore further evaluation of other phosphorylation sites 
and subunits is required. Although the role of AP-1 in our model is yet to be identified, 
AP-1 subunits, c-Jun and JunD, and ATF2 were found to be regulated by NF-κB along 
with LPAR4, 1/3, PKC, JNK, and ERK. Inhibition of PI3K did not affect ATF2 whereas 
inhibition of LPAR2 did not affect JunD. 
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Chapter 6 
The regulation of cardiac specific 
transcription factors in LPA mediated 
cardiac differentiation of P19 cells
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6.1 Introduction  
A complex gene regulatory network is involved in the development of the heart fields 
and their specification. GATA4, NKX2.5, and MEF2C are expressed in cardiac 
precursor cells and act in combination with several cofactors to regulate cardiac 
specification (Bruneau, 2013; Dodou et al., 2004; Paige et al., 2015; Roche, Czubryt, 
& Wigle, 2013). The precise regulation of these factors is elusive, and several 
compensatory mechanisms identified further complicate the endeavour. GATA4 
activity has been suggested to be the earliest amongst several of the transcription 
factors, and MEF2C and NKX2.5 contain GATA sites in their enhancer region. These 
proteins are frequently used to assess differentiation into a cardiac fate and 
overexpression of GATA4, NKX2.5, or MEF2c in aggregated P19 cells induces cardiac 
differentiation without the addition of other factors. Overexpression of one of these 
factors result in the upregulation of the other two factors whereas upregulation is not 
seen in dominant negative GATA4 or NKX2.5 cells, and cardiac differentiation is 
arrested demonstrating a positive regulatory loop (Grepin, Nemer, & Nemer, 1997; 
Jamali et al., 2001; Skerjanc et al., 1998).   
Upstream signalling of these transcription factors is not well defined. MAPKs, ERK 
and p38, have both been implicated in their regulation and this has further been 
evidenced in P19 cells overexpressing noggin, a natural BMP antagonist. BMP 
signalling via TAK1 and possible downstream MAPK may regulate cardiac specific 
transcription factors as the combined overexpression of GATA4 and NKX2.5 or TAK1 
(Monzen et al., 1999) alone rescues the cardiac phenotype. Involvement of p38 MAPK 
in MEF2c nuclear localisation has also been reported (Han et al., 1997; Hernandez-
Torres et al., 2008; Zhao et al., 1999). NKX2.5 was shown to be a direct target of the 
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JNK substrate NFAT and regulates NKX2.5 during cardiac differentiation with GATA4 
co-ordination (Chen & Cao, 2009).  
In this study, we aim to determine the expression profile of GATA, MEF2C, and 
NKX2.5 during LPA mediated cardiac differentiation. We further aim to evaluate the 
regulation of these factors by LPAR1-4, PI3K, PKC, NF-κB, and the MAPKs, as they 
have been found to be critical in our experimental model. 
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6.2 Materials and Methods  
6.2.1 Determining the effect of LPA treatment on the expression of 
cardiac-specific transcription factors 
The differentiation process was carried out as described in chapter 2 section 2.2. 
Lysates were generated on days 6, 8, and 10, and protein quantification was carried 
out as described in chapter 2 section 2.3.2 and 2.3.3 respectively. Western blot was 
carried out as outlined in chapter 2 section 2.4 with the following modifications. The 
GATA-4 and the MEF2C (Cell Signaling Technology) primary antibodies were used at 
a dilution of 1:1000. The anti-NKX2.5 (Abcam) primary antibody was used at dilutions 
of 1:1000, 1:2500, and 1:5000 in both 5% non-fat milk blocking buffer and 5% BSA 
blocking buffer. The anti-rabbit IgG, HRP-linked secondary antibody (Cell Signaling 
Technology) was used at a dilution of 1:4000 for the detection of GATA4 and MEF2C 
and at dilutions of 1:4000 and 1:6000 for the detection of NKX2.5 Statistical analysis 
was done as described in chapter 2 section 2.7. 
6.2.2 Determining the regulation of cardiac-specific transcription factors 
in LPA treated cells by LPA receptors 1-4, MAPKs, PKC, PI3K, and NF-κB 
The differentiation process was carried out as described in chapter 2 section 2.2. EBs 
were seeded in the presence of antagonists for LPA receptor 1/3 (20µM Ki16425), 2 
(7.5nM H2L5186303), and 4 (0.1mg/mL Suramin) and inhibitors for PI3K (20µM 
LY294002), PKC (10µM BIM-1), ERK (20µM PD98059), JNK (10µM SP600125) and 
NF-κB (0.01nM CAY10470) for 60 minutes before treatment with 5µM LPA. Lysates 
were generated on day 10 of the differentiation process as described in chapter 2 
section 2.3.2. Protein quantification and western blot were carried out as described in 
chapter 2 section 2.3.3 and 2.4 respectively with the following modifications: The 
GATA-4 and the MEF2C (Cell Signaling Technology) primary antibodies were used at 
a dilution of 1:1000. The anti-rabbit IgG, HRP-linked secondary antibody (Cell 
Signaling Technology) was used at a dilution of 1:4000. Statistical analysis was done 
as described in chapter 2 section 2.7.
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6.3 Results  
6.3.1 Expression of cardiac-specific transcription factors in LPA treated 
cells. 
Lysates were generated on days 6, 8, and 10 of the differentiation process. The 
expression of both GATA4 (Figure 6.0) and MEF2C (Figure 6.1) was below 25% in 
both untreated and treated cells on day 6. GATA4 expression remained near this basal 
expression on days 8 and 10 in untreated cells, but the expression in LPA treated cells 
increased substantially on day 8 and was sustained until day 10. In comparison, the 
increase in MEF2C expression was time-dependent in LPA treated cells with a 
maximum expression on day 10. The untreated cells exhibited an unchanged basal 
expression from days 6-10. 
NKX2.5 expression could not be determined as further optimisation with the primary 
antibody was required. The anti-NKX2.5 primary antibody was used at dilutions of 
1:1000, 1:2500, and 1:5000 in both 5% non-fat milk blocking buffer and 5% BSA 
blocking buffer. A dilution of 1:1000 of primary antibody and 1:4000 dilution of the anti-
rabbit IgG, HRP-linked secondary antibody is shown in Figure 6.2A. Too many 
unspecific bands were obtained, and a further dilution of 1:2500 of the primary 
antibody with the previously used dilution of secondary antibody was attempted (B). A 
further dilution of 1:5000 of primary antibody and 1:6000 dilution of the anti-rabbit IgG, 
HRP-linked secondary antibody is shown in Figure 6.2C.
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Figure 6.0. LPA induces GATA4 expression in a time-dependent manner 
P19 cells were seeded in the absence or presence of 5µM LPA in non-tissue grade 
Petri dishes for 4 days. EBs were then transferred and cultured in tissue grade 6-well 
plates for a further 6 days. Lysates were generated on days 6, 8, and 10 of the 
differentiation process for expression of GATA4 determined by western blot. Statistical 
comparisons were performed by two-way ANOVA with Bonferroni post hoc test 
(α=0.05). The data represent the means ± S.E.M. of 3 experiments.
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Figure 6.1. LPA induces MEF2C expression in a time-dependent manner 
P19 cells were seeded in the absence or presence of 5µM LPA in non-tissue grade 
Petri dishes for 4 days. EBs were then transferred and cultured in tissue grade 6-well 
plates for a further 6 days. Lysates were generated on days 6, 8, and 10 of the 
differentiation process for expression of MEF2C determined by western blot. Statistical 
comparisons were performed by two-way ANOVA with Bonferroni post hoc test 
(α=0.05). The data represent the means ± S.E.M. of 3 experiments.
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Figure 6.2. Optimization of the NKX2.5 antibody  
P19 cells were seeded in the absence or presence of 5µM LPA in non-tissue grade 
Petri dishes for 4 days. EBs were then transferred and cultured in tissue grade 6-well 
plates for a further 6 days. Lysates were generated on days 6, 8, and 10 of the 
differentiation process for expression of NKX2.5 determined by western blot. 
Optimization of the primary antibody was attempted using a dilution of 1/1000 (A) and 
1/2500 (B) with a 1/4000 dilution of the anti-rabbit IgG, HRP-linked secondary antibody 
and with a dilution of 1/5000 and 1/6000 for the primary and secondary antibody (C). 
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6.3.2 The regulation of cardiac specific transcription factors in LPA 
treated cells by LPA receptors 1-4, MAPKs, PKC, PI3K, and NF-κB 
6.3.2.1 GATA4 
From the study above, maximum GATA4 expression was observed on day 10 of the 
time points analysed, therefore, we next set out to determine if the inhibition of the 
LPA receptors or specific kinases changed this expression. 
As seen in Figure 6.3, the expression of GATA4 was reduced by the inhibition of each 
of the LPA receptors. Inhibition of receptor 4 by Suramin was the most effective and 
reduced levels to below basal. Inhibition of receptor 1/3 and 2 by Ki16425 and 
H2L5186303 respectively were similar, with a mean expression of approximately 25% 
compared to cells treated with only LPA (5µM). Inhibition of PKC by BIM-1 also 
reduced expression levels to below basal while inhibition of PI3K by LY294002 
showed a mean decrease of approximately 30%. Inhibition of JNK by SP600125 
reduced the mean expression of GATA4 by over 80%. The decrease in GATA4 
expression by the inhibition of ERK by PD98059, although significant, was less 
effective than JNK. Like ERK, the inhibition of NF-κB also reduced GATA4 expression 
by half compared to cells treated with LPA alone.  
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Figure 6.3. Regulation of GATA4 in LPA treated P19 cells  
P19 cells were seeded in the presence of 5µM LPA after a 60-minute pre-treatment 
with antagonists for LPA receptor 1/3 (20µM Ki16425), 2 (7.5nM H2L5186303), and 4 
(0.1mg/mL Suramin) and inhibitors for PI3K (20µM LY294002), PKC (10µM BIM-1), 
ERK (20µM PD98059), JNK (10µM SP600125) and NF-κB (0.01nM CAY10470) in 
non-tissue grade Petri dishes for 4 days. EBs were then transferred and cultured in 6-
well tissue grade plates for a further 6 days. Lysates were generated on day 10 of the 
differentiation process using 1x RIPA buffer, as described in chapter 2 section 2.3.2, 
for expression of GATA4 determined by western blot. Statistical comparisons were 
performed by one-way ANOVA with Dunnett’s post hoc test (α=0.05). The data 
represent the means ± S.E.M. of 3 experiments. 
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6.3.2.2 MEF2C 
From the study above, maximum MEF2C expression was observed on day 10 of the 
time points analysed, therefore, we next set out to determine if the inhibition of the 
LPA receptors or specific kinases changed this expression. 
As seen in Figure 6.4, the expression of MEF2c was reduced by the inhibition of LPA 
receptor 4, 1/3, and 2 by approximately 65%, 80% and 65% respectively compared to 
LPA treatment alone. Inhibition of PKC and PI3K also significantly decreased the 
expression of MEF2c with BIM-1 reducing levels to basal and LY294002 reducing 
expression by approximately 40%. The inhibition of JNK also brought expression 
levels back to basal whereas inhibition of ERK caused 50% less expression compared 
to LPA treatment alone. Inhibition of NF-κB did not significantly change the expression 
of MEF2C. 
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Figure 6.4. Regulation of MEF2C in LPA treated P19 cells  
P19 cells were seeded in the presence of 5µM LPA after a 60-minute pre-treatment 
with antagonists for LPA receptor 1/3 (20µM Ki16425), 2 (7.5nM H2L5186303), and 4 
(0.1mg/mL Suramin) and inhibitors for PI3K (20µM LY294002), PKC (10µM BIM-1), 
ERK (20µM PD98059), JNK (10µM SP600125) and NF-κB (0.01nM CAY10470) in 
non-tissue grade Petri dishes for 4 days. EBs were then transferred and cultured in 6-
well tissue grade plates for a further 6 days. Lysates were generated on day 10 of the 
differentiation process using 1x RIPA buffer, as described in chapter 2 section 2.3.2, 
for expression of MEF2C determined by western blot. Statistical comparisons were 
performed by one-way ANOVA with Dunnett’s post hoc test (α=0.05). The data 
represent the means ± S.E.M. of 3 experiments. 
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6.4 Discussion 
The expression of cardiac-specific transcription factors is used to validate the 
commencement of the cardiac program. However, the in vitro regulation of these 
factors is not entirely known, but transcription factors typically have multiple levels of 
control and often work in conjunction with other cell type dependent and independent 
transcription factors.  
The expression of GATA4, MEF2C, and NKX2.5 in P19 cells exposed to 1% DMSO 
is typically evident after cells have been transferred to tissue culture plates (Harada et 
al., 2008; Yilbas et al., 2014). Therefore, we evaluated the expression of these factors 
in response to LPA treatment on day 6, 8, and 10 of the differentiation process. The 
expression of GATA4 in untreated cells remained relatively stable through days 6-10 
with less than 30% expression. A similar expression was seen in LPA treated cells on 
day 6, with a dramatic increase in expression observed on day 8 which was sustained 
on day 10. The expression of MEF2C in untreated cells also remained stable on days 
6, 8 and 10 with less than 30%. MEF2C expression in LPA treated cells on day 6 was 
comparable to the expression in untreated cells and gradually increased until day 10.  
As maximum expression of GATA4 and MEF2C was observed on day 10 of the time 
points analysed, we next sought out to determine if treatment with kinase-specific 
inhibitors altered this expression. Inhibition of LPAR4 by Suramin abolished the 
expression of GATA4 and MEF2C whereas inhibition of LPAR2 by H2L5186303 and 
inhibition of LPAR1/3 by Ki16425 brought the expression of both to the basal level. 
These findings correlate to findings discussed in chapter 3 where treatment with 
Suramin (0.1mg/mL) resulted in the MLC1v expression being below that of basal 
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expression and treatment with H2L5186303 (7.5nM) and Ki16425 (20µM) returned 
levels of MLC1v to basal.  
Inhibition of PKC by BIM-1 inhibited GATA4 and MEF2C expression by 85% and 65% 
respectively. PKC mediated GATA4 regulation has been observed by groups studying 
signalling in the context of cardiac hypertrophy (Wang et al., 2005) however, in the 
context of cardiac differentiation, PKC regulation of GATA4 has not been well 
supported (Gallagher et al., 2014).   
Treatment with LY294002 had marginal effects on GATA4 and MEF2C, with 
approximately 30% and 40% reduction in expression respectively. Bekhite et al. (2011) 
have provided data suggesting inhibition of PI3K inhibits GATA4 expression when 
induced by VEGF. Naito et al. (2003) also demonstrated that 20µM LY294002 inhibited 
GATA4 expression in P19 cells. Tamir and Bengal (2000) reported MEF2C regulation 
by PI3K.  
Inhibition of NF-κB decreased GATA4 expression by 50% whereas little effect was 
seen on the expression of MEF2C. Using a zebrafish model to study cardiac 
regeneration, Karra et al. (2015) found NF-κB activity was responsible for the induction 
of GATA4 regulatory sequences and that over-expression of GATA4, with NF-κB 
inhibition, was not enough to restore the regeneration program suggesting 
multifactorial regulation by NF-κB. Treatment with ERK inhibitor, PD98059, also 
decreased the expression of GATA4 and MEF2c by half which is line with the results 
of Ling et al. (2017)  who used 50µM PD98059 to block the upregulation of GATA4 
and MEF2C observed by the inhibition of miR155-3p. 
JNK inhibition by SP600125 returned expression of GATA4 and MEF2C to the basal 
level. These findings are supported by the work of Geng, Liu, and Chen (2014) who 
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used BMP9 to induce cardiac differentiation and the expression of both GATA4 and 
MEF2C was negatively affected by JNK inhibition.  
The same evaluation was attempted for NKX2.5 however further optimisation of the 
primary antibody is needed. All primary antibodies used were purchased from Cell 
Signaling Technology other than MLC1v and anti-NKX2.5. The predicted band size is 
34kDa, but on the data sheet accompanying the product, the band shown was not in 
this range, therefore, making it more difficult to identify the appropriate band on the 
blots generated in our studies. Currently, Cell Signaling Technology does not have an 
anti-NKX2.5 antibody that reacts with mouse samples, therefore, the antibody from 
Abcam needs to be further optimised or sourced from elsewhere to accurately 
determine the expression profile of NKX2.5 using western blotting. Other studies have 
indicated that NKX2.5 expression is in line with the expression of GATA4 and MEF2C 
or lags slightly (Grepin, Nemer, & Nemer, 1997; Harada et al., 2008; Naito et al., 2003; 
Yilbas et al., 2014).  
In conclusion, GATA4 and MEF2C expression is upregulated on day 8 and 10 in 
response to LPA treatment. This expression is inhibited by LPAR1-4 antagonists which 
correspond to the effect of these antagonists on MLC1v expression. PKC inhibition 
also decreased GATA4 and MEF2C expression to basal whereas PI3K inhibition 
resulted in 30-40% decrease in GATA4 and MEF2C expression. NF-κB and ERK 
inhibition resulted in a 50% loss of GATA4 expression while only the latter had a similar 
effect of MEF2C expression. JNK inhibition abolished both GATA4 and MEF2C 
expression.
167 
 
 
 
 
 
 
 
Chapter 7 
The regulation of the Hippo pathway in 
LPA mediated cardiac differentiation of 
P19 cells
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7.1 Introduction  
Members of the Hippo pathway were individually identified earlier, but the pathway 
was pieced and studied together in the Drosophila only in the mid-1990's and the 
mammalian homologs of the core proteins comprising the pathways have since been 
identified (Del Re, 2014; Meng, Moroishi, & Guan, 2016). The mammalian hippo 
pathway contains mammalian Ste20-like 1 and 2 (MST1/2) and large tumour 
suppressor 1 and 2 (LATS1/2) Ser/Thr proteins that require co-activator regulatory 
proteins, Salvador homolog 1 (SAV1) and Mps One binder 1 (MOB1). MST1/2, 
activated by SAV1, phosphorylates both LATS1/2 and MOB1 (Callus, Verhagen, & 
Vaux, 2006; Chan et al., 2005; Praskova, Xia, & Avruch, 2008). Active MOB1 
increases the binding affinity to LATS1/2 resulting in full activation. The Yes-
associated protein (YAP) is a transcriptional modulator that is retained in the 
cytoplasm when phosphorylated by MOB1 bound LATS1/2 (Huang et al.,2005). YAP 
was initially recognised to regulate proliferation, but several other roles have since 
emerged that are both cell and tissue-specific (Dong et al., 2007; Zhao et al., 2008; 
Zhao et al., 2010). The earliest cell fate decision during embryonic development 
involves YAP, and co-activated TEAD (Nishioka et al., 2009), and later regulates organ 
size, including the heart, and cardiomyocyte proliferation (Zhou et al., 2015b). YAP 
has been shown to regulate other transcription factors including Smads (Ferrigno et 
al., 2002) and Tbx5 (Murakami et al., 2005). Yu et al. (2012) found that YAP was 
phosphorylated following serum starvation but rapidly dephosphorylated upon serum 
addition in multiple cell lines. They discovered that LPA, found in serum, inhibits 
LATS1/2, acting in parallel with MST1/2, thereby allowing YAP to translocate into the 
nucleus.  
In this study, we aimed to evaluate the effect of LPA treatment on YAP phosphorylation 
and further determine the regulation of YAP and MOB1 by LPAR1-4 and JNK. 
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7.2 Materials and Methods 
7.2.1 Determining the expression of phosphorylated YAP and MOB in 
LPA treated cells   
The differentiation process was carried out as described in chapter 2 section 2.2 and 
lysates were generated 18, 24, 48 and 72 hours after initial seeding as described in 
chapter 2 section 2.3.2. Protein quantification and western blot were carried out as 
specified in chapter 2 section 2.3.3 and 2.4 respectively with the following 
modifications: Blocking buffer was made with 5% BSA in TBS-T, and Phospho-YAP 
(Ser397), Phospho-YAP (Ser127), and Phospho-MOB1 (Thr35) primary antibodies 
(Cell Signaling Technology) were used at a dilution of 1:1000 and anti-rabbit IgG, 
HRP-linked secondary antibody (Cell Signaling Technology) was used at dilution of 
1:4000. SuperSignal West Dura Substrate (Thermo Fisher) was used for protein 
detection. Statistical analysis was done as described in chapter 2 section 2.7. 
7.2.2 Determining the regulation of YAP and MOB1 in LPA treated cells by 
JNK and LPAR1-4   
The differentiation process was carried out as described in chapter 2 section 2.2. EBs 
were seeded in the presence of antagonists for LPA receptor 1/3 (20µM Ki16425), 2 
(7.5nM H2L5186303), and 4 (0.1mg/mL Suramin) and JNK (10µM and 20µM 
SP600125) for 60 minutes before treatment with 5µM LPA. Lysates were generated 
24 and 48 hours after initial seeding as described in chapter 2 section 2.3.2 for analysis 
of phosphorylated MOB1 and phosphorylated YAP respectively. Protein quantification 
and western blot were carried out as specified in chapter 2 section 2.3.3 and 2.4 
respectively with the following modifications: Blocking buffer was made with 5% BSA 
in TBS-T, and Phospho-YAP (Ser397), Phospho-YAP (Ser127), and Phospho-MOB1 
(Thr35) primary antibodies (Cell Signaling Technology) were used at a dilution of 
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1:1000 and anti-rabbit IgG, HRP-linked secondary antibody (Cell Signaling 
Technology) was used at dilution of 1:4000. SuperSignal West Dura Substrate 
(Thermo Fisher) was used for protein detection. Statistical analysis was done as 
described in chapter 2 section 2.7. 
7.2.3 Determining the expression of Hippo pathway members in LPA 
treated cells 
The differentiation process was carried out as described in chapter 2 section 2.2 and 
lysates were generated 18, 24, 48 and 72 hours after initial seeding as described in 
chapter 2 section 2.3.2. Protein quantification and western blot were carried out as 
specified in chapter 2 section 2.3.3 and 2.4 respectively with the following 
modifications: LATS1, MOB1, MST1, MST2, SAV1, and TAZ primary antibodies (Cell 
Signaling Technology) were used at a dilution of 1:1000 and anti-rabbit IgG, HRP-
linked secondary antibody (Cell Signaling Technology) was used at dilution of 1:4000. 
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7.3 Results 
7.3.1 The effect of LPA on phosphorylated YAP and MOB  
EBs were seeded in the absence or presence of 5µM LPA and lysates were collected 
18, 24, 48, and 72 hours after initial seeding. YAP was comparably phosphorylated at 
serine residue 127 (Figure 7.0) in both treated and untreated cells 18 hours after initial 
seeding. In untreated cells, this was sustained for 48 hours but radically decreased in 
LPA treated cells at 24 and 48 hours whereas phosphorylation was barely detectable 
at 72 hours in both groups. A similar trend was observed at the serine 397 residue 
(Figure 7.1). The untreated cells maintained phosphorylated YAP for 48 hours and 
then rapidly decreased at 72 hours whereas phosphorylation gradually decreased in 
LPA treated cells. The difference between untreated and treated cells at 24 hours, 
although significant, was not as drastic at serine 397 as serine 127 however, results 
were comparable at 48 and 72 hours.  
Moderate phosphorylation of MOB1 (Figure 7.2) was seen at 18 hours and was 
comparable between untreated and treated cells. Phosphorylation decreased in LPA 
treated cells but increased in untreated cells at 24 hours. Both groups showed a 
comparable decrease in phosphorylation at 48 hours and 72 hours with a minuscule 
increase at the latter time point.
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Figure 7.0. The effect of LPA treatment on p-YAP (Ser127) in P19 cells 
The P19 cells were seeded in the absence or presence of 5µM LPA in non-tissue 
grade Petri dishes for 18, 24, 48 and 72 hours. Lysates were generated using 1x RIPA 
buffer, as described in chapter 2 section 2.3.2, for expression of phospho-YAP 
(Ser127) determined by western blot. Statistical comparisons were performed by two-
way ANOVA with Bonferroni post hoc test (α=0.05). The data represent the means ± 
S.E.M. of 3 experiments.
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Figure 7.1. The effect of LPA treatment on p-YAP (Ser397) in P19 cells 
The P19 cells were seeded in the absence or presence of 5µM LPA in non-tissue 
grade Petri dishes for 18, 24, 48 and 72 hours. Lysates were generated using 1x RIPA 
buffer, as described in chapter 2 section 2.3.2, for expression of phospho-YAP 
(Ser397) determined by western blot. Statistical comparisons were performed by two-
way ANOVA with Bonferroni post hoc test (α=0.05). The data represent the means ± 
S.E.M. of 3 experiments.
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Figure 7.2. The effect of LPA treatment on p-MOB1 in P19 cells 
The P19 cells were seeded in the absence or presence of 5µM LPA in non-tissue 
grade Petri dishes for 18, 24, 48 and 72 hours. Lysates were generated using 1x RIPA 
buffer, as described in chapter 2 section 2.3.2, for expression of phospho-MOB1 
determined by western blot. Statistical comparisons were performed by two-way 
ANOVA with Bonferroni post hoc test (α=0.05). The data represent the means ± S.E.M. 
of 3 experiments.
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7.3.2 Regulation of YAP and MOB in LPA treated cells by JNK and 
LPAR1-4 
From the studies above, the difference in YAP activity at serine 127 and serine 397 
between LPA treated and untreated cells was greatest at 48 hours after initial seeding, 
therefore, this time point was used to determine changes in activity by the presence 
of LPAR antagonists or JNK inhibition. YAP serine 127 phosphorylation (Figure 7.3) 
was maintained in the untreated cells and cells treated with 10 or 20µM SP600125. 
Phosphorylation decreased in LPA treated cells and was unaffected by inhibition of 
LPAR4 by 0.1mg/mL Suramin treatment. Inhibition of LPAR2 by 7.5nM H2L5186303 
also had minimal effect on phosphorylation whereas inhibition of LPAR1/3 by 20µM 
Ki16425 caused a significant increase in phosphorylation compared to LPA treatment 
alone. Untreated and SP600125 (10 and 20µM) treated cells displayed the same 
increased phosphorylation at serine 397 (Figure 7.4). 5µM LPA treatment alone and 
with Suramin also exhibited similarly decreased phosphorylation at serine 397 as 
serine 127. LPAR1/3 inhibition by Ki16425 significantly increased phosphorylation, 
and unlike at serine 127, serine 397 phosphorylation was maintained with the inhibition 
of LPAR2 by H2L5186303 although not as predominantly as with Ki16425 treatment.  
Unlike YAP, the greatest difference in MOB activity between LPA treated and 
untreated cells was 24 hours after initial seeding, therefore, this time point was used 
to determine changes in activity by the presence of LPAR antagonists or JNK 
inhibition. MOB phosphorylation (Figure 7.5) at 24 hours in response to LPAR1-4 and 
JNK inhibition was similar to YAP serine 397. Untreated and cells treated with 
SP600125 (10 or 20µM) maintained phosphorylation whereas LPA treatment alone 
and with Suramin decreased phosphorylation. Inhibition of LPAR2 and LPA1/3 by 
H2L5186303 and Ki16425 respectively increased phosphorylation compared to LPA 
treatment alone, however, phosphorylation with treatment using the latter was higher 
in comparison. 
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Figure 7.3. Regulation of p-YAP (Ser127) in LPA treated P19 cells 
P19 cells were seeded in the presence of 5µM LPA after a 60-minute pre-treatment 
with antagonists for LPA receptor 1/3 (20µM Ki16425), 2 (7.5nM H2L5186303), and 4 
(0.1mg/mL Suramin) or JNK inhibitor (*10µM or **20µM SP600125) in non-tissue 
grade Petri dishes for 48 hours. Lysates were generated using 1x RIPA buffer, as 
described in chapter 2 section 2.3.2, for expression of phospho-YAP (Ser127) 
determined by western blot. Statistical comparisons were performed by one-way 
ANOVA with Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. 
of 3 experiments. 
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Figure 7.4. Regulation of p-YAP (Ser397) in LPA treated P19 cells 
P19 cells were seeded in the presence of 5µM LPA after a 60-minute pre-treatment 
with antagonists for LPA receptor 1/3 (20µM Ki16425), 2 (7.5nM H2L5186303), and 4 
(0.1mg/mL Suramin) or JNK inhibitor (*10µM or **20µM SP600125) in non-tissue 
grade Petri dishes for 48 hours. Lysates were generated using 1x RIPA buffer, as 
described in chapter 2 section 2.3.2, for expression of phospho-YAP (Ser397) 
determined by western blot. Statistical comparisons were performed by one-way 
ANOVA with Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. 
of 3 experiments.  
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Figure 7.5. Regulation of p-MOB1 in LPA treated P19 cells 
P19 cells were seeded in the presence of 5µM LPA after a 60-minute pre-treatment 
with antagonists for LPA receptor 1/3 (20µM Ki16425), 2 (7.5nM H2L5186303), and 4 
(0.1mg/mL Suramin) or JNK inhibitor (*10µM or **20µM SP600125) in non-tissue 
grade Petri dishes for 24 hours. Lysates were generated using 1x RIPA buffer, as 
described in chapter 2 section 2.3.2, for expression of phospho-MOB1 determined by 
western blot. Statistical comparisons were performed by one-way ANOVA with 
Dunnett’s post hoc test (α=0.05). The data represent the means ± S.E.M. of 3 
experiments. 
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7.3.3 Expression of Hippo pathway members 
The total protein expressed for each member of the Hippo cascade was also 
determined at 18, 24, 48, and 72 hours after EB formation with and without LPA 
treatment. LATS1, SAV1, MOB1, and MST1 were unchanged at the time points 
assessed however MST2 was undetectable. Total TAZ was also unchanged 
throughout, but a decrease was observed in LPA treated cells after 72 hours. 
Experiments conducted to determine the changes in TAZ expression were preliminary 
and need to be further expanded to verify this trend and significance (Figure 7.6).
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Figure 7.6. The effect of LPA treatment on kinases of the Hippo cascade 
The P19 cells were seeded in the absence or presence of 5µM LPA in non-tissue 
grade Petri dishes and cultured in suspension for 18, 24, 48 and 72 hours. Lysates 
were generated using 1x RIPA buffer, as described in chapter 2 section 2.3.2, for 
expression of LATS1, MOB1, MST1, MST2, SAV1, and TAZ as determined by western 
blot. The data represent 3 individual experiments except for the latter, which 
represents 2 experiments.
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7.4 Discussion 
Soon after birth, the heart grows by increased cardiomyocyte size instead of 
cardiomyocyte proliferation (Ahuja, Sdek, & MacLellan, 2007; Li et al., 1996; Maillet, 
van Berlo, & Molkentin, 2013). The loss of mitotic potential in cardiomyocytes prevents 
endogenous cardiac repair post-ischaemic injury. Efforts to identify cell cycle 
regulators capable of promoting cardiomyocyte proliferation have demonstrated a key 
role for the Hippo pathway. Evolutionarily conserved from the Drosophila to human, 
the Hippo pathway controls organ size including that of the heart (Zhou et al., 2015b).   
The main effector of the Hippo pathway is the Yes-associated protein (YAP), typically 
regulated through MOB activated LATS. In addition to regulating organ size, this 
kinase cascade is involved in early embryonic development, stem cell pluripotency, 
and differentiation (Aylon et al., 2014; Li et al., 2013; Posfai & Rossant, 2016).  
Phosphorylation of YAP at serine 127 or 381 by LATS tags the protein for cytoplasmic 
sequestration by binding to 14-3-3 and ubiquitination dependent degradation 
respectively. In 2012, two independent groups identified S1P and LPA responsible for 
YAP activation (Miller et al., 2012; Yu et al., 2012). Yu et al. (2012) demonstrated 
rapid, although transient, de-phosphorylation of YAP, at serine 127 and 381, and 
nuclear localisation of YAP in response to stimulation by serum after serum starvation 
in several different cell lines. Furthermore, the serum component driving the nuclear 
localisation of YAP was found to be LPA, and this effect was unchanged by growth 
factors including FGF, EGF, insulin, and PDGF, or inhibitors for MEK, PI3K, mTOR, 
and p38.   
Our findings, consistent with those of Yu et al. (2012), suggest YAP has a transient 
window of de-phosphorylation between 24-48 hours after commencing the 
differentiation process in the presence of 5µM LPA. We determined the 
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phosphorylation profile of YAP at serine residues 127 and 397 during EB formation in 
LPA treated and untreated cells. As reported by Zhao et al. (2010) the serine 397 
residue of the YAP protein isoform 1 corresponds to the serine 381 residue of the YAP 
protein isoform 2. EBs collected 18 hours after initial seeding exhibited high 
phosphorylation at both serine residues irrespective of treatment. Phosphorylation 
was maintained in untreated cells for 48 hours and decreased rapidly at 72 hours at 
both sites. In LPA treated cells, phosphorylation at serine residue 127 decreased 
rapidly much earlier, at 24 hours, to below 30% compared to untreated cells whereas 
phosphorylation dropped by less than 50% at serine 397 at the same time point but 
dropped further at 48 hours to 25% with stable expression at serine 127. Expression 
levels were below 20% after 72 hours at both sites and equivalent in LPA treated and 
untreated cells. Further investigation is required to evaluate the possibility of YAP 
degradation. This was initiated by looking at changes in total YAP expression, 
however, time constraints did not allow for full optimisation of the antibody. Studies 
were also undertaken to determine the cellular localisation of YAP in LPA treated and 
untreated cells. This was to establish the involvement of the Hippo pathway in LPA 
induced cardiac differentiation of P19 cells. However, due to prolonged mycoplasma 
contamination, time constraints did not permit for these studies to be repeated after 
the contamination had been identified and resolved.   
LPA is a ligand for multiple GPCRs initiating a complex signalling network that is 
difficult to fully decipher as the expression of GPCRs is cell-type specific and bound 
to an array of Gα proteins. Multiple Gα subunits, in the order of 12/13>q>i/o, have 
been identified to be potent inhibitors of the Hippo pathway and de-phosphorylation of 
YAP has been known to occur through LPA receptors 1 and 3 relayed via Rho 
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GTPases to inhibit LATS whereas Gs signalling induces YAP phosphorylation (Cai 
and Xu, 2013; Jeong et al., 2013; Yu et al., 2012).  
In line with these studies, our finding also suggests that LPA receptors 1 and 3 are 
largely responsible for regulating YAP activity. Treatment with Ki16425 abolished YAP 
de-phosphorylation by LPA, with a greater effect at serine 397. However, our findings 
also suggest a partial role for LPA receptor 2. As with Ki16425, treatment with 
H2L5186303, had a greater effect at serine 397, increasing phosphorylation to 
approximately 70%, compared to LPA treatment alone but only approximately 40% at 
serine 127. Treatment with Suramin yielded no change in expression compared to 
LPA treatment alone possibly because LPA receptor 4 utilises Gs signalling (Lee et 
al., 2007).  
JNK and YAP are well-defined regulators of multiple cellular processes, and JNK 
activation of YAP (Grusche et al., 2011; Shaw et al., 2010; Staley & Irvine, 2010; Sun 
& Irvine, 2011; Sun & Irvine, 2013) is context dependent. JNK mediated regulation of 
YAP occurs upon mechanical stress and promotes the proliferation of epithelial cells 
through inactivation of LATS1 by LIMD1 (Codelia, Sun, & Irvine, 2014). In the context 
of UV irradiation, JNK directly phosphorylates YAP, further promoting UV induced 
apoptosis (Tomlinson et al., 2010). Aside from JNK, other kinases critical to cardiac 
differentiation also regulate YAP including Wnt/β-catenin, PKC, and ERK (Heallen et 
al., 2011; Imajo et al., 2012; Konsavage et al., 2012; Tomlinson et al., 2010; Wang et 
al., 2013).  
The expression profile of pYAP in P19 cells exposed to LPA discussed above, 
correlated to the phosphorylation of JNK, discusses in chapter 4. We found interruption 
of the JNK pathway using SP600125 disrupted cardiac differentiation and proliferation 
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in a dose-dependent manner. As YAP has been implicated in both differentiation and 
proliferation and found to be activated by LPA and JNK we furthered our investigation 
to determine the effect of SP600125, both 10µM and 20µM, on YAP activation at both 
serine 127 and 397 residues in EBs treated with 5µM LPA for 48 hours. We found that 
Inhibition of JNK maintained phosphorylation levels equivalent to untreated cells at 
both serine residues irrespective of the concentration of SP600125 used. As 
insufficient EB proliferation is seen with 20µM SP600125 treatment within 48 hours of 
EB seeding, and equivalent phosphorylation of YAP was observed irrespective of the 
concentration of SP600125 as stated above, it is unlikely that YAP alone is involved 
in JNK mediated proliferation of EBs however, it is important to investigate YAP activity 
in the presence of 20µM SP600125 prior to 48 hours and the effect of JNK inhibition 
on other kinases implicated in EB proliferation which was not done here due to time 
constraints. YAP may be involved in regulating JNK mediated cardiac differentiation 
of P19 cells in the presence of LPA. YAP phosphorylation was not determined 
between 48 and 72 hours, however if YAP phosphorylation in untreated cells was 
sustained for several hours after the 48-hour time point examined, it may be possible 
that the lack of cardiac differentiation, observed with SP600125 treatment 48 hours 
after initial seeding, is due to continued YAP phosphorylation in untreated cells and 
de-phosphorylation of YAP in LPA treated cells that is disrupted upon JNK inhibition.   
Hippo-dependent phosphorylation of YAP requires the full activation of LATS by the 
binding of phosphorylated MOB and studies have indicated LATS modulation by LPA 
but also de-phosphorylation of MOB by LPA in HSG cells (Hwang et al., 2014). In P19 
cells we found that MOB1 is moderately phosphorylated 18 hours after EB formation 
irrespective of LPA treatment but quickly decreased in LPA treated cells at 24 hours 
to less than 20% whereas expression in untreated cells doubled. Expression in LPA 
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treated cells was sustained near 30% thereafter with an equivalent expression 
observed in untreated cells at 48 and 72 hours. De-phosphorylation of MOB1 in P19 
cells 48 hours after initial seeding irrespective of LPA treatment may indicate sustained 
MOB1 phosphorylation is not required in untreated cells for YAP phosphorylation 48 
hours after EB formation or that dual regulatory mechanisms exist for YAP regulation.  
The difference in MOB1 phosphorylation between LPA treated and untreated cells was 
most evident 24 hours after initial seeding. This expression profile was dramatically 
changed in the presence of JNK inhibitor, SP600125, and LPAR1/3 antagonist, 
Ki16425, compared to LPA treatment alone, both of which returned phosphorylation 
levels to near maximum. Treatment with Suramin was without effect whereas 
treatment with H2L5186303 increased phosphorylation expression to approximately 
60% compared to LPA treatment alone.  
In conclusion, the data discussed above suggests that LPAR1/3, and partially LPAR2 
mediated JNK signalling targets the Hippo kinase, MOB1, for de-phosphorylation of 
YAP in the presence of LPA. However, sustained de-phosphorylation of MOB1 may 
not be required for prolonged YAP de-phosphorylation implying that multiple regulatory 
mechanisms may act on YAP in this context. To confirm this, other phosphorylation 
sites of MOB1 and MOB2 would need to be examined. The cellular localisation of both 
YAP and MOB1 also require investigation to determine the involvement of the Hippo 
pathway in LPA induced cardiac differentiation of P19 cells.
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Chapter 8 
General Discussion
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Cardiovascular diseases are a major cause of morbidity and mortality around the 
globe, and the increasing awareness of stem cell research is linked to the hope of 
reversing the debilitating damage ensued by events such as myocardial infarction. The 
use of multipotent stem cells is being evaluated in multiple clinical trials, and thus far, 
improvement in cardiac function has not been substantial, therefore, there is growing 
interest in directed differentiation of stem cells for cardiac regeneration.   
The role of endogenous molecules in facilitating stem cell differentiation into 
cardiomyocytes is yet to be fully understood. SPC and S1P, common biolipids, 
promote differentiation of mesenchymal stem cells and cardiac progenitor cells to 
cardiomyocytes (Li et al., 2016; Zhao et al., 2011). However, little was known about 
the same potential of closely related LPA until recently (Pramod, 2017). 
The initial cardio-protection offered by elevated LPA levels in response to acute 
myocardial infarction (Chen et al., 2003) and the ability of this biolipid to mediate 
cardiac differentiation (Pramod, 2017) served as a rationale to investigate the signal 
transduction mechanisms mediating LPA induced cardiac differentiation of the murine 
P19 teratocarcinoma cell line. The mechanisms of cardiac differentiation have been 
widely studied in this cell line typically in response to DMSO. 
8.1 The Differentiation Protocol 
Differentiation of P19 stem cells into cell types representative of the three germ layers 
occurs when cultured in suspension through the spontaneous formation of EBs 
(Edwards, Harris, & McBurney, 1983; McBurney & Rogers, 1982; McBurney et al., 
1982). The number of cardiomyocytes derived this way is very low but can be 
enhanced with manipulation of the culture medium. In our experimental model, LPA 
induced cardiac differentiation of P19 cells in a manner comparable to DMSO. This 
was achieved using LPA at physiologically relevant concentrations with maximal 
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induction attained with 5µM as previously shown by Pramod (2017). Differentiation 
was assessed by examining the expression of the ventricular myosin light chain 
protein (MLC1v). Beating clusters of cells were routinely observed on day 10 of the 
differentiation process, however, this was not uniform, and the presence of other cell 
types was not determined. Further studies were conducted to examine the role of 
signalling molecules critical to lineage commitment including the PI3K and PKC 
pathway (chapter 3), the MAPK pathway (chapter 4), NF-κB pathway (chapter 5), and 
their regulation of transcription factors, AP-1 (chapter 5), GATA4, and MEF2C (chapter 
6). Furthermore, preliminary studies were conducted investigating the regulation of 
YAP in differentiating stem cells (chapter 7). The major findings of this thesis are 
summarised in Figure 8.0 and further discussed below.  
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Figure 8.0. Signal transduction mechanisms for LPA induced cardiac 
differentiation of P19 stem cells. 
LPA induces cardiac differentiation through LPA receptor 2 and partially through LPA 
receptor 1/3 signalling. Downstream to these receptors, the PKC and PI3K pathways 
converge on the regulation of ERK and possibly JNK. The MAPKs converge on the 
regulation of the ubiquitous transcription factors, AP-1/ATF2, which are also regulated 
by NF-κB signalling, which itself may be regulated by the JNK pathway. ERK, JNK, 
and NF-κB converge on the regulation of cardiac specific transcription factors, GATA4 
and MEF2C, however, whether the AP-1 complex lies upstream and acts as a co-
activator of these cardiac specific transcription factors is currently unknown. JNK 
regulates the Hippo pathway in this experimental model but the cellular localisation 
and role of YAP in LPA induced cardiac differentiation is yet to be determined.  
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8.2 LPA receptors 
After confirming the suitability of the differentiation protocol followed by Pramod (2017) 
we examined the roles of LPARs 1-4 in LPA induced cardiac differentiation. Pramod 
(2017) found LPAR 1/3 and 4 to be involved using Ki16425 and Suramin, respectively, 
to antagonise the actions of these receptors. Ki16425 is selective for LPARs 1 and 3 
at low concentrations but targets LPAR2 with an IC50 of 6.5µM. Pramod (2017) and 
studies carried out in this thesis have used 10µM or greater to target LPAR1/3, 
therefore, it is important to highlight that there is a possibility that the results obtained 
are due to LPAR2 inhibition. The current thesis determined the role of LPAR2 using 
H2L5186303, a highly selective antagonist, in LPA mediated cardiac differentiation. 
LPAR2 is a critical receptor in this experimental model and its inhibition blocks LPA 
induced MLC1v expression but in addition also blocks the phosphorylation of JNK 
which was found to be a critical signalling molecule. Inhibition of JNK phosphorylation 
was, however, more profound with Ki16425 treatment. The same effects were 
observed when investigating the regulation of YAP and MOB. These results suggest 
that LPAR1/3 either independently or in conjunction with LPAR2 regulate critical 
kinases and, therefore, merit further investigation into the precise role of LPAR1 and 
3. Pramod (2017) established a role of LPAR4 using Suramin and this was confirmed 
in the current thesis. Suramin is a broad-spectrum antagonist and has a multitude of 
off-target effects including promoting differentiation of stem cells into sinus node cells 
and inhibiting the binding of various key extracellular targets. Although, studies 
completed in this thesis provide preliminary indication for the involvement of LPAR4, 
in the absence of a selective established pharmacological inhibitor, for confirmatory 
studies, siRNA may be a useful tool to explore the role of LPAR4. Therefore, we can 
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conclude that LPAR2 is a critical receptor and LPAR1/3 are partially involved and 
LPAR4 may possibly be involved in LPA induced cardiac differentiation.  
8.3 The JNK pathway 
JNK signalling was determined to be necessary for our differentiation model and 
regulated through LPA receptors 1-3, however, the specific regulation by LPAR1/3 
requires further investigation as discussed above. Phosphorylation of JNK was 
transient during EB formation irrespective of LPA treatment. The use of 10µM 
SP600125, a JNK inhibitor, inhibited LPA induced MLC1v expression whereas 20µM 
SP600125 impacted the proliferation capacity of the aggregating EBs. The inhibition 
of LPAR 1/3 and 2 did not impact on proliferation suggesting the JNK isoforms 
regulated are the same as those targeted by 10µM SP600125 and that additional JNK 
isoforms or kinases are targeted by 20µM SP600125. Inhibition of specific JNK 
isoforms, perhaps using siRNA, may establish isoform specific roles during various 
stages of EB formation and rule out the possibility of non-selective kinase inhibition by 
SP600125. 
The program of cardiac differentiation initiated by LPA may also involve the regulation 
of late genes by JNK as inhibition of the pathway 48 hours after initial EB seeding in 
the presence of LPA, using 10µM or 20µM SP600125, abolished the expression of 
MLC1v. Whether JNK signalling is required during early EB formation solely for 
proliferation, irrespective of an inducing agent, requires further investigation. For this, 
we initiated studies evaluating the regulation of the Hippo pathway, as it is implicated 
in the proliferation of several cell types and a target of both LPA and JNK. 
Phosphorylation of YAP at serine 127 and 397 was reduced in LPA treated cells during 
early EB formation and was found to be regulated by JNK. No difference was seen 
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between treatment of 10µM or 20µM SP600125 suggesting YAP is not required for 
proliferation in this context. The role of YAP was not identified in this study. To 
establish YAP as a critical signalling molecule in LPA induced cardiac differentiation, 
it is important to determine its cellular localisation and the effect its deletion would have 
on differentiation. Studies were initiated to determine the cellular localisation of YAP 
in LPA treated and untreated cells during EB formation using the Life Technologies 
NE-PER extraction kit. The results were, however, inconclusive as mycoplasma 
contaminations disrupted the programme of studies and time constraints did not allow 
for the experiments to be completed after the contamination had been resolved.  
8.4 The NF-κB Pathway 
LPA induced MLC1v expression was blocked by the inhibition of NF-κB, using 
CAY10470, during EB formation. Exploring the expression profile of NF-κB during LPA 
induced cardiac differentiation revealed that NF-κB is phosphorylated at serine 536 in 
both LPA treated and untreated EBs after an 18-hour incubation. Earlier time points 
could not be examined as the size of the pelleted EBs was very small making protein 
extraction difficult and consistency could not be assured. Although, due to time 
constraints, an ELISA kit was used to determine the changes in early NF-κB 
phosphorylation at serine 468 and 536 upon LPA treatment in adherent cells, it may 
be possible to study the changes in NF-κB phosphorylation at earlier time points in 
EBs if the initial seeding density is increased or if identical treatments are cultured and 
pooled together resulting in a larger EB pellet and easier protein extraction. Changes 
in early NF-κB phosphorylation at serine 468 or 536 were not evident upon LPA 
treatment in adherent cells. NF-κB phosphorylation at serine 536 and 468 was found 
to be mediated by JNK signalling, but, regulation at only serine 468 may be initiated 
through LPA receptors 1-3 as inhibition of these receptors did not affect serine 536. 
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Phosphorylation of the latter has been suggested to be a negative regulator of NF-κB 
activity (Pradere et al., 2016), and further investigation into the possibility of negative 
regulation by JNK dependent phosphorylation at this residue or possible cross-talk 
through AP-1 is required. It is important to mention that previous studies within the 
research group have found that treatment with LPA without an EB formation stage 
does not induce cardiac differentiation. It is possible that the signalling cascade 
leading to and from NF-κB phosphorylation is different in these culturing conditions.  
8.5 Transcription Factors 
Pramod (2017) determined that LPA induced expression of MLC1v was blocked by 
the inhibition of PKC, PI3K, or ERK, and further found that both PI3K and PKC 
converged on the regulation of ERK in LPA induced cardiac differentiation. While only 
the former was confirmed in the current thesis, we further established the regulation 
of AP-1/ATF2 by PI3K, PKC, and ERK. JunD and cJun were found to be regulated by 
PI3K/PKC-ERK whereas only FosB was regulated in a PI3K-ERK manner and ATF2 
was regulated by PKC-ERK. JNK and NF-κB were also found to regulate cJun, JunD, 
and ATF2. Although critical signalling molecules converge on the regulation of AP-
1/ATF2, the necessity of AP-1 in LPA mediated cardiac differentiation of P19 cells 
requires evaluation before concluding the regulation by critical kinases as anything 
more than observational. 
PKC, MAPKs, and NF-κB signalling converged on the regulation of GATA4, however, 
PI3K inhibition by LY294002 was shown to target AP-1 subunits. The combinatorial 
regulation by GATA4-AP-1 complexes have been suggested by several groups (Martin 
et al., 2012; Schroder et al., 2006; Suzuki et al., 1999) and perhaps PI3K regulates 
the differentiation into cardiomyocytes through modulating the GATA4 co-factor AP-1 
rather than GATA4 directly. Zeidler et al. (2016) also suggested that both AP-1 and 
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GATA4 may synergistically regulate genes during cardiac maturation after analysing 
the co-occurrence of several transcription factors during specific stages of heart 
muscle development. The role of AP-1 in differentiating P19 cells was not directly 
investigated in this study although it would be interesting to identify GATA4 co-factor 
activity, if any, in LPA mediated cardiac differentiation.  
Aside from NF-κB signalling, all pathways converged on the regulation of MEF2C. As 
FosB regulation was found to be mediated through the NF-κB independent PI3K-ERK 
pathway, it may be possible that this pathway regulates MEF2C. The necessity of dual 
regulation for full MEF2C activity is unknown as inhibiting PKC and JNK signalling also 
affected MEF2C expression. The possibility of JNK regulation by PKC and PI3K are 
yet to be established in this experimental model, although, it may be possible that 
MEF2C is regulated in a PI3K-ERK and PKC-JNK manner. 
8.6 Summary and Conclusion 
The studies carried out in this thesis have shown that LPA mediates the cardiac 
differentiation of P19 cells through LPAR2 and partially through LPAR 1/3 and possibly 
through receptor 4. The inhibition of PKC, PI3K, JNK, ERK, or NF-κB signalling blocks 
LPA induced MLC1v expression. JNK is a critical signalling molecule downstream of 
LPARs 1-3 along with ERK. Conceivably, PKC and PI3K may regulate JNK as they 
have shown to converge on the ERK pathway. Further downstream ERK, JNK, along 
with NF-κB converge on the regulation of AP-1/ATF2, and GATA4/MEF2C. Whether 
the AP-1 complex lies upstream of the examined cardiac specific transcription factors 
or if there is any co-factor activity between AP-1/ATF2 and GATA4/MEF2C is yet to 
be established. The regulation of YAP was found to be mediated by JNK, however, 
the role of YAP in the proliferation or cardiac differentiation of P19 cells requires further 
investigation.  
195 
 
Although these results are encouraging, the evaluation of LPA as a mediator of cardiac 
differentiation is in its infancy. The actions of LPA must be reproducible in more 
clinically relevant stem cells types. LPA accumulates after the onset of an acute 
myocardial infarction and has shown to protect stem cells against hypoxic injury. 
Evaluating the profile of LPA receptors in the healthy and ischaemic heart followed by 
examining the effects of both overexpression and knockdown of each receptor may 
provide insight into a potential additional pharmacological avenue for the use of LPA 
as a strategy to alleviate some of the detrimental effects, enhance survival and 
differentiation of the transplanted stem cells, or enhance the activity of resident cardiac 
progenitor stem cells. Prolonged LPA accumulation, however, can have detrimental 
effects. Therefore, identifying the ideal window of LPA activity would be vital. For this, 
in vivo studies utilizing molecular imaging and labelling techniques may prove useful 
as it is beyond the scope of conventional dish-based methods to assess the dynamic 
cellular responses to the microenvironment and stimuli during an acute myocardial 
infarction. 
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